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Abstract
Elucidating molecular alterations underlying tumor development and chemoresistance are critical
to expand our understanding of the disease pathophysiology. This dissertation is focused on
analyzing the cellular and molecular alterations associated with LPA-induced chemoresistance in
clear cell renal cell carcinoma (ccRCC) cells and chronic iron-induced deregulation of miRNA
expression in fallopian tube secretory epithelial cells (FTSECs).
Kidney cancer is one of the ten most common cancers worldwide with <15% survival rate
at advanced stage (American Cancer Society). ccRCC is the most common type of kidney cancer
and is described as a metabolic disease characterized by deregulated lipid metabolism leading
to increased intracellular lipid droplets [9, 10]. The current molecular-targeted treatment strategies
involve VEGF/VEGFR and mTOR inhibition [9, 12]. However, there are limitations to these
approaches leading to the reduced efficacy and/or increased resistance in ccRCC cells [13, 14].
Therefore, it is important to decipher the factors involved in compromising the chemosensitivity in
these cells.
Lysophosphatidic acid (LPA), a

bioactive phospholipid, was previously reported to

increase resistance against Sunitinib (VEGFR/PDGFR inhibitor) in ccRCC cells and to increase
migration and invasion in various tumors [15-17]. In Chapter 3 of this dissertation, we analyzed
the role of LPA in mediating chemotherapeutic resistance in ccRCC cells by reversing the effects
of an mTOR inhibitor Temsirolimus (TEMS). We further identified that LPA reverses the TEMSinduced changes in cellular viability, lipid droplets and mitochondrial networks, autophagy and
PI3K/mTOR pathway markers in vitro [19]. We also observed that LPA increases lipid droplets
partially in a MAPK-dependent manner [19]. Overall, these results indicate the role of LPA in
inducing potential
xi

chemoresistance in ccRCC cells, which can be further explored for pre-clinical research
applications in future.
Since epithelial ovarian cancer (EOC) is commonly diagnosed at advanced stage, it is
imperative to investigate the molecular alterations associated with initiation of the disease [3436]. HGSOC initiation from transformed fallopian tube stem cells was reported to be associated
with iron addiction and deregulated iron homeostasis markers [40]. The contribution of chronic
iron exposure in mediating oncogenic transformative events in FTSECs was previously studied in
our lab [22]. We have extended these studies in Chapter 4 of this dissertation using a multi-omics
approach to determine the global protein and miRNA alterations in chronic iron exposed FTSECs.
Interestingly, ~57% of the altered miRNAs were located at chromosome 14q32 [43]. Chromosome
14q32 harbors a cluster of 54 miRNAs, which are deregulated in various tumor types, including
ovarian cancer [25, 26, 422]. However, the role of iron-induced deregulation of 14q32 miRNAs in
FTSECs had not been previously studied. We focused on the two most downregulated (~100fold) 14q32 miRNAs – miR-432-5p and miR-127-3p and their common protein targets. We
identified that overexpression of miR-432-5p reduced cell numbers induced by long-term iron
exposure in FTSECs. We also identified that combinatorial treatment with methyltransferase and
deacetylation inhibitors reversed the expression of miR-432-5p and miR-127-3p, suggesting that
chronic iron treatment downregulates miRNA expression via epigenetic alterations.
Additionally, miR-138-5p was also downregulated in chronic iron exposed FTSECs. This
miRNA is located at chromosome 3 (which also harbors EVI1, a common transcriptional activator
in EOC). We identified a potential EVI1 binding site in miR-138 promoter region and therefore
analyzed whether miR-138 transcription is regulated by EVI1. Although our studies indicated that
miR-138-5p is regulated independently of EVI1, TERT RNA was found to be partially regulated
by miR-138-5p [43]. Overall, this study reveals global molecular alterations induced by iron,
potentially associated with transformation of FTSECs.

xii

Collectively, these studies suggest the involvement of LPA in reversing ccRCC
chemosensitivity and highlight the potential role of iron-induced 14q32 miRNA downregulation in
FTSEC transformation. In future, a detailed study of the mechanism involved in LPA-mediated
chemoresistance, and the role and regulation of miRNAs at 14q32 will expand our understanding
of their functional consequences, which will also prove useful to design clinically improved
therapeutic strategies.
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Chapter 1
Introduction
Note to reader
One sub-section of this chapter has been adopted from “Iron Pathways and Iron Chelation
Approaches in Viral, Microbial, and Fungal Infections (MDPI: Pharmaceuticals) Doi:
10.3390/ph13100275 with the copyright permission as included in Appendix A.

Renal Cancer
Renal Cancer is one of the top ten causes of cancer-related deaths worldwide, as per the data
reported by the American Cancer Society. The heterogeneous group of cancers arising from renal
epithelium is known as Renal Cell Carcinoma [6], comprising >90% kidney cancers [7]. In 2021,
the National Cancer Institute [9] statistical prediction estimated 76,080 new RCC cases (4% of
total cancer cases), and 13,780 deaths in the United States. Within the last four decades, there
has been an increase in RCC incidence by 5-fold and increase in RCC-caused mortality by 2-fold
[12, 13].
RCC incidence is higher for men than for women and increases with age. The gender ratio
is approximately 2:1 for males and females. The exact reason behind this gender bias is not
known, though these variations were reported to be due to alterations of androgen receptors in
one study, which may play distinct roles in stage/tissue- or gender-specific manner [14]. The major
established risk factors for RCC include excess body weight, hypertension, and cigarette smoking
[16]. Individuals with chronic kidney disease on dialysis for a long-term are also at greater risk of
developing RCC [26]. As per the American Joint Committee on Cancer (AJCC), RCC is staged
1

clinically and pathologically using the TNM (Tumor origin site, lymph Node involvement and
Metastasis to distant organs) staging classification, as shown in figure 1.
The five major histological sub-types of RCC include: clear cell RCC (70-80% patient cases),
papillary (10%), chromophobe (5%), oncocytoma (~3-7%) and collecting duct (>1%) [28]. Three
to five percent of RCC tumors remain unclassified, with no clear distinction between different subtypes [13].

Figure 1: Different stages of RCC representing increase in disease aggressiveness with
TNM classification (T: primary tumor site, N: regional lymph node and M: metastasis)
At stage I, RCC tumors are 7cm or less, with no involvement of lymph node and no metastasis.
At stage II, the RCC tumors are larger than 7cm, without involving lymph node or metastasis,
confined only to kidney. At stage III, the large RCC tumors may or may not involve lymph node,
but these have metastasized to the surrounding kidney tissues, growing into renal vein/vena cava.
At stage IV, the large RCC tumors most commonly involve lymph nodes, and are metastasized
outside the kidney into adrenal glands and other surrounding tissues [7].

2

Clear cell RCC (ccRCC) cells contain glycogen-, lipid- and mitochondria- rich cytoplasm,
with a clear histological appearance [31, 32]. Sub-classification of ccRCC has revealed two subgroups with differentiating biological features: (i) ccA, associated with changes in genes involved
in angiogenesis, fatty acid metabolism, and pyruvate metabolism; (ii) ccB, associated with genes
involved in TGFβ signaling and cell cycle changes [34]. ccRCC has a worse survival rate than
localized papillary RCC and chromophobe RCC [35, 36].

Molecular characterization of clear cell Renal Cell Carcinoma (ccRCC)
Genetic and Signaling Pathway alterations
Somatic copy number alterations (SCNAs) in ccRCC are characterized with higher percentage of
deletions involving entire chromosomes or chromosomal arms (17%) as compared to focal
alterations (0.4%) [37]. Most commonly, arm-level mutations encompass loss of chromosome 3p
(including four commonly mutated genes: VHL, PBRM1, BAP1 and SETD2). Biallelic inactivation
of VHL tumor suppressor gene has been reported to be caused by Loss of heterozygosity [35],
homozygous deletion and chromosomal rearrangement at this locus in ~90% of ccRCC patients
[38, 39]. VHL mutation is an “obligate” event in ccRCC, leading to stabilization and accumulation
of hypoxia inducible factors (HIF-1α and HIF-2α). These transcription factors then activate the
genes responsible for hypoxic response, angiogenesis and other signaling pathways, including
vascular endothelial growth factors (VEGF), platelet-derived growth factors (PDGF) and glucose
transporter 1 (Glut1), leading to increased tumor cell survival and metastasis [38, 40-42]. Arm
level loss at chromosome 14q, harboring HIF1A gene and DLK1-DIO3 gene locus, is reported to
be associated with ~45% of patients and is associated with increased disease aggressiveness
and poor survival outcome [37, 43, 44]
PI3K/AKT/mTOR pathway alterations are actively involved in increased ccRCC
progression [37]. Mutations at chromosome 5q35.3 harboring GNB2L1 (Guanine Nucleotide
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Binding Protein (G Protein), Beta Polypeptide 2-Like 1 or RACK1) and SQSTM1 (Sequestosome
1 or p62) genes are associated with PI3K signaling activation [45, 46]. Additionally, VEGF and
PDGF bind to their receptor tyrosine kinases (VEGFR, PDGFR) on RCC tumor cells activating
PI3K, and promoting phosphatidylinositol-3,4,5-triphosphate (PIP3) formation, which recruits AKT
to the cell membrane. AKT is phosphorylated and activated, leading to apoptosis inhibition,
inactivation of GSK-3β, activation of transcription factors such as c-Myc, β-catenin, c-Jun and
Notch, as well as mTOR activation [47, 48]. PTEN tumor suppressor gene is also negatively
regulated leading to Akt activation in RCC [49] and mutations in TSC1/2 lead to further
aggressiveness of the disease [50]. mTOR pathway is further activated by Wnt/β-catenin pathway
via inhibition of GSK3 [51].
The role of autophagic pathway dysregulation has been well studied in various cancer
types, including ccRCC [52-55]. Autophagy is a lysosome-dependent intracellular degradation
process, which is activated under cellular stress conditions, such as nutrient deficiency and
starvation [56-59]. Maintenance of cell survival and homeostasis is majorly regulated by
autophagy in normal cells [60, 61]. This process can perform tumor suppressive function by
degrading mutated DNA and damaged proteins [59, 62]. Cancer cells can exploit this process by
deregulating autophagic markers for increased cell survival and tumorigenicity and/or by protein
aggregation [63, 64]. Low levels of LC3-II and Beclin 1 autophagic markers have been shown to
be associated with poor prognosis of ccRCC [65]. Additionally, p62 (SQSTM1, overexpressed via
gain at chromosome 5 in RCC) is an autophagic marker and an agonist of NRF2 (Nuclear factorerythroid factor 2-related factor 2) [54, 66]. p62 links the autophagy pathway and the ubiquitin–
proteasome system upon ubiquitinated protein degradation [67]. NRF2 is released from KEAP1
(Kelch-like ECH-associated protein 1) by competitive binding of p62 and activates downstream
genes for RCC tumor cell survival [68]. Additionally, increased promoter methylation of KEAP1
gene has been shown to be associated with increased progression of ccRCC [69].
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Current Treatment Strategies for ccRCC
Based on ccRCC staging and risk assessment, patients with small cortical tumors (originated in
renal tubules) [70] of <3cm can be subjected to radiofrequency ablation [71], microwave ablation
[72] or cryoablation treatments, although the preferred option is partial nephrectomy of tumors
<7cm diameter, confined within the kidney [73]. In advanced RCC cases, immunotherapeutic
cytokine treatments, such as use of interferon-α and high-dose IL-2 are used alone or in
combination, though these can be associated with significant toxicity and low response rates [74].
More recently, inhibitors of T-cell immune checkpoint markers and monoclonal antibodies
programmed cell death protein 1, such as Nivolumab, are being used to exploit intrinsic anti-tumor
immune response in patients [1].
Management of advanced and metastatic ccRCC requires alternative strategies. Since
signaling pathway alterations play a key role in ccRCC pathogenesis, molecular systemic
strategies are commonly used alone or as adjuvant to the above-mentioned treatments. ccRCC
is commonly targeted using tyrosine kinase inhibitors targeting VEGF, PDGF, fibroblast growth
factors and their respective receptors, using drugs such as sunitinib, pazopanib, sorafenib,
bevacizumab [6, 47, 48, 75, 76], as well as drugs targeting Glut1 and Warburg effect, such as
STF 31 (Selective inhibitor of Glucose Transporter 1) [77], as shown in figure 2. Everolimus and
temsirolimus (TEMS) are FDA-approved allosteric inhibitors of mTOR (as shown in figure 1).
These are used clinically for RCC treatment and are being studied for combinational regimens as
well as sequential therapy with VEGF pathway in various clinical trials [78-81].

Chemoresistance in ccRCC
Majority of ccRCC tumors are prone to resistance towards chemotherapeutics [82]. The
resistance can be “intrinsic” leading to immediate inefficacy of treatment, or “acquired” leading to
tumor re-growth after an initial disease regression [83, 84]. The sub-optimal efficacy of
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chemoresistance has been reported to be due to lysosomal sequestration of tyrosine kinase
inhibitors [85], mutation in mTOR inhibitor binding site such as FKBP-12 [86, 87], activation of
angiogenic factors [4, 88-90], increase in cholesterol levels [91] and/or intratumoral heterogeneity
[92].

Figure 2: Commonly altered signaling pathways and chemotherapeutic approach in ccRCC
PI3K/AKT/mTOR pathway is hyperactivated leading to increased tumor growth and survival. Loss
of VHL tumor suppressor gene leads to accumulation of HIF1α, which in turn activates markers
involved in angiogenesis such as VEGF and PDGF and altered cellular metabolism such as Glut1,
ultimately leading to increase in metastatic potential of the ccRCC tumor. Parts of this figure
adapted from [4, 5].
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Drugs targeting PI3K/AKT/mTOR pathway can also activate autophagy, which could be
another key mechanism of chemoresistance in ccRCC cells [93]. To overcome this resistance,
autophagic flux inhibitors chloroquine and hydroxychloroquine (HCQ) have been reported to be
used in combination with chemotherapeutic drugs for ccRCC treatment [94, 95], though more indepth research would be required for clinical applications.

Metabolic Reprogramming in ccRCC
Clear cell renal cancer is known as a metabolic disease, with alterations in various pathway
mediators involved in glycolysis, TCA cycle, protein biosynthetic pathways, nucleotide
biosynthesis, as well as lipid metabolism [96-100], which are directly associated with increased
RCC development as shown in Figure 3. Kidney epithelial cells are associated with high numbers
of glucose transporters, which are further upregulated in VHL mutated ccRCC cells [101] leading
to enhanced glycolysis [102]. Further, loss of rate-limiting gluconeogenetic enzyme fructose-1bisphophatase (FBP1) expression was reported in 100% of the 600 RCC tumors analyzed [103].
The hyperactivated mTOR pathway also regulates HIF-mediated gene expression by inducing
hypoxia response elements to activate the genes involved in enhanced metabolism (such as
PDK1, Glut1) and in angiogenesis (such as VEGF) [104], as shown in Figure 3. Well-known HIFmediated ccRCC effects also include increased expression of LDH (lactate dehydrogenase),
PDK1 (pyruvate dehydrogenase kinase), and HK (hexokinase) [105-108].
Activated oxidative and non-oxidative glucose metabolism via pentose phosphate
pathway (PPP) is also reported to be activated in RCC cells [109], along with increased
expression of glucose-6-phosphate dehydrogenase (G6PD) augmenting RCC progression [110].
Furthermore, altered expression of TCA cycle genes, such as reduction in succinate
dehydrogenase (SDH), Fumarate dehydrogenase (FH) and isocitrate dehydrogenase (IDH) are
shown to be associated with ccRCC tumors [99, 111-113].
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As the “clear cell” phenotype in ccRCC tumors can be histologically attributed to its lipid
and glycogen rich cytoplasmic deposits [98, 114], it is well established that alterations in lipid
metabolic pathways are hallmarks of this disease. Increased metabolic demands of proliferating
ccRCC tumor cells are met by either enhanced uptake of exogenous lipids or by hyper-activating
the endogenous lipid synthesis (i.e., lipogenesis and cholesterol synthesis) [114-116] (as shown
in figure 3). Increased expression of lipogenic enzymes, such as acetyl-CoA carboxylase (ACC)
and fatty acid synthase (FASN), and ATP citrate lyase (ACLY) that promote cholesterol synthesis
have been reported in ccRCC [115, 117-119].
Excessive lipids and cholesterol in ccRCC are stored in the form of lipid droplets [77, 120].
LDs are often found in close vicinity with the endoplasmic reticulum, mitochondria, endosomes,
peroxisomes, and the plasma membrane [121]. These organelle associations assist in the lipid
exchange, either for LD growth (anabolic) or for their catabolic breakdown [122]. Alternatively,
LDs provide a means of transporting lipids between organelles within the cell [123] and may
protect mitochondria during autophagy by acting as an energy source by supplying fatty acids for
mitochondrial β-oxidation and by sequestering excessively accumulated lipids that arise during
autophagic degradation of membranous organelles [124].
High LDs and stored-cholesteryl ester content in tumors have are also associated with
ccRCC aggressiveness [125]. ccRCC is characterized by increased cellular esterified cholesterol,
very low density lipoprotein (VLDL), Low density lipoprotein (LDL) and ACAT activity (acetyl-coA
cholesterol acetyl transferase) as well as reduced high density lipoprotein (HDL), which lead to
increased lipid accumulation or diminished efflux [96, 126-128].
Lipid droplet accumulation in ccRCC can also be attributed to defects in autophagic LD
turnover, via lipophagy [129]. MAP1S (member of the microtubule-associated protein family 1), a
positive regulator of autophagic flux, is downregulated in ccRCC tissues and cell lines, as
compared to the normal renal cells which consequently reduces lipophagy of LDs, contributing to
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Figure 3: Metabolic Reprogramming in Renal Cell Carcinoma
Glycolysis and Pentose phosphate pathway are upregulated in ccRCC. GLUT transporters
mediate Glucose transport, which generates pyruvate via glycolysis. Pyruvate goes through TCA
cycle to generate ATP. Flux of pyruvate into TCA cycle decreases in ccRCC and consequently
pyruvate undergoes lactic acid fermentation for the increased production of ATP. Activated
PI3K/AKT/mTOR pathway and VHL mutation lead to HIF1α stabilization, leading to increase in
hypoxia response elements to aid cancer cells with increased bioenergetic needs and
angiogenesis. These cells are also characterized by upregulation of fatty acid biosynthesis.
Enzymes in Blue are downregulated, and Red are upregulated. Partially adapted from [8].
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increase in lipid droplet accumulation, potentially enhancing ccRCC development [130].
Interestingly, mTOR targeting chemotherapeutic agents (such as TEMS) is shown to reduce LD
formation [131]. Further studies based on targeting lipid pathway alterations can provide novel
direction to ccRCC treatment.

Role of Lysophosphatidic acid in ccRCC
Signaling pathways regulated by phospholipids contribute to pathophysiology of cancer [132].
Overall phospholipid content is reported to be higher in renal tumors as compared to normal
kidney cells and is increased with cellular transformation [133]. Lysophosphatidic acid (LPA) is a
glycerophospholipid, that acts via G-protein coupled receptors and occurs naturally in nearly
every organ of human body, including the kidneys [134]. LPA can be produced extracellularly by
Autotaxin (ATX) that functions as a lysophospholipase D enzyme to hydrolyze phosphodiester
bonds in lysophospholipids [10], as shown in Figure 5. ATX mRNA levels are significantly
increased in RCC tumors [135]. LPA is reported to be associated with RCC progression by
activating Arf6 to promote mesenchymal malignancy and LPA-ATX axis is shown to promote
acquired resistance against sunitinib (VEGFR inhibitor) to mediate tumorigenesis [136].
Intracellularly, LPA can be formed by phospholipase A1 and A2 enzymes from phosphatidic acid
(PA). PA is shown to form supersized lipid droplets in yeast [137], but the involvement of LPA in
LD biology, role of LPA-LD relation in RCC and the mechanism by which LPA mediates these
effects needs further investigation in renal tumor biology.

Ovarian Cancer
Often known as “silent killer” or “whispering disease” [138], ovarian cancer (OVCA) is the fifth
leading cause of cancer deaths in women, usually diagnosed at an advanced stage leading to
poor disease outcome [139]. The American Cancer Society data predicted diagnosis of ovarian
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cancer in 21,410 women and 13,770 deaths in 2021, accounting for highest number of
gynecological cancer-related deaths in women.

Figure 4: Lipid and Cholesterol metabolic pathways commonly altered in ccRCC
Lipid biogenesis, increased uptake and decrease in lipolysis are utilized to maintain increased
proliferation of cancer cells and excessive lipids are stored in the form of lipid droplets. Excessive
fatty acids in ccRCC cells provide membrane biosynthetic substrates and work in conjunction with
mitochondria through β-oxidation to increase cellular growth and proliferation [2, 3].

Risk factors associated with OVCA development can be genetic (such as hereditary
mutations in genes including, BRCA1/BRCA2, MMR, BRIP1, MSH6 [140, 141]) and non-genetic
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Figure 5: Model for crosstalk between Lysophosphatidic acid and mTOR pathway
Phosphatidylcholine is commonly found in the exoplasmic or outer leaflet of a cell membrane.
Autotaxin (ATX) generates LPA from plasma membrane phospholipids and from circulating
lysophosphatidylcholine (LPC) bound to albumin. This is followed by subsequent binding of LPA
to endothelial differentiation gene receptors. Activation of EDG receptors lead to increased
signaling through the Ras/Raf/MEK/ERK pathway, which represses TSC1/2 to inhibit Rheb,
releasing mTOR for activation. LPA can also be generated intracellularly from phosphatidylcholine
(PC) and phosphatidic acid. Alternatively, LPA can also potentially migrate into and out of the
cytosol, though the mechanism involved is not known. Intracellular LPA can form PA via 1acylglycerol-3-phosphate-O-acyltransferase (AGPAT) enzyme. PA can directly bind to mTOR
leading to its activation [10] [11].

such as smoking, obesity and hormonal replacement therapy [142]. Treatment strategies are
employed based on the OVCA tumor staging; these are divided into stages I to IV, according to
the FIGO (International Federation of Gynecology and Obstetrics) system. In stage I, tumor is
found in one or both ovaries; in stage II, OVCA cells are spread to other pelvic organs such as
12

fallopian tubes or uterus; in stage III, cells have metastasized to nearby organs outside of pelvis
such as lymph nodes, diaphragm, intestine, or liver; in stage IV cells spread beyond the abdominal
region into lungs and spleen [143]. Most common treatment in early stages is surgical removal of
tumor or affected ovary and in advanced stages, these tumors are treated by cytoreductive
surgery (or debulking of tumor), followed by chemotherapy [144]. Chemotherapeutic strategies
include carboplatin/ paclitaxel combination, bevacizumab, poly (ADP-ribose) polymerase
inhibitors and platinum-based therapies amongst others [144, 145]. However, chemoresistance
and mortality rate are high because most OVCA cases are diagnosed are advanced stages [146,
147]. Further understanding of OVCA pathophysiology and determination of significant earlystage markers are required to combat the disease.
There are three main types of ovarian cancer: epithelial ovarian cancer (EOC) is the most
common type which occurs in ~95% of OVCA cases; germ-cell and sex-cord stromal comprise of
~5% of the cases and are less common [148]. Epithelial ovarian cancers have four common
histological sub-types: endometrioid, mucinous, clear cell and serous [149]. Endometrioid,
mucinous, and clear cell contribute to 10%, 3% and 10% of EOC, respectively. Serous OVCA is
further classified into high grade serous ovarian carcinoma (HGSOC) contributing to ~70-80% of
EOCs and low grade serous ovarian carcinoma (LGSOC) accounting for <5% of the cases [150].

Origin of High Grade Serous Ovarian Carcinoma: Existing theories and Proof of Concept
Due to early metastasis and lack of distinct anatomical barriers in peritoneal cavity, HGSOC cells
are transported via physiological peritoneal fluid and disseminates within the abdominal cavity
[151]. However, this contributes to increased tumor heterogeneity, along with the distinct
clinicopathological features in HGSOC cells which has led to the challenges in identifying the cell
of origin [152].
Historically, ovarian surface epithelium (OSE) was believed to be the precursor due to
“incessant evolution hypothesis” suggesting that repetitive ovulation events lead to pro13

inflammatory microenvironment by causing trauma, hormonal changes, and oxidative stress
induced DNA damage, followed by subsequent and/or inadequate repair [153, 154]. This concept
is further supported by reports suggesting that patients harboring mutations in BRCA1/2
(responsible for homologous recombination-mediated repair of double strand breaks) are at
higher risk of developing HGSOC [154]. Since this theory co-related HGSOC development with
high number of ovulatory cycles, it was reinforced by studies suggesting that pregnancy,
breastfeeding, and oral-contraceptive hormonal pills, which suppress ovulation, can reduce the
risk of developing this disease [155, 156]. Ovulatory repair can also result in invagination of
sections of OSE to get entrapped beneath cortical inclusion cysts (CICs), which have been
proposed to possess oncogenic potential to differentiate into Mullerian phenotype, prior to
malignant transformation into HGSOC [157]. However, there is lack of convincing mechanistic
evidence for this theory and due to absence of any precursor lesions identified from OSE within
the ovary, this concept was challenged with alternative hypotheses [158].
The tubal origin of high-grade serous carcinoma was proposed with the discovery of small
dysplastic lesions similar to HGSOC within the fallopian tubes [159]. The severely dysplastic
lesions also have highly proliferating cells and accumulation of p53 gene mutation, characteristic
of HGSOC [160]. These lesions are known as serous tubular intra-epithelial carcinomas (STICs)
and are reported to overexpress DNA-double strand break marker γH2AX [161] and shortened
telomeres [162], which are hallmarks of early-stage cancer. STICs are reported as precursor
lesions in both BRCA 1/2-mutation carrier women [163] as well as in non-BRCA1/2 mutation
carriers [164, 165]; more specifically fallopian tube secretory epithelial cells (FTSECs) were
reported to be cells of origin for HGSOC [166].
Fallopian tube precursor concept was reinforced by literature evidence, such as the study
of fallopian tube stem cell transformation in vitro recapitulating the molecular and histological
alterations characteristic of HGSOC [167], generation of novel mouse model with induced
mutations in same genes commonly affected in human patients (BRCA, Tp53, and PTEN genes)
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used to demonstrate transformation of STIC to HGSOC, mimicking the underlying molecular
alterations [168]; transcriptomic analysis of OSE cells, FTSECs and HGSOC cells showed highest
similarities between FTSECs and a cohort of ~400 HGSOC samples [169].
To directly compare between the two cells of origin, a study was conducted to generate
genetically engineered mouse models from organoids targeting the same genetic aberrations as
found in OSE and in fallopian tube epithelia (FTE) [170]. Despite the identical driver mutations,
tumor development was affected by the cell of origin, increased p53 signaling in FTE-derived
tumors, and enhanced DNA repair pathways in OSE tumors [170]. In comparison with the TCGA
human data, it was found that OSE-derived tumors resembled HGSOC of the proliferative subtype, while FTE-derived tumors showed mesenchymal subtype features of HGSOC [170]. Their
response to chemotherapeutic drugs was also variable in vitro [170]. This suggests that both OSE
and FTE can possibly serve as precursors to development of HGSOC. However, the factors that
contribute to development of HGSOC from either of these cells of origin remain understudied and
thus require further investigation.

Iron metabolism and Role of Iron in Ovarian Cancer
Excessive iron is reported to be associated with development and progression various cancer
types including breast, ovarian, prostate, colon, renal cancer, melanoma, osteosarcoma [171173]. Fenton reaction-induced reactive oxygen species (ROS) generation has also been reported
to increase cell migration, angiogenesis, and aggressiveness in cancer stem cells [174].
Transformed fallopian tube epithelial stem cells (described as tumor initiating cells) are also
reported to be addicted to iron, promoting tumor initiation and growth by accumulating excessive
iron content [175]. Iron overload caused by hemochromatosis is associated with increased risk of
OVCA [176, 177]. In normal cells, iron homeostasis is tightly regulated. Cells require iron to
maintain balance between the level required for metabolic needs, such as functioning as co-factor
for DNA polymerases and helicases, mitochondrial respiration, citric acid cycle enzymes [178]
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and iron homeostasis deregulation leading to excessive iron, which can contribute to tumor
initiation and progression [179]. Iron can be detrimental to the cells due to its ability to generate
reactive oxygen species contributing to free radical formation, inducing oxidative stress and DNA
damage [179, 180]. Iron accumulation can also lead lipid alterations in cancer cells, leading to
ferroptosis [27]. However, cancer cells can reprogram iron metabolism by deregulating the iron
regulatory proteins, such as increase in TFR1 and TFR2 [181, 182], downregulation of FPN [183],
decrease in ferritin [184], increase in hepcidin [185] and overexpression of DMT1 [186], as shown
in figure 6. Some of the possible causes of iron induced OVCA development include oxidative
stress [187], retrograde menstruation [188] and iron deposition in endometriotic cysts of fallopian
tubes [189], in pelvic cavity [190] as well as in follicular fluid [191].
Long-term iron exposure of FTSECs with a NTBI form (Ferric Ammonium Citrate (FAC))
was shown to increase cell numbers and migration potential, DNA damage response protein
(FANCD2), hTERT mRNA and EVI1 transcriptional regulator [19], providing preliminary evidence
regarding role of iron in initiating transformative events in FTSECs. However, a detailed
mechanism of alterations caused by iron to induce transformative or tumorigenic effects needs
further investigation.

Micro-RNAs
Role in Cancer
Mature micro-RNAs (miRNAs) are short non-coding RNAs (20-23 nucleotides in length) and
function by repressing the target mRNA to play major role in various biological processes [192].
miRNA biogenesis involves transcription of primary miRNA (pri-miRNA) by RNA polymerase II,
followed by processing into precursor miRNA (pre-miRNA) by DGCR8/Drosha. Pre-miRNA is ~85
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Figure 6: Iron Homeostasis in normal and cancer cells
Transferrin, a carrier glycoprotein which binds to iron (TBI), facilitates the transport of iron into
cells via the transferrin receptor (CD71) [17]. Cellular entry of TBI occurs via an endocytic process
which is followed by the release of iron from transferrin. STEAP3 (Six Transmembrane Epithelial
Antigen of Prostate 3) mediates reduction of the Fe3+ (ferric) to the Fe2+ (ferrous) [20]. Once
reduced, the iron is released from the endosomal compartment to the cytosol via endosomal
DMT1 (Divalent Metal Transporter 1). The divalent metal transporter ZIP8 (Solute carrier family
39 member 8 (SLC39A8)) is one way through which NTBI can enter cells [21]. Another
mechanism underlying NTBI uptake, specifically into small intestinal cells, involves the reduction
of ferric iron via duodenal cytochrome b (DCYTB) [22], followed by its transport via cell surface
localized DMT1 [23-25]. The imported iron (from either NTBI or TBI) can either (1) be stored in a
complex with ferritin (FTN), (2) be added to the labile iron pool, (3) be exported extracellularly via
ferroportin (FPN), or (4) be integrated within key enzymes involved in regulating cellular metabolic
processes [29]. Extracellular export involving FPN is the only means of exporting iron out of cells
and its levels are regulated by HAMP [30]. Excess iron can also be stored in the form of labile
iron pool. PCBP1 binds to ferritin and facilitates the loading of iron into ferritin [33]. The mediators
of iron altered in cancer are denoted with arrows showing upregulation or downregulation in
different cancer types.
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nucleotide stem-loop structure which is transported from nucleus to cytoplasm by Exportin 5/RanGTP complex. In the cytoplasm, pre-miRNAs are further processed by Dicer to a miRNA/miRNA*
duplex (* indicates the passenger strand and the strand complementary to it is the mature or guide
strand). The duplex is unwound, and mature miRNA is incorporated into RNA-induced silencing
complex (RISC), which is targeted to the respective mRNA for translational repression or mRNA
degradation [15], as shown in figure 7. Target recognition by miRNAs is determined by
nucleotides 2 to 7 at the 5’ end of the miRNA, known as “seed sequence” [193]. Mismatched
target recognition without the seed sequence is known as non-canonical targeting and is
associated with lower repression levels [194]. miRNAs also possess tumor suppressive or
oncogenic properties in various cancer types, including cancer of breast, liver, lung, ovaries,
colon, prostate, pancreatic, cervical, kidney and blood, which not only serve to alter tumorigenic
properties of cells, but also confer chemoresistance by directly altering molecular mechanisms
involved in cell cycle, DNA damage repair, cell death, disease progression, among others [195].

miRNA – Genomic Organization and miRNA cluster at 14q32
Non-protein coding RNA transcripts encode for approximately 50% miRNAs, and the rest can be
encoded from introns or exons [196, 197]. Based on their genomic location, the miRNA genes
can be categorized as: a). Intergenic miRNAs, which have their own promoter region and can be
monocistronic (encoded as a single miRNA) or polycistronic (encoded as miRNA cluster); b).
Exonic miRNAs, which are rare and are often transcribed by their own promoter overlapping
between intron and exon of a coding region; c). Intronic miRNAs, which are located within introns,
can have their own promoter or can use host promoter and can be monocistronic or polycistronic
[198].
Many clustered miRNAs are transcribed as a polycistronic unit [196]. It is reported that
clustered miRNAs are generated via gene duplication events or de novo miRNA-like hairpin
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formation in the existing miRNA transcripts [199], are evolutionarily conserved [200] and
can exert cooperative repressive effects to target functionally related genes [201]. Interestingly,
miRNAs from the same cluster can belong to different miRNA families (derived from different
precursor miRNAs) and can target multiple mRNAs. These mRNAs translate into proteins that
can either interact with each other or belong to the same signaling pathway, suggesting an
intricately regulated miRNA network for carefully nuanced functional consequences [202].

Figure 7: miRNA biogenesis pathway
miRNA gene transcription generated primary miRNA (pri-miRNA) via RNA polymerase III.
Precursor miRNA (pre-miRNA) is generated from pri-miRNA via Drsoha/DGCR8, which is
transported outside the nucleus into the cytoplasm via exportin5/Ran-GTP. In cytoplasm, Dicer
cleaves pre-miRNA to generate two miRNA strands, which are loaded onto RNA-induced
silencing complex (RISC) via Argonaute 2 (Ago2). This leads to formation of mature miRNA, which
targets specific miRNAs [15].
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Approximately 25% of human miRNA genes are organized to be transcribed as miRNA
clusters, including chromosome X with 18 clusters, chromosomes 1 and 17 with 13 clusters each
and chromosome 19 harboring a large miRNA cluster [203]. One of the largest miRNA clusters
on human genome exists on chromosome 14q32 (C14MC) containing 54 mature miRNAs and is
genomically imprinted [204]. Imprinted genes are expressed in parent-of-origin specific manner,
where one allele (from one parent) is transcriptionally active, while the other is silent [205]. The
14q32 miRNA cluster (also known as DLK1-DIO3 cluster) is expressed from the maternal allele
[204, 206, 207]. The miRNAs at 14q32 are reported to induce aortic valve disease [208], are
differentially expressed, acting as potential biomarkers in Non-alcoholic fatty acid liver disease
[209] and can increase neovascularization [210]. Either individually, or in form of cluster/subclusters, these miRNAs have oncogenic or tumor suppressive functions in a tissue-specific or
disease progression-specific manner [211, 212]. Existing literature evidence suggests their role
in various cancer types, including lung adenocarcinoma [206], osteosarcoma [213], breast cancer
[214], thyroid cancer [215] and Hepatoblastoma [216]. However, its functional significance and
role in renal cancer and initiation of ovarian cancer had not been well studied, which was the focus
of part of our study.

miRNA Regulation: Epigenetic control of 14q32 miRNAs
miRNAs can be regulated via (1) transcription factors such as Myc, E2F, FOXO1, β-catenin [203,
217]; (2) genetic alterations such as chromosomal translocation and miRNA localization to fragile
sites [218]; [27] altered expression of miRNA processing genes such as Drosha, Dicer or
Argonaute 2 [203] and (4) epigenetic mechanisms such as methylation or acetylation [203, 219,
220].
Gene transcription occurs when chromatin is in “open” configuration. Epigenetic
modifications like methylation and acetylation can affect this state [25]. As shown in Figure 7,
hypermethylation of DNA (with more CpG islands located near the transcription start site), recruit
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methyl-binding proteins triggering a silencing cascade by sequentially deacetylating and
methylating histones, which results in a compact “silent” chromatin [25]. On the other hand, DNA
demethylation does not allow recruitment of histone deacetylating enzymes but rather increases
affinity for histone acetyltransferases, which leads to acetylated state of histones, whereby
promoting transcription [221].
The chromosomal locus at 14q32 possess differentially methylated regions: Intergenic
(IG-DMR), MEG3-DMR and MEG8-DMR, located within the DLK1-DIO3 gene locus [222]. These
DMRs has been reported to be epigenetically silenced in various cancer types, including
melanoma, lung cancer, liver cancer and hepatoblastoma [5, 216, 223, 224]. However, whether
the epigenetic regulation of 14q32 locus is responsible for aberrant miRNA expression in ovarian
cancer initiation had not yet been investigated, which we have analyzed and explained in Chapter
4. Additionally, there is contrasting literature evidence regarding 14q32 miRNA transcription as a
polycistronic unit via epigenetic mechanisms [204] or via independent regulation at unique miRNA
promoters by nuclear receptors including Estrogen related receptor (ERRγ)/small heterodimer
partner [225] [226]. Further investigation would be required to understand the regulation of this
miRNA cluster in detail.

Role of Iron in regulating miRNAs
Micro-RNA induced post-transcriptional gene expression targeting iron homeostasis pathway has
been extensively studied, including expression of genes involved in iron acquisition (transferrin
receptor and divalent metal transporter), iron export (ferroportin), iron storage (ferritin) and iron
utilization (ISCU), amongst others [227-230]. However, the role of iron in regulating miRNAs is
understudied. One literature evidence supporting the contribution of iron-induced reactive oxygen
species (ROS) in miRNA expression suggests that upregulating or downregulating ROS by iron
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treatment or antioxidants, respectively, can synergistically alter the expression of miRNAs-125b
and miR-146b in astroglial primary cells [231].

Figure 8: Model for epigenetic regulation of 14q32 miRNA cluster
There are three differentially methylated regions present in the promoter site of 14q32 miRNAs.
DNA methylation and Histone acetylation at these sites can lead to epigenetic alteration in the
miRNA expression, leading to upregulation or downregulation of these miRNAs in different
disease states [18].

Role of iron in the form of heme is reported to increase DGCR8 dimerization during pri-miRNA
processing [232]. Increased cytosolic iron was also shown to regulate miRNA processing by
modulating the association between PCBP2 and Dicer, reducing PCBP2 multimerization and
thereby altering the miRNA precursor processing [233]. However, detailed mechanism of how
iron can regulate miRNA gene expression needs to be further examined.

Hypotheses and Aims
The goal of our studies was to analyze the cellular and molecular alterations associated with clear
cell renal cancer pathophysiology and ovarian cancer initiation.
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As stated previously, chemotherapeutic efficiency in ccRCC is sub-optimal and therefore,
it is imperative to understand the factors involved in mediating resistance. It is well known that
lipid and mitochondrial dysregulation are characteristics of ccRCC, however, whether these
alterations are associated with chemoresistance via bioactive phospholipid LPA has not yet
investigated. Therefore, we hypothesized that LPA reverses the TEMS-mediated alteration of lipid
droplets and mitochondrial networks, enhancing chemotherapeutic resistance. Further, LPA
increases lipid droplets via modulation of the signaling pathways commonly altered in ccRCC.
Additionally, mechanism of OVCA initiation and role of iron in mediating any potential
changes is not yet well studied. It is known that OVCA cells are addicted to iron, and iron can lead
to transformative changes in FTSECs. However, the role of iron in mediating specific miRNA
alterations is a novel aspect covered in our study. We hypothesized that long-term iron treatment
can alter miRNA expression by regulating epigenetic status, which leads to the FTSECtransformative changes potentially leading to OVCA-like characteristics.

Based on these hypotheses, the specific aims for each study are as follows:
Specific Aim 1 (Chapter 3): We will assess whether lysophosphatidic acid can reverse
temsirolimus-induced chemoresistance and the molecular alterations involved in mediating this
effect.
1.1 Analyze the effect of temsirolimus on lipid droplets, cell viability, mitochondrial networks and
signaling pathways altered in renal cells in vitro.
1.2 Determine the role of lysophosphatidic acid in counteracting these effects to mediate
chemoresistance
Specific Aim 2 (Chapter 4): We will analyze whether iron can confer epigenetic changes leading
to miRNA alterations in fallopian tube secretory epithelial cells.
2.1 Proteomics and microarray analyses of long-term iron treated fallopian tube secretory
epithelial cells.
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2.2 Inhibit methylation and deacetylation to analyze 14q32 miRNA expression
2.3 Assess the mechanism and functional effects of iron-mediated miRNA alterations

Overall Significance
These studies will help expand our understanding of the molecular mechanisms involved in
chemotherapeutic responsiveness of ccRCC cells and if LPA can regulate this pathway. Further,
examining the function of the miRNA cluster at 14q32 as a potential tumor suppressor in FTSECs
in vitro and the role of iron in mediating miRNA deregulation will also contribute towards
determining the cellular and molecular changes associated with ovarian cancer initiation. Both
these studies will direct our focus towards exploring novel treatment strategies to target these
diseases.
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Chapter 2
Methods
Note to reader
Some of the materials and methods included in this chapter were derived in part or in full, from
the following published articles:
•

Chhabra

R,

Nanjundan

M.

PLoS

One.

2020

Jun

3;15(6):

e0233887.

doi:

10.1371/journal.pone.0233887, included here with an open access license from PLOS
ONE.
•

Chhabra R, Rockfield S, Guergues J, Nadeau OW, Hill R, Stevens SM Jr, Nanjundan M.
Sci Rep. 2021 Mar 18;11(1):6270. doi: 10.1038/s41598-021-85342-y), included here with
an open access Creative Commons Attribution 4.0 international license from Springer
nature.

See Appendix A for copyright permissions.
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Cell Culture and Propagation
Table 1: List of cell lines used in dissertation and their respective information.
Cell lines

Cells/Tissue of
Origin

Culture Media

Passage
number

Purchased/Obtained
from

RPTEC

Primary Renal
Proximal Tubule
Epithelial Cells;
Normal, Human

Basal Epithelial
Media
(supplemented
with growth
components)

p = n+2 – n+5

ATCC

HEK293T

Human embryonic
kidney epithelial

RPMI-1640

p = n+2 –
n+12

Dr. Gordon B Mills,

cells

MD Anderson
Cancer Center

p = n+4 –
n+20

ATCC

RPMI-1640

p = 41 – 54

ATCC

Kidney Epithelial
Carcinoma cells

RPMI-1640

p = 113 – 127

ATCC

A-498

Kidney Epithelial
Carcinoma cells

EMEM

p = 38 – 53

ATCC

FTSECs:
FT194

Human
immortalized
fallopian tube
secretory epithelial
cells

DMEM:F12 phenol red,
supplemented
with 2%
Ultroser G
Serum
Substitute

P = 30 – 52

Dr. Ronald Drapkin

HK-2

Human
papillomavirus 16
(HPV-16)
transformed
kidney,
cortex/proximal
tubule cells

K-SFM
(supplemented

769-P

Kidney Epithelial
Carcinoma cells

786-O

with BPE and
EGF)
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The cell lines used in this dissertation are summarized in Table 1 along with information
regarding their tissue of origin, culture media, passage numbers and source. All cell lines were
maintained at 37°C with 5% CO2; these were STR profiled and tested mycoplasma negative.
RPTEC, 769-P, 786-O, and A-498 cells were maintained in a BSL-I incubator, while FTSEC, HK2, and HEK293T cells were maintained in a BSL-II incubator. The RPMI-1640 (#SH30027-01
Cytiva, Marlborough, MA used for culturing 769-P, 786-O, HEK293T cells) and EMEM media with
L-Glutamine ATCC: 30-2003) used for A-498 cells) was supplemented with 8% Fetal Bovine
Serum (FBS) and 5% Penicillin/Streptomycin. The Keratinocyte serum free media (K-SFM, #17005-042, Fisher Scientific, Pittsburgh, PA) used for culturing HK-2 cells) was supplemented with
5% Penicillin/Streptomycin, bovine pituitary extract (BPE) and epidermal growth factor Basal
epithelial media (ATCC: PCS-400-010) used for maintaining RPTEC cells was supplemented with
5% Penicillin/Streptomycin, and Renal Epithelial Cell Growth Kit (ATCC: PCS-400-04) comprised
of 0.5% FBS, 10nM Triiodothyronine, 10 ng/ml rh EGF, 100 ng/ml Hydrocortisone Hemisuccinate,
5 µg/ml rh Insulin, 1 µM Epinephrine, 5 µg/ml Transferrin, and 2.4 mM L-Alanyl-L-Glutamine.
Immortalized FTSEC-FT194 cells were maintained in phenol red-free DMEM:F12 (1:1, #21041025, ThermoFisher, Waltham, MA, USA) supplemented with 8% charcoal dextran-stripped FBS
and 1% Penicillin/Streptomycin (without Phenol Red media), as previously described [19]. All cells
were sub-cultured using 1 ml/T-25 flask or 2 ml/T-75 flask Trypsin-EDTA (# 25-053-Cl Corning
0.25% Trypsin, 2.21 nM EDTA 1X sodium bicarbonate)) and collected using respective complete
media, apart from RPTEC and HK-2 cells which were trypsinized using 1:5 dilution of trypsinEDTA and collected using neutralization buffer (5% FBS in PBS solution). Once collected, cells
were pelleted at 1000 rpm for 5 minutes at room temperature, followed by resuspension in the
respective media, counting the cells using a hemocytometer, and seeding/plating at an
appropriate cell density.
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Mycoplasma Testing
Supernatant from confluent cell culture flasks was collected for mycoplasma testing. Two sets of
1.5 ml eppendorf tubes per sample and two sets of 0.2ml PCR tubes were labelled, including one
tube for Negative control (-) and one tube for Positive control (+). Except for the reaction mixture
reagent (glycerol-based and kept directly on ice), all of the other mycoplasma test reagents (e.g.,
Nuclease-free water and Buffer Solution) were thawed and kept on ice until ready. When samples
were ready to analyze, they were inverted to mix and 1ml aliquoted to their respective eppendorf
tubes using filtered pipet tips. Next, they were centrifuged for 1 minute at 250 g, using the
refrigerated centrifuge. The supernatant was then collected and then transferred to a new set of
eppendorf tubes. These were then centrifuged for 10 minutes at 20,000g at 4°C. The following
reagents were added to one set of PCR tubes using p10 pipet: 8 µl Nuclease-free water (add to
sample and Positive control tubes); 10 µl Nuclease-free water to Negative control tube; 2.5 µl
Reaction Mixture to sample, Positive, and Negative tubes; 1 µl of Buffer Solution to the Positive
Control tube only. After centrifugation, media was discarded in the sink. Using p200, the pellet
was suspended in 25 µl of Buffer solution and was transfer to the respective second set of 0.2ml
PCR tube. These tubes were then added into thermocycler for “Instant Incubation” at 95˚C with
heated lid for 3 minutes.
After 3 minutes, the Instant Incubate cycle was ended and all the samples were removed,
placing directly on the rack on ice. 1.25 µl of heated sample was transferred to the respective 2nd
set of PCR tubes. Samples were checked to ensure all solution was contained at the bottom of
the tube. 0.2ml PCR tubes were pulse spun at 1000 rpm for 10 seconds. Negative control tube
was added to the thermocycler first, then the samples. The positive control template was obtained
from -20°C and prepared by adding 2 µl of stock template to 2 µl of nuclease-free water, 5 µl of
positive template was added to the positive control tube which was then placed this into the
thermocycler away from the samples and negative control. Standard-3 (STD-3) program was
used in thermocycler for 35 cycles with the following settings:
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94˚C for 30 seconds
94˚C for 30 seconds

35 times

60˚C for 2 minutes
72˚C for 60 seconds
72˚C for 5min
4˚C forever (hold)

Remaining samples (in Buffer solution) were stored in -20˚C freezer overnight. A 1%
agarose gel was poured (with 10 µl of 10 mg/ml ethidium bromide) and this was stored overnight
at 4˚C. TAE buffer (0.5X) was prepared by adding 5 ml of 50X TAE to 495 ml of nanopure Water,
or 10ml of 50X TAE to 990 ml water, and was mixed thoroughly to store at 4˚C.
To analyze the samples on agarose gel, reaction PCR tubes and controls were pulse spun
(using eppendorf adapters) at 1000 rpm for 10 seconds. After setting up the agarose gel and 0.5X
TAE buffer in the appropriate apparatus, 2 µl of 6X loading dye was added to each sample and
controls. 5 µl of DNA ladder, 10 µl of samples and controls were loaded. The agarose gel was run
at 150V for approximately 1 hour and images were viewed/captured under UV light (using UV
protective shield).

Cellular Treatments
Temsirolimus (TEMS, #50-811-7, Fisher Scientific, Pittsburgh, PA): TEMS, an mTOR inhibitor,
was prepared by dissolving the powder in dimethyl sulfoxide (DMSO) at 10 mM concentration and
filter sterilized using a 0.22-micron filter. 50 µM sub-stock was prepared by dissolving the 10 mM
stock in respective media for each cell line, to be used at a final concentration of 10 µM. Control
sample was prepared by adding similar volume of DMSO in respective media.
Hydroxychloroquine (HCQ, AC263011000, Fisher Scientific, Pittsburgh, PA): HCQ, an
inhibitor of autophagic flux, was prepared at 50 mM stock concentration in phosphate buffer saline
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(PBS) and filter sterilized using 0.22-micron filter. 25 µM final concentration was used by dilution
into respective media for each cell line.
Oleic acid (#O1383, Sigma-Aldrich, St. Louis, MO): OA, an unsaturated fatty acid, was
prepared in siliconized glass tubes by dissolving the stock solution in 100% ethanol to generate
a 0.354 M solution stock followed by filter sterilization using a 0.22-micron filter. Sub-stocks were
also prepared in siliconized tubes with 100% ethanol to use at a final concentration of 0.25 mM
in respective media for each cell line.
Fatty acid-free bovine serum albumin (FAF-BSA, BP9704-100, Fisher Scientific,
Pittsburgh, PA): FAF-BSA as a control for OA was prepared by dissolving in respective media for
each cell line to prepare 10% BSA solution, which was then used at 1% final concentration in OA
treatment. A similar concentration of FAF-BSA was used for control treatments, along with
respective media and 100% ethanol. Alternatively, FAF-BSA utilized for lysophosphatidic acid
(LPA) was prepared in PBS at a 0.5% stock concentration.
1-Oleoyl-2-hydroxy-sn-glycerol-3-phosphate (sodium LPA salt in chloroform, #857130C,
Avanti Polar Lipids, Alabaster, AL): LPA, a bioactive phospholipid, was prepared in siliconized
glass tubes. The aliquoted LPA was air-dried, followed by addition of FAF-BSA to prepare a 3.5
mM stock. Ten micromolar final concentration was prepared in respective media.
U0126 (#9903S, Cell Signaling Technology, Danvers, MA): U0126, a MAPK inhibitor, was
prepared in DMSO for a 10 mM stock concentration and was then used at final concentration of
10 µM by adding it directly in respective media.
Combinatorial treatments of U0126 and LPA was done by first adding 10 µM of U0126,
followed by a one-hour incubation at 37°C followed by the subsequent addition of 10 µM LPA.
5-Azacytidine (Aza, #S1782, Selleck Chemicals, Houston, TX): Aza, a nucleoside cytidine
analog, was used for inhibition of DNA methyltransferases. A 50 mM stock was prepared by
adding 1 mg of Aza powder into 81.9 µl of DMSO. 500µM sub-stock was prepared in respective
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complete media and filtered using a 0.22-micron filter and then added directly at doses ranging
from 0.5 µM to 10 µM.
Vorinostat or suberoylanilide hydroxamic acid (SAHA, #S1047, Selleck Chemicals,
Houston, TX): SAHA, a histone deacetylase inhibitor, was prepared as 50 mM stock by adding 1
mg powder into 75.7 µl of DMSO. Sub-stock at 500 µM dose was prepared in respective complete
media and filtered using a 0.22-micron filter and then added directly at doses ranging from 0.5
µM to 50 µM. Final concentrations selected for combinatorial treatment were 1 µM Aza and 50
µM SAHA, 24-hour post-seeding.

Knockdown via siRNA Transfection
HK-2 cells were seeded at 350,000 cells/well in six-well plates while FT194 cells were seeded at
500,000 cells/well in six-well plates or 1,000,000 cells/dish in 60 mm dishes. Following overnight
adherence, cells were treated with ON-Target Plus non-targeting control siRNA (#D-001810-1020, Dharmacon (Lafayette, CO, USA)) as control; EVI1-targeting siRNA (siB, custom designed
as described previously) [19] was transfected into FT194 cells using RNAiMax (#13778-075,
Invitrogen, Carlsbad, CA, USA); ribosomal protein S6 (RPS6) siRNA (#L-003024-00-0005) and
ribosomal protein S6 kinase B1 (p70S6K1) siRNA (#L-003616-00-0005) was transfected in the
HK-2 cells using Dharmafect I (#NC1308404, Fisher Scientific, Pittsburgh, PA).
For transfection (post cell adherence), cell culture complete media was replaced with
serum-free media. Transfection mixture was prepared in eppendorf tubes with 100 µl serum free
media, 5 µl of respective siRNAs and 4 µl appropriate transfection reagent. The reaction mixture
was incubated at room temperature for 20 minutes and 100 µl of the reaction mixture was added
into respective wells in a spiral motion dropwise, followed by placing the dishes/plates gently back
to the incubator. Overlay with complete media was completed 3 hours post-transfection. Twentyfour hours post-transfection, cells were replenished with pre-warmed complete media and forty-
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eight hours post transfection these were used for further protein/miRNA/RNA isolation and
analysis.

miRNA mimic Transfection
Untreated and long-term FAC treated FT194 cells were seeded in 6-well plates at 250,000
cells/well and in 60 mm dishes at 500,000 cells/well. Next day after seeding (post cell adherence),
cells were transfected with 200pmol (100 µl) of respective mimics: control mimic (mirVana miRNA
mimic Negative control 1, #4464059, Life Technologies, Grand Island, NY) or hsa-miR-138-5p
(mirVana miRNA mimic, Assay ID# MC11727, Life Technologies, Grand Island, NY), hsa-miR432-5p (mirVana miRNA mimic, Assay ID# MC10941, Life Technologies, Grand Island, NY), or
hsa-miR-127-3p (mirVana miRNA mimic, Assay ID# MH10400, Life Technologies, Grand Island,
NY) using Fugene HD (Promega, Madison, MI).
Complete media in 6-well plates and 60mm dishes were replaced with serum free media.
Transfection mixture was prepared in cryovials by adding 100 µl serum free media, 4 µl of
respective miRNAs and 3 µl of Fugene HD. vials were flicked, tapped, and incubated at room
temperature for 15 minutes. These vials were flicked and tapped again followed by addition of
100µlreaction mixture into respective wells in a spiral motion dropwise, followed by placing the
dishes/plates gently back to the incubator. Overlay with complete media was completed 6 hours
post-transfection. Cells were recovered with pre-warmed complete media 24 hours posttransfection, and 48 hours post-transfection these were used for protein/miRNA isolation and
further analysis.

Protein Isolation and Western Blotting analysis
Total cell lysates were collected using previously described methods [234]. In brief, cells were
seeded at an appropriate density, most commonly 250,000 cells/well, unless otherwise specified.
Post-treatment, cells were lysed for 1 hour using the lysis buffer, containing 1 mM MgCl2, 150 mM
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NaCl, 1% Triton X-100, 10% glycerol, 1 mM EGTA, 50 mM HEPES and protease inhibitor tablet
(Roche, Madison, WI), with nanopure water. Following lysis, the cells were gently scraped with
cell scrapers and the cell extract was collected in eppendorf tubes. This was centrifuged at 14,000

Table 2: Antibodies list for Western Blotting analysis.
Antibody

Company

Catalog
numbers

Dilutions Secondary
antibody

ALDH1A2

Cell Signaling Technology 83805

1:1000

Rabbit Polyclonal

Acetyl Histone

Cell Signaling Technology 9677

1:1000

Rabbit polyclonal

ATG7

Molecular biolabs (MBL)
International

PM039

1:1000

Rabbit Polyclonal

Beclin-1

Cell Signaling Technology 3738S

1:1000

Rabbit Polyclonal

B-catenin

Cell Signaling Technology 9587

1:1000

Rabbit polyclonal

BMI1

Cell Signaling Technology 6964

1:1000

Rabbit monoclonal

Cas9

Cell Signaling Technology 14697

1:1000

Mouse monoclonal

Cyclin D1

Santa Cruz biotechnology sc-718

1:1000

Rabbit polyclonal

Cyclin E

Santa Cruz biotechnology sc-247

1:500

Mouse monoclonal

CRYAB

Cell Signaling Technology 45844

1:500

Rabbit Monoclonal

DRP1

Cell Signaling Technology 8570

1:1000

Rabbit Monoclonal

DNMT1

Cell Signaling Technology 5032

1:1000

Rabbit Monoclonal

EVI1

Cell Signaling Technology 2593

1:500

Rabbit Monoclonal

hVPS34

Cell Signaling Technology 3358

1:1000

Rabbit Monoclonal

ITGA2

Invitrogen (ARCO457)

MA5-35243 1:1000

Rabbit monoclonal

LC3B

Cell Signaling Technology 2775

1:1000

Rabbit Polyclonal

MAPK

Cell Signaling Technology 4695S

1:1000

Rabbit Monoclonal

p-AKT (Ser 473)

Cell Signaling Technology 4060

1:1000

Rabbit Monoclonal

p-AKT (Thr 450)

Cell Signaling Technology 9267

1:500

Rabbit Polyclonal

H3 (Lys9/Lys14)
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Table 2 (Continued)
p-AKT (Thr 308)

Cell Signaling Technology

9275

1:500

Rabbit Polyclonal

Pan-AKT

Cell Signaling Technology

4685

1:1000

Rabbit Monoclonal

Pan-Actin

Cell Signaling Technology

4968

1:1000/1:500Rabbit Polyclonal

PARP

Cell Signaling Technology

9542

1:1000

Rabbit Polyclonal

p-DRP1 (Ser-616) Cell Signaling Technology

4494

1:1000

Rabbit Monoclonal

Perilipin

Santa Cruz Biotechnology

SC-390169

1:500

Mouse Monoclonal

p-GSK3

Cell Signaling Technology

9331S

1:1000

Rabbit Polyclonal

p-MAPK (p42/44)

Cell Signaling Technology

9101

1:750

Rabbit Polyclonal

p-S6 (Ser 235/236) Cell Signaling Technology

4858

1:1000

Rabbit Monoclonal

P62

BD biosciences

610832

1:1000

Mouse Monoclonal

P21

Cell Signaling Technology

2946

1:500

Mouse monoclonal

Pax8

Proteintech

10336-1-AP 1:1000

Rabbit polyclonal

p70S6K

Cell Signaling Technology

2708P

1:1000

Rabbit Monoclonal

TOM20

Santa Cruz Biotechnology

SC-11415

1:7500

Rabbit Polyclonal

TOM40

Santa Cruz Biotechnology

SC-365467

1:1000

Mouse Monoclonal

TOM70

Santa Cruz Biotechnology

SC-390545

1:1000

Mouse Monoclonal

S6

Cell Signaling Technology

2217S

1:1000

Rabbit Monoclonal

rpm for 10 minutes and the supernatant was extracted. Bicinchoninic acid (BCA) assay kit (Pierce,
Fischer Scientific, Pittsburgh, PA) was then used to determine the protein concentration, and all
protein samples were normalized to the minimum concentration determined or 1500 ng,
whichever was lowest. These lysates were analyzed by running on 8%, 10% or 12% SDS-PAGE
gel followed by western blotting analysis using respective antibodies, as mentioned in table 2.

Densitometric Analysis for Western Blots via Image J
For densitometric analysis of western blot, the loading control (most commonly Pan-Actin) was
first quantified, followed by analysis of the experimental bands in question and their comparison
with the loading control as follows:
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For quantification, scanned image of the loading control western blot was opened using
ImageJ software. The desired bands were selected with rectangular box tool (default selection).
Where the bands were not already horizontal, “Image->Transform->Rotate” function was used to
make the bands horizontal. “1 and Yes” were typed and clicked, respectively. The rectangular
box was then dragged to a clear area on the blot, followed by selection of “2” then “3” to generate
a plot. Lines were then drawn at the troughs between peaks (also on both ends of the plot),
ensuring they were completely vertical and extended to the bottom of the plot. Using the wand
tool, the peaks on the top plot were then selected and then the generated values were copied into
Excel. Then, using the wand tool, the peaks on the bottom (background) plot were selected and
values generated were then copied into Excel. The background was then subtracted from the total
density (total – background) and utilized to plot onto an appropriately labelled column graph.
These were then saved as “Tiff” images. These steps were repeated for all sample sets for all blot
exposures. The optimal exposure time(s) was identified and then utilized for normalization.
For the second part of densitometric analysis, the experimental image bands were
quantified using the loading control analysis. The original Western blot page scan was opened
using ImageJ software and a densitometric plot was generated as mentioned above. Appropriate
loading control plot (same replicate, same side of the blot) was opened and lined up with
experimental antibody plot. Vertical lines were drawn on antibody plot in the same places as on
the loading control plot and total density and background values were coped into Excel file as
mentioned above. Then, background value was subtracted from the total density (total –
background), appropriate loading control values were copied, and density values were
normalized. Normalized values were used to generate a column graph. Densitometry plot and
Western blot images were saved as “Tiff” images. These steps were repeated for every replicate
on every set of samples for every antibody used, for multiple exposures (if possible/applicable)
and the excel file was saved.
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miRNA Isolation
Forty-eight hours post-transfection or 24 hours post-treatment, miRNAs were isolated using the
mirVana Isolation Kit (#AM1561, ThermoFisher Scientific, Waltham, MA, USA) following the
manufacturer’s instructions, with modifications described below. Before starting the process, the
phenol-chloroform bottle was placed in the fume hood to thaw. Once thawed, the phenol
chloroform was mixed thoroughly by inversion multiple times to ensure homogeneity followed by
maintenance at room temperature to enable separation of the layers.
PBS (2 ml) was added to each dish for a washing step, followed by aspiration to dryness. Lysis
buffer (~450μl or depending on the cell confluency) was then added to each dish and scraped
lightly using a P1000 tip, followed by collection to respective tubes. Forty-five microliters of miRNA
homogenate additive (containing 2 M sodium acetate) were added to the samples and mixed by
inversion followed by incubation on ice for 10 minutes. Next, 450 μl phenol-chloroform (equal
volume to the lysis buffer) was added to the samples in the fume hood (by bubbling method).
Each sample was then vortexed for 30 seconds and centrifuged at 10,000 rcf for 10 minutes.
After centrifugation, ~150 μl (on top of the interface) of clear liquid was carefully collected
from the top aqueous layer. 1.25X volume 100% ethanol was added, followed by mixing and
layering on top of a filter cartridge inside a collection tube. This was centrifuged at 10,000 rcf for
20 seconds. This was followed by an initial wash step using 700 μl of Wash Solution 1 and
centrifugation at 10,000 rcf for 10 seconds. After discarding the flow-through, 500 μl of Wash
Solution 2/3 was added and centrifuged at 10,000 rcf for 10 seconds. During this centrifugation,
a tube with an appropriate volume of RNAase free water was placed into a heating block set at
95°C. After centrifugation, the flow-through was discarded and 500μl of Wash Solution 2/3 was
again added, followed by centrifugation at 10,000 rcf for 2 minutes. The flow-through was
discarded and the tubes were centrifuged at 10,000 rcf for 1 minute to remove any residual
volume. The filter cartridge was then transferred to fresh eppendorf tubes and 25μl of 95°C heated
RNase free water was added followed by centrifugation at maximum speed (14,000 rpm or 20,817
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rcf) for 30 seconds and filter cartridge was discarded. miRNAs that were eluted were then
quantified using the Nanodrop and stored at -80°C freezer for subsequent qPCR analysis.

miRNA - qPCR Analysis
Two different methods for qPCR of miRNA samples were utilized and these are described below
as Method 1 and Method 2:
Method 1: 100 ng/µl of miRNA dilution was prepared for each miRNA sample and 167 ng
(1.67 µl) per sample was ultimately used. cDNA was first generated using the Reverse
Transcription kit (#4366596, Applied Biosystems™ TaqMan™ MicroRNA Reverse Transcription
Kit). Arrangement of samples on thermocycler block was recorded and temperature changes
monitored. Real-time PCR was then performed using the TaqMan RNA-to-CT 1-Step Kit
(#4392938, ThermoFisher Scientific, Waltham, MA, USA) with the respective probes and primers
as described in Table 9, set up in clear 96-well qPCR plates (#AB0600, Thermo Scientific™ PCR
Plate). The fold-change in miRNA expression was calculated using the 2-ΔΔCT correlative method,
in which Ct values were normalized to the RNU6B control (assay ID #: 001093, ThermoFisher
Scientific, Waltham, MA, USA). A sample calculation with detailed steps is shown below.

Example:
I.

Generation of Reverse Transcription (RT) Master Mix:

2 samples for any three miRNA analyses (2 samples X 3 miRNAs at 2.33 µl /reaction)
2.33 X 6= 13.98 µl required for each miRNA
To prepare 15 µl total RT master mix:
Nuclease free Water: 2.3961 µl
10 mM dNTPs: [(2.143/10) *15] = 3.2145 µl (final concentration = 2.413mM)
10X RT Buffer: [(1.5/7) *15] = 3.214 µl
RNase inhibitor (2U/µl): [(0.5434*15)/2] = 4.0755 µl (final concentration = 0.5434U/µl)
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RT Multiscribe Enzyme: (15/7) = 2.1428 µl
Total: 15 μl
To prepare 10mM dNTP sub-stock:
(100mM) (x) = (10mM) (4 µl)
X= 0.4 µl stock + 3.6 µl water
To prepare 2U/µl RNase inhibitor sub-stock:
(20u/µl) (x) = (2U/µl) (5 µl)
X = 0.5 µl stock + 4.5 µl water
•

First, 2.33 µl reaction mix/ tube was added, followed by 1.67 µl miRNA dilution and 1 µl
5X RT primer.

•

This was mixed by swirling and was centrifuged briefly (1000 rpm for 5 seconds) to collect
the contents at the bottom.

Total 5 μl RT reaction/ PCR tube was generated.
•

PCR tubes were placed on ice and proceeded to RT reaction in thermocycler:

Cycle conditions in thermocycler:
30 minutes 16°C; 30 minutes 42°C; 5 minutes 85°C; 4°C Forever
II.

qPCR Reaction

Number of reactions for three miRNA analyses (in 3 different qPCR master mix tubes) –
For each: 2 reactions*2 (Duplicates) + 1 extra -> n=5
Master mix:
PCR Mix: 10 μl X 5 = 50 µl
Water: 7 μl X 5 = 35 µl
Primer: 1 μl X 5 = 5 µl
Master mix 18 µl was added to each well +2 μl RT product (cDNA)
Total 20 µl reaction was set up to run at the following cycle conditions:
10 minutes 95°C (holding stage)
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50 cycles (cycling stage):
15 seconds 95°C
60 seconds 60°C
Method 2: 250 ng of each miRNA sample was utilized. cDNA was generated first using
the Reverse Transcription kit (#4366596, Applied Biosystems™ TaqMan™ MicroRNA Reverse
Transcription Kit). cDNAs for all miRNA samples was generated in duplicate and a non-template
water control was prepared in duplicate as well for comparison. Arrangement of samples on
thermocycler block was recorded and temperature changes were monitored. Real-time PCR was
then performed using the TaqMan RNA-to-CT 1-Step Kit (#4392938, ThermoFisher Scientific,
Waltham, MA, USA) with the respective probes and primers as mentioned in Table 3, set up in
clear 96-well qPCR plates (#AB0600, Thermo Scientific™ PCR Plate). Each cDNA duplicate
sample was loaded in duplicates again, ultimately generating quadruplets for each miRNA
sample. The fold-change in miRNA expression was calculated using the 2-ΔΔCT correlative method,
in which Ct values were normalized to the RNU48 control (assay ID #: 001006, ThermoFisher
Scientific, Waltham, MA, USA). The reason for selecting an alternative endogenous control
(RNU48) in this method was based on prior experimentation showing variability in RNU6B values
between different renal cancer cell lines. The literature evidence supports RNU48 as one of most
common normalization probes [235, 236], which also proves to be an appropriate endogenous
control for renal cell lines under our experimental conditions. A sample calculation with detailed
steps is shown below.
Example:
To prepare miRNA dilution – Example sample concentration: 444.575 ng/µl
RNA stock was added 2.728 µl stock + 12.272 µl water (15 µl total volume) to generate 80.8617
ng/ µl sub-stock
This will be added to the 5 µl final cDNA sample to generate 250 ng concentration.
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To Generate Master Mix for RT reaction- 10XRT buffer was added first, followed by dNTPs,
RNAse inhibitor and Multiscribe RT enzyme. cDNA generation was done in duplicate, therefore,
number of reactions required to prepare 5 samples (duplicates)= 10 + 2 non-template controls =
12 for each miRNA -> 2 miRNAs: 12*2 = 24
PCR tubes were taken for 24 reactions and prepared enough for 26 reactions (2 extra):
I.

RT reaction set up in a PCR tube:

For RT reaction master mix (5 µl total cDNA reaction):
•

100 mM dNTPs stock: Final concentration 0.25 mM

(100 mM) (x) = (0.25 mM) (5 µl)
X = 0.0125 µl
0.0125 µl X 26 = 0.325 µl
•

10X RT Buffer: Final concentration 1X

(10X) (x) = (5 µl) (1X)
X = 0.5 µl 10X RT buffer in one reaction
0.5 µl X 26 = 13 µl
•

RNase inhibitor (20 U/ul): Final concentration 0.25 U/µl

(20 U/µl) (x) = (0.25 U/µl) (5 µl)
X= 0.0625 µl
0.0625 µl X 26= 1.625 µl
•

RT Multiscribe Enzyme (50 U/µl): Final concentration 3.33 U/ul

(50 U/µl) (x)= (3.33 U/µl) (5 µl)
X= 0.333 µl in one reaction
0.333 X 26= 8.658 µl in total master mix
Total 0.9083 µl in one reaction.
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•

Master mix was mixed by swirling and the appropriate volume (0.9083 µl) was added to
all the PCR tubes.

•

RT primer was flicked and tapped before opening. RT primer (5X at 1 µl) was added to
the respective tubes, spraying the pipette thoroughly between different primers.

•

miRNA sub-stock 3.0917 µl of 80.8617ng/µl was added to the respective PCR tubes to
generate 250 ng final concentration in one cDNA sample.
Overall, 0.9083 µl RT master mix + 1 µl RT Primer+ 3.0917 µl miRNA dilution were added
to each tube.

•

These tubes were spun down at 1000 rpm for 20 seconds in the empty (without lid) tubes.

•

PCR tubes were kept in the block and made note of where the tubes were being placed.

Cycle conditions in thermocycler: 30 minutes 16°C; 30 minutes 42°C; 5 minutes 85°C; 4°C
Forever
II.

qPCR Reaction:

For 10 sample cDNA duplicates+2 non template control) for each miRNA= 12
Samples = 12*2 (duplicates)= 24+ 2 extra = 26 reactions for each miRNA
5 µl 2X PCR mix X 26 = 130 µl
0.5 µl Tm primer X 26 = 13 µl
3.83 µl water X 26 = 99.58 µl
Master mix (9.33 µl) was added to the respective wells in duplicates. After RT reaction was done
(~1 hour 10 minutes), appropriate volume (0.67 µl) was added to the appropriate master mix
added in the wells. Overall, 9.33 µl per well + 0.67 µl RT product = Total 10 µl reaction set up at
the following cycle conditions:
10 minutes 95°C (holding stage) ; 50 cycles (cycling stage)
15 seconds 95°C; 60 seconds 60°C
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Table 3: miRNA probes and primers information list utilized in these studies.
miRNA Probes/Primers

Assay ID (50RT/150 PCR reactions)

miR-432-5p

001026

miR-127-3p

000452

miR-138-5p

002284

miR-493-5p

001040

miR-431-5p

001979

miR-411-5p

001610

miR-495-3p

001663

miR-539-5p

001286

miR-323b-3p

244080_mat

miR-410-3p

001274

miR-433-5p

001028

miR-494-5p

002365

RNA Isolation and qPCR Analysis
Total RNA was isolated using the RNeasy Mini kit (QIAGEN, Valencia, CA) according to the
manufacturer’s instructions and previously published methods [19, 234]. Real-time PCR utilized
the TaqMan RNA-to-CT One-Step Kit (#4392938, ThermoFisher Scientific, Waltham, MA) and
the FAM-labelled probes and primers, as mentioned in table 4. β-actin (#401846, ThermoFisher
Scientific, Waltham, MA) and/or Cyclophilin (PP1A, # Hs04194521_s1, ThermoFisher, Waltham,
MA, USA) were used as endogenous controls, as appropriate for each experimental condition.
RNA-fold changes were calculated using the 2−ΔΔCT method.

LipidTOX Staining
Lipid Droplet staining was performed as previously reported [237]. Briefly, HK-2, 769-P, 786-O
and A-498 cells were seeded at 250,000 cells/well onto glass coverslips in 6-well plates. After
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overnight attachment, cells were treated with 10 µM TEMS or with 0.25 mM oleic acid for 24
hours. The media was then removed from the cells and rinsed with 2 ml PBS. The cells were next
fixed with 1 ml 4% formaldehyde (in PBS) for 30 minutes at room temperature. Three 2 ml PBS

Table 4: List of RNA qPCR probes/primers utilized in these studies.
RNA qPCR Probes/Primers

Assay ID

Phospholipid Phosphatase 1 (PLPP1)

Hs00170356_m1

Diacylglycerol O-acyltransferase 2 (DGAT2)

Hs01045913_m1

Perilipin 1 (PLIN1)

Hs00160173_m1

Cell death-inducing DFFA-like effector c
(CIDEC)

Hs00535724_gH

Adipose Triglyceride Lipase (ATGL/PNPLA2)

Hs00386101_m1

Autotaxin (ATX/ENPP2)

Hs00905117_m1

hTERT

Custom designed:
Forward Primer: 5’CGCAGGGCTCCATCCT-3’
Reverse Primer: 5’TCCCCGCAAACAGCTTGT-3’
Probe Sequence: 5’CTCTGCAGCCTGTGCTAC-3’

washes (5 minutes each) were performed, following which 500 µl of 1:400 dilution of the lipidTOX
green neutral lipid stain (#H34475, Life Technologies, Grand Island, NY) in PBS was added for 1
hour at room temperature. After incubation, lipidTOX stain solution was discarded and 2 ml PBS
was added as a rinse solution. The cover slips were next mounted onto glass slides containing
20 μl DAPI. Slides were viewed and imaged at 63X (oil immersion) magnification using the
PerkinElmer UltraVIEW Confocal spinning disc microscope (CMMB Core Facility, University of
South Florida, Tampa, Florida).
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Image J analysis of Lipid Droplets
LipidTOX stained immunofluorescence images were analyzed using Image J to quantify LD size
(area covered by LD) and number (number of particles). From the “Image” option, the “color
threshold” of the images was selected. This was then adjusted by using the Hue, Saturation,
Brightness (HSB) color model; the hue and saturation were kept constant at 0 and the brightness
using the red threshold color was adjusted but kept consistent for different treatments within an
independent experiment to allow appropriate comparison to facilitate an unbiased analysis. LDs
within each image were analyzed for the number of LDs as well as the area covered by each
droplet by selecting “Analyze particles” and setting the size limit: “0 to infinity”. This provided a list
of number and sizes of LDs associated with each particle. This was then copied into an excel file
and the total number of LDs and their sizes were calculated for each image with respect to the
total number of cells present (i.e., number of DAPI stained nuclei within the image) to obtain the
total area covered by LDs per cell as well as the total number of LDs per cell. The values obtained
from treated samples were normalized to the values obtained from the corresponding untreated
samples. This was used to generate appropriate graphs representing the LDs size and numbers
corresponding to each experimental treatment.

Immunofluorescence
Immunofluorescence staining methods have been previously described [237, 238]. Briefly, HK-2,
769-P, 786-O and A-498 cells were seeded onto glass coverslips at 250,000 cells/well (in 6-well
plates). After overnight attachment, cells were treated with 10 µM TEMS or with 0.25 mM oleic
acid for 24 hours. Next day, the media was discarded, and cells washed with 2 ml PBS. The cells
were then fixed with 1 ml/well 4% formaldehyde (prepared in PBS) for 30 minutes. This was
followed by rinsing with 2 ml PBS and incubation with 1 ml/well blocking solution (1 ml blocking
solution was prepared by adding 50 µl of 100% goat serum to generate 5% final concentration; 5
µl of 20% Triton X-100 to generate 0.1% final concentration and 945 µl PBS) at room temperature
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for 1 hour. The cells were then rinsed again with 2 ml PBS. The coverslips were then placed into
respective primary antibody (50µl each) onto petri dishes overnight inside a humidifying chamber
at 4°C. Primary antibody was next prepared (1% goat serum, 0.1 % Triton X-100 and appropriate
volume of primary antibody, at an appropriate concentration, in PBS). Mitochondrial networks
were assessed using antibodies targeting TOM20 (1:100) or TOM70 (1:100) followed by
incubation using the appropriate fluorophore-conjugated secondary antibodies. The secondary
antibody was prepared (1% goat serum, 0.1% Triton X-100 in PBS) at 500µl for each coverslip.
The coverslips were removed from the petri dishes inside the humidifying chamber and placed
into respective wells containing 2ml PBS. The cells were then washed with 2 ml PBS three times,
each for 5 minutes. The secondary antibody was then applied dropwise to the center of coverslip
and incubated for 1 hour at room temperature. PBS (2 ml) was added 3 times, each for 5 minutes.
Coverslips were next mounted onto glass slides containing 20 µl anti-fade DAPI solution, which
were viewed and imaged using the 63X objective (oil immersion) on the PerkinElmer UltraVIEW
Confocal spinning disc microscope (CMMB Core Facility, University of South Florida, Tampa,
Florida). For quantification, the mitochondrial patterns were categorized according to the following
five categories: (1) Tubular elongated; (2) Tubular shortened; [27] Tubular shortened fragmented;
(4) Fragmented mitochondria; and (5) Fused not elongated [18]. One hundred cells per sample
were assessed and cells were assigned to these five categories.

Crystal Violet Cell Viability Assay
First, 160 ml of nanopure water was added to the stock CV stain bottle. Methanol (40 ml) was
measured in a 50 ml tube and added to the water inside the CV stain bottle. One gram of 0.5%
crystal violet powder was next added to the bottle followed by mixing by gently swirling.
HK-2, 769-P, 786-O and A-498 cells were seeded in a 96-well plate at 7,500 cells for
TEMS and OA treatment; 769-P and 786-O cells were seeded at 4,000 cells per well and 786-O
and A-498 cells at 2000 cells/well in 96-well plate for HCQ and TEMS combinatorial treatment;
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and HK-2 cells were seeded at 125,000 cells per well in a 6-well plate. After cellular treatment for
appropriate time periods, cells were stained with 100 µl with crystal violet for 15 minutes, followed
by extensive washing with nanopure water and overnight drying. Next day, 200 µl of Sorenson’s
buffer was added to each sample for solubilization and incubated for 2 hours at room temperature
on a rotating platform, followed by reading at 570 nm with a Biotek plate reader according to
previously published methods [237, 239].

Total Cholesterol Measurement
769-P and HK-2 cells were seeded at 125,000 cells whereas 786-O and A-498 cells were seeded
at 62,500 cells in 6-well plates; all cells were kept in culture for 72 hours. Total protein lysates
were collected and normalized using the BCA assay as previously described [234]. In these
samples, the Amplex Red Cholesterol Assay Kit (#A12216) obtained from Life Technologies
(Grand Island, NY) was utilized to assess total cholesterol levels as previously described [237].
Briefly, the cholesterol standards were prepared as detailed in table 5.
Table 5: Cholesterol assay standard concentrations and composition.
Concentrations
(µg/ml)

Component H (Cholesterol
reference standard) (µl)

IX Reaction buffer (µl)

0

0

1000

2.5

1.25

998.75

5.0

2.5

997.50

7.5

3.75

996.25

10

5

995

Next, 1X reaction buffer was prepared by adding 2 ml of 5X reaction buffer to 10 ml of
nanopure water (5X reaction buffer contains: 0.5 M potassium phosphate (used to maintain pH
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7.4), 0.25 M NaCl, 25 mM cholic acid and 0.5% Triton X-100). The Amplex Red working solution
was then prepared as follows:
1X Reaction buffer (thaw at room temperature and keep on ice): 1205 µl
Amplex red (at room temperature): 18.75 µl
HRP (on ice): 12.5 µl
Cholesterol oxidase (on ice): 12.5 µl
Cholesterol esterase (on ice): 1.25 µl
The positive controls were prepared by diluting the 20 mM H2O2 working solution to 10 μM in 1X
Reaction Buffer by adding 0.25 μl in 500ul 1X reaction buffer. Standards (50 µl) were next added
to a black 96-well plate in duplicate. The positive control was added (50 μl) to a black 96-well
plate. No cholesterol control (negative control) was prepared directly in well by adding 10μl of
RPPA lysis buffer followed by 40 μl of 1X reaction buffer. Next, 10 µl sample was added to the
plate followed by 40 μl of 1X reaction buffer. The pre-prepared Amplex Red solution was next
added to all the standards, controls, and samples (50 µl). The plate was then incubated for 30
minutes at 37°C. The fluorescence was then measured in a fluorescence microplate reader using
an excitation in the range of 528/20 nm with an emission at 590/35 nm.

Mammalian Antibiotic Selection for Stable Cell Line Generation
For identification of an appropriate antibiotic dose for stable cell line generation, cells were seeded
in 96-well plate. Cells were generally seeded at 2500 cells/well for half plate and 5000 cells/well
(96-well plate subdivided in half), except for the primary normal RPTEC cells which were seeded
at 2500 cells/well density (due to limiting cell numbers).
Following overnight adherence, cells were next treated with the appropriate doses of antibiotics
(puromycin or blasticidin in combination with puromycin) along with a control column of cells
(untreated). 48-hours post-treatment, the plates were removed from the incubator for CV staining
(please see CV staining section for details).
47

Proteomics and microarray analysis
Please refer to Chapter 4 for detailed methodology.

Bioinformatics analysis of EVI1 at miR-138 promoter site
Please refer to Chapter 4 for detailed methodology.

Table 6: Antibiotic doses for selection of stable cell lines used via CRISPR-Cas9.
Cell Line

Antibiotic

Dose selected

RPTEC

Puromycin

0.75 µg/ml

HEK293T

Puromycin

2 µg/ml

HEK293T

Blasticidin

3.5 µg/ml

HK-2

Puromycin

0.1 µg/ml

769-P

Puromycin

1 µg/ml

786-O

Puromycin

1 µg/ml

A-498

Puromycin

1 µg/ml

FT194-FAC

Puromycin

0.75 µg/ml

FT194-FAC

Blasticidin

5 µg/ml

Chronic Iron exposure of FTSECs
Please refer to Chapter 4 for details and Dr. Stephanie Rockfield’s thesis (pages 108-109). The
detailed timeline for maintenance of long-term iron (Ferric ammonium citrate (FAC)) treated and
untreated FT194 cells is located on the Cloud Box storage drive at the University of South Florida
in Stephanie Rockfield’s “Experimental_Results_2018” within the subfolder “Mar 5 through Mar
11”:” FT194 Rep 1 Timeline” and “Updated Timeline for FT194 cells”.
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Statistical analysis
All data obtained was analyzed using the Graphpad Prism software, version 6.04 (La Jolla, CA,
USA). Error bars represent the mean  SD and p-values were determined through the nonparametric Student’s t-test for which “ns” represents non-significant values, * indicates p ≤ 0.05,
** indicates p ≤ 0.01, *** indicates p ≤ 0.001, and **** indicates p ≤ 0.0001. Fold changes and
percent reductions were calculated from the average of at least three independent experiments.
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Chapter 3
Lysophosphatidic Acid reverses Temsirolimus-induced changes in lipid droplets and
mitochondrial networks in renal cancer cells
Note to Reader
This chapter is a reorganized and reformatted version of the published article (Chhabra R,
Nanjundan M. PLoS One. 2020 Jun 3;15(6): e0233887. doi: 10.1371/journal.pone.0233887). This
has been reproduced here with an open access license from PLOS ONE (see Appendix A for
copyright permissions).
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Introduction
Renal cell cancer is one of the most common urological malignancies. Contributing factors to
disease pathogenesis include smoking, obesity, as well as mutations in Von Hippel-Lindau (VHL)
[240]. Of the five major subtypes of RCC, clear cell RCC (ccRCC) is the most common and lethal
subtype; it is a metabolic disease characterized by dysregulated lipid metabolism, altered gene
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regulation due to multiple genomic aberrations, and increased abundance of lipid droplets [77,
114, 240, 241]. Regrettably, the overall patient survival rate is <15% for advanced RCC disease
[240] and thus an improved understanding of the underlying mechanisms of RCC pathogenesis
is direly needed to develop improved treatment regimens. There currently exists several first-line
targeted therapies which are FDA approved for ccRCC, including mTOR targeting agents [6]. The
PI3K/AKT/mTOR pathway is highly deregulated in ccRCC [242]; targeting mTOR (which
modulates cellular survival, blood vessel development, and nutrients) with rapamycin can
modulate LD formation [243]. Specifically, mTORC1 can regulate the lipogenesis and lipolysis
pathways via peroxisome proliferator-activated receptor gamma (PPAR-γ) and sterol regulatory
element-binding protein 1 (SREBP1) [242, 243]. Notably, LDs can physically associate with
mitochondria at defined contact sites; these organellar interactions promote cellular protection
from stress via the process of β-oxidation (the breakdown of fatty acids to acetyl-CoA, which can
then be utilized in the citric acid cycle to generate cellular energy) [244]. However, the role of
mTOR clinical targeting agents (including Rapalogs such as TEMS) [245] in the regulation of
mitochondrial networks and LD biogenesis has not yet been investigated in ccRCC.
mTOR inhibitors are associated with low clinical efficacy and this may be due to the
activation of the cytoprotective autophagic pathway (a “self-eating” mechanism) [246] which may
then antagonize the cell death promoting effects of such inhibitors. Indeed, improvements to
cellular sensitivity to mTOR inhibitors has been demonstrated by co-targeting of the autophagic
pathway [94]. In a phase I clinical trial combining TEMS with hydroxychloroquine (HCQ), there
was improved clinical response in melanoma patients [94, 247]. Another potential contributor to
diminished cellular sensitivity to mTOR inhibitors may include the presence of the potent lipid
mitogen, lysophosphatidic acid (LPA), which activates G-protein coupled receptors to increase
cellular proliferation, migration, and invasive potential via activation of the AKT pathway [248,
249]. This mitogen is produced via the action of autotaxin (ATX), a member of the endonucleotide
pyrophosphatase and phosphodiesterase family
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of

enzymes (ENPP2),

which elicits

lysophospholipase D (lysoPLD) activity (which hydrolyses lysophosphatidylcholine (LPC) to
generate LPA [248, 249]. Interestingly, ATX mRNA and protein in addition to its lysoPLD activity
are elevated in RCC (relative to normal epithelium) [135, 250, 251]. Furthermore, the LPA-ATX
axis can contribute to resistance against sunitinib in RCC pathogenesis [135]. Although a
derivative of LPA (phosphatidic acid, PA) has been shown to contribute to LD enlargement by
promoting their fusion [137], to the best of our knowledge, it remains unclear whether LPA can
modulate lipid droplet abundance, a key characteristic of ccRCC, in renal cancer cells.
Herein, we have analyzed the effect of TEMS in a series of ccRCC cell lines (769-P, 786O, and A-498) together with an immortalized normal human kidney cell line (HK-2) to identify
alterations in signaling, lipid droplet formation, and mitochondrial networks following treatment
with TEMS alone. We also assessed whether combinatorial treatment of TEMS with the
autophagic inhibitor, hydroxychloroquine (HCQ) could modulate cellular viability and lipid droplet
abundance. Finally, we investigated whether the presence of LPA could hinder the effect of TEMS
treatment in the ccRCC cell lines in terms of lipid droplet abundance and AKT/mTOR signaling.
Collectively, our results identify that the LPA-ATX signaling axis may be an important target for
combating the resistance acquired by RCC cells towards molecular-based therapies.

Materials and methods
Cell culture
Human epithelial renal cancer cell lines (769-P, 786-O, and A-498) and an immortalized kidney
proximal tubule cell line (HK-2) [252] were purchased from ATCC (Manassas, VA). HK-2 cells
were cultured in Keratinocyte-serum free media (K-SFM, #17-005-042, Fisher Scientific,
Pittsburgh, PA) supplemented with 50 µg/ml bovine pituitary extract (BPE, #10450-013) and 5
ng/ml human recombinant epidermal growth factor (EGF, #13028-014). 769-P and 786-O cells
were grown in RPMI 1640 media containing 8% fetal bovine serum (FBS) and 1%
penicillin/streptomycin whereas A-498 cells were cultured in EMEM media supplemented with 8%
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FBS and 1% penicillin/streptomycin. All cell lines used in this manuscript were authenticated by
Short Tandem Repeat (STR) profiling (Genetica DNA Laboratories, Cincinnati, OH) and were
tested to be mycoplasma negative. For the experiments presented in this manuscript, the above
cell lines were utilized at the following passage numbers: (1) 769-P cells, p = 41-54; (2) 786-O
cells, p = 113-127; [27] A-498 cells, p = 38-53; and (4) HK-2 cells, p = n+4 – n+20.

Cell treatments
A 10 mM stock of the mTOR inhibitor, Temsirolimus (TEMS, #50-811-7, Fisher Scientific,
Pittsburgh, PA) was prepared by reconstitution in dimethyl sulfoxide (DMSO) and used at a final
concentration of 10 µM. Oleic acid (#O1383, Sigma-Aldrich, St. Louis, MO) was reconstituted in
100% ethanol to prepare a 0.35 M solution, which was utilized at a final concentration of 0.25 mM.
The autophagic flux inhibitor, hydroxychloroquine (HCQ, AC263011000, Fisher Scientific,
Pittsburgh, PA), was prepared in phosphate buffered saline (PBS) at 50 mM and used at a final
concentration of 25 µM. The MAPK inhibitor, U0126 (#9903S, Cell Signaling Technology,
Danvers, MA), was reconstituted in DMSO at a concentration of 10 mM and utilized at a final
concentration of 10 µM.
Fatty acid-free bovine serum albumin (FAF-BSA, BP9704-100, Fisher Scientific,
Pittsburgh, PA) was dissolved in PBS to generate a 0.5% stock solution. 1-Oleoyl-2-hydroxy-snglycero-3-phosphate (sodium LPA salt in chloroform, #857130C, Avanti Polar Lipids, Alabaster,
AL) was air-dried and reconstituted in 0.5% FAF-BSA to generate a stock solution of 3.5 mM and
used at a final concentration of 10 µM.

siRNA transfections
HK-2 cells were seeded at 350,000 cells/well in 6-well plates. After overnight adherence, cells
were transfected with the following siRNA using Dharmafect I (#NC1308404, Fisher Scientific,
Pittsburgh, PA) according to previously published methods [19, 237]: ribosomal protein S6
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(RPS6) siRNA (#L-003024-00-0005), ribosomal protein S6 kinase B1 (p70S6K1) siRNA (#L003616-00-0005), or non-targeting ON-TARGETplus (D-001810-10-20) siRNA (Dharmacon,
Lafayette, CO). The day after transfection and following cell recovery, cells were treated with 10
µM LPA (or with an equivalent volume of 0.5% BSA) for 24 hours followed by protein analyses or
immunofluorescence LD staining (as described below).

Protein isolation and western analyses
Using previously published methodology [19, 234, 237], protein lysates were collected and
normalized to at least 1,000 µg/ml using the Bicinchoninic Assay (BCA, Fisher Scientific,
Pittsburgh, PA). The samples were then run on 10% SDS-PAGE gels and analyzed by western
blotting using primary antibodies at the following dilutions: (1) Beclin-1 rabbit polyclonal (#3738,
1:1000), DRP1 rabbit monoclonal (#8570, 1:1000), hVPS34 rabbit monoclonal (#3358, 1:1000),
LC3B rabbit polyclonal (#2775, 1:1000), p-AKT (Ser-473) rabbit monoclonal (#4060, 1:1000), pGSK3 (Ser-21/Ser-9) rabbit polyclonal (#9331, 1:1000), p-S6 ribosomal protein (Ser-235/236)
rabbit monoclonal (#4858, 1:1000), Pan-Actin rabbit polyclonal (#4968, 1:500), PARP rabbit
polyclonal (#9542, 1:1000), p-DRP1 (Ser-616) rabbit monoclonal (#4494, 1:1000), p-p42/44
MAPK (Thr-202/Tyr-204) rabbit polyclonal (#9101, 1:750), Pan-AKT rabbit monoclonal (#4685,
1:1000), p42/44 MAPK rabbit monoclonal (#4695, 1:1000), p70S6K rabbit monoclonal (#2708,
1:1000), and S6 rabbit monoclonal (#2217, 1:1000) which were obtained from Cell Signaling
Technology (Danvers, MA); (2) p62 mouse monoclonal (#610832, 1:1000) was obtained from BD
Biosciences (San Jose, CA, USA); [27] Perilipin mouse monoclonal (#SC-390169, 1:500), TOM20
rabbit polyclonal (#SC-11415, 1:7500), TOM40 mouse monoclonal (#SC-365467, 1:1000), and
TOM70 mouse monoclonal (#SC-390545, 1:1000) were obtained from Santa Cruz Biotechnology
(Dallas, TX, USA); and (4) ATG7 rabbit polyclonal (#PM039, 1:1000) from MBL International
Corporation (Woburn, MA, USA).
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RNA isolation and real-time PCR
Total RNA was isolated using the RNeasy Mini kit (QIAGEN, Valencia, CA) according to
previously published methods [19, 234]. Real-time PCR utilized the TaqMan RNA-to-CT OneStep Kit (#4392938, ThermoFisher Scientific, Waltham, MA) and the following FAM-labelled
probes and primers: (1) Phospholipid Phosphatase 1 (PLPP1), Hs00170356_m1; (2)
Diacylglycerol O-acyltransferase 2 (DGAT2), Hs01045913_m1;

[27] Perilipin 1 (PLIN1),

Hs00160173_m1; (4) Cell death-inducing DFFA-like effector c (CIDEC), Hs00535724_gH; (5)
Adipose Triglyceride Lipase (ATGL/PNPLA2) Hs00386101_m1; and (6) Autotaxin (ATX/ENPP2),
Hs00905117_m1. Normalization of CT values was performed using β-actin (#401846,
ThermoFisher Scientific, Waltham, MA) and RNA-fold changes were calculated using the formula
2−ΔΔCT.

Cell viability assay
Cells were seeded at 7,500 cells (Fig 2B) or at 4,000 cells (Fig 4C) per well in a 96-well plate or
at 125,000 cells per well (Fig 5B) in a 6-well plate. After cellular treatment for appropriate time
periods, cells were then stained with crystal violet for 15 minutes, extensive washing with
nanopure water, and overnight drying. Next, samples were solubilized with 200 µl of Sorenson’s
buffer, incubated for 2 hours at room temperature on a rotating platform, and then read at 570 nm
with a Biotek plate reader according to previously published methods [237, 239].

Mitochondrial network staining via immunofluorescence
Immunofluorescence staining methods have been previously described [237, 238]. Briefly, cells
were seeded onto glass coverslips at 250,000 cells/well (in 6-well plates). After overnight
attachment, cells were treated with 10 µM TEMS or with 0.25 mM oleic acid for 24 hours.
Mitochondrial networks were assessed using antibodies targeting TOM20 (1:100) or TOM70
(1:100) followed by incubation using the appropriate fluorophore-conjugated secondary
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antibodies. Coverslips were mounted using anti-fade solution (containing DAPI) onto glass slides
which were viewed and imaged using the 63X objective (oil immersion) on the PerkinElmer
UltraVIEW Confocal spinning disc microscope (CMMB Core Facility, University of South Florida,
Tampa, Florida). For quantification, the mitochondrial patterns were categorized according to the
following five categories: (1) Tubular elongated; (2) Tubular shortened; Tubular shortened
fragmented; (4) Fragmented mitochondria; and (5) Fused not elongated [237]. One hundred cells
per sample were assessed and cells were assigned to these five categories.

Lipid droplet (LD) staining using LipidTOX
LD staining was performed as previously reported [237]. Briefly, cells were seeded at 250,000
cells/well onto glass coverslips in 6-well plates. After overnight attachment, cells were treated with
10 µM TEMS or with 0.25 mM oleic acid for 24 hours. LDs were stained using LipidTOX neutral
lipid dye. Slides were viewed and imaged at 63X (oil immersion) magnification using the
PerkinElmer UltraVIEW Confocal spinning disc microscope (CMMB Core Facility, University of
South Florida, Tampa, Florida).
LipidTOX stained immunofluorescence images were analyzed using Image J to quantify
LD size (area covered by LD) and number (number of particles). The color threshold of the images
analyzed were adjusted by using the Hue, Saturation, Brightness (HSB) color model; the hue and
saturation were kept constant at 0 and the brightness using the red threshold color was varied
but kept consistent for different treatments with an independent experiment to allow appropriate
comparison between them to facilitate an unbiased analysis. LDs within each image were
analyzed for the number of LDs as well as the area covered by each droplet (size: 0 to infinity).
The total number of LDs and their sizes were then calculated for each image with respect to the
total number of cells present (i.e., number of DAPI stained nuclei within the image) to obtain the
total area covered by LDs per cell as well as the total number of LDs per cell. The values obtained
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from treated samples were normalized to the values obtained from the corresponding untreated
samples.

Measurement of cholesterol
Total protein lysates were normalized using the BCA assay as previously described [237]. In these
samples, the Amplex Red Cholesterol Assay Kit (#A12216) obtained from Life Technologies
(Grand Island, NY) was utilized to assess total cholesterol levels as previously described [237].

Statistical analyses
All experiments were performed independently at least three times. The error bars shown in all
displayed figures represent standard deviations; p-values were obtained using the standard
student’s t-test using the GraphPad Prism software (**** = p ≤ 0.0001, *** = p ≤ 0.001, ** = p ≤
0.01, * = ≤ 0.05, and ns = not significant (p>0.05)).

Results
Comparative analyses of normal and a subset of malignant renal cell lines
It is well established that genomic aberrations are characteristic of numerous cancer types and
such alterations provide insight into patient survival as well as response to chemotherapeutic
regimens [253, 254]. In ccRCC, loss of 3p (which harbors the VHL gene) appears to be an
obligate event in RCC pathogenesis [254, 255]. The additional loss of chromosome 14q leads to
increased aggressiveness of ccRCC and is associated with a poor patient outcome [254, 256].
Apart from these 3p and 14q alterations, gain at 5q (harboring SQSTM1) is another common
alteration in ccRCC [54, 254]. To correlate responsiveness of ccRCC cell lines to established
forms of treatments with extent of genomic aberrations, we analyzed a subset of malignant clear
cell renal cell lines, via The Cancer Genome Atlas (TCGA) [257, 258]. Indeed, TCGA analysis
showed that 769-P cells contained the least percentage of genomic alterations at 17.9%, followed
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by 786-O at 43.9%, and A-498 at 61.5% (Fig 1A). Specifically, the 769-P and A-498 cells were
characterized by extensive deletions at both the 3p and 14q loci; however, although the 786-O
cell line contained 14q deletions, it was lacking chromosomal losses at the 3p locus.
Since the AKT/mTOR and autophagy pathway has been reported to be dysregulated in a
variety of tumors including ccRCC [242, 259, 260] with potential to alter chemotherapeutic cellular
response, we assessed the baseline expression and activation status of key signaling mediators
in the AKT/mTOR pathway across a subset of malignant renal cancer cell lines. As presented in
Fig 9B, the activation status of phospho-S6 was elevated in 769-P and 786-O cells relative to A498 cells whereas phospho-AKT was markedly elevated in 786-O and A-498 cells relative to 769P cells. These patterns, however, did not correlate with the 3p and 14q TCGA-defined extent of
genomic aberrations. Similarly, no association was uncovered with lipidated LC3B and other key
autophagic markers (Fig 9B) as identified by immunofluorescence LipidTOX staining and their
quality/abundance did not appear to be correlated with the extent of genomic alteration at 3p and
14q (Fig 9C). Since ccRCC is characterized by the presence of LDs [240, 241] and lipidomic
analyses have uncovered alterations within the lipidome [261], we next assessed the quality and
abundance of LDs across these cell lines.

Figure 9: Status of genetic alterations, AKT/mTOR pathway, and LDs across normal and
malignant renal cell lines (*Continued on next page)
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Figure 9: Status of genetic alterations, AKT/mTOR pathway, and LDs across normal and
malignant renal cell lines (*Continued on next page)
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Figure 9: Status of genetic alterations, AKT/mTOR pathway, and LDs across normal and
malignant renal cell lines
(A) Copy number alterations (CNA) across three malignant ccRCC cell lines (769-P, 786-O, A498) and mutational status [165] derived from TCGA. (B) Western blot analyses of ccRCC cell
lines and HK-2 cells with the indicated antibodies. Three independent experiments were
performed, and representative blots are displayed. (C) LD assessment of ccRCC cell lines and
HK-2 cells via immunofluorescence staining using LipidTOX. Three independent experiments
were performed, and representative images are displayed. (D) Real-time PCR analyses of genes
involved in LD biogenesis and regulation in ccRCC cell lines and HK-2 cells. Data shown is the
composite of three independent experiments.

All cell lines assessed contained LDs Furthermore, the RNA levels (via real-time PCR) of
key mediators involved in LD formation/turnover such as phospholipid phosphatase 1 (PLPP1,
which converts PA to DAG), diacylglycerol acyltransferase 2 (DGAT2, which converts DAG to
TAG), adipose triglyceride lipase (ATGL, which regulates lipolysis), and cell death inducing
activator like effector C (CIDEC, involved in LD enlargement) were more elevated in the A-498
cell line (relative to the normal immortalized HK-2), a cell line associated with increased genomic
aberrations. All malignant renal cell lines had detectable expression of these LD markers with the
exception of CIDEC in HK-2 cells (Fig 9D).

TEMS reduces cellular viability in normal and malignant renal cell lines
Since targeting the mTOR pathway is a part of the chemotherapy regimen for advanced kidney
cancer patients [242], we next assessed whether the responsiveness to this agent was correlated
with the extent of genomic aberrations at 3p and at 14q. Thus, we first tested a variety of doses
of the mTOR inhibitor (100 nM to 10 µM of TEMS) in 769-P, 786-O, A-498 malignant renal cancer
cells as well as the normal immortalized HK-2 cell line. Cell lysates were collected following a 24hour treatment period and analyzed via western blotting for mTOR pathway mediators as well as
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autophagy markers. As shown in Fig 10A, phospho-S6 was markedly reduced with TEMS
treatment across all four cell lines, which validated mTORC1 inhibition. Phospho-AKT (at Ser473) increased in the 769-P and 786-O cells as well as the HK-2 cells with increasing doses of
TEMS whereas in the A-498 cells, the activation status of AKT decreased. With respect to the
autophagy pathway, both lipidated LC3B and p62 were subtly reduced with increasing doses of
TEMS in HK-2 as well as 786-O and A-498 cells. Since we noted that the TEMS-induced cellular
changes were most striking at 10 µM, this dose was selected to assess changes in cellular viability
across these four renal cell lines. We noted that all cell lines were susceptible to growth inhibition
in response to TEMS up to 3 days of treatment (Fig 10B). Specifically, the cell numbers of HK-2,
786-O, 769-P, and A-498 were reduced by 42.6%/70.5%, 26.9%/67.7%, 16.8%/55.5%, and
19.3%/53.4%, respectively on day 1/day 3 of treatment, respectively, although this was not
accompanied by alterations in PARP cleavage (a marker of caspase-dependent apoptosis)
(Figure 10A).

TEMS alters LD abundance and mitochondrial networks in malignant renal cell lines
Since increased LDs are a characteristic feature of ccRCC [240, 241], we next assessed whether
LD size and/or abundance was altered by targeting the mTOR pathway with TEMS. Thus, we
treated the three malignant cell lines (769-P, 786-O, and A-498) and the normal immortalized HK2 cells with TEMS for 24 hours followed by staining with LipidTOX. As shown in Fig 11A, we
observed increased LD abundance in 769-P and 786-O cells, smaller more numerous numbers
of LDs in A-498 cells, and a slight LD increase in HK-2 cells. Furthermore, the mRNA levels of
lipid droplet regulators (PLPP1, CIDEC, DGAT1, ATGL and PLIN1) following 24-hours of TEMS
treatment showed significantly marked alterations in their expression (Fig 11B), notably in the
malignant renal cell lines. Interestingly, ATGL contributes to the process of lipolysis, which may
lead to the increased numbers of LDs following TEMS treatment in A-498 cells.
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Since LDs are composed of cholesteryl esters as well as triacylglycerides and since
cellular cholesterol is linked with cancer progression [262], we next assessed total cellular
cholesterol levels upon 72 hours of TEMS treatment in the three malignant RCC cell lines as well
as HK-2 cells. Using the Amplex Red Assay, we noted that cholesterol was significantly higher in
the malignant ccRCC cells (769-P, 786-O, and A-498) relative to the normal immortalized kidney
HK-2 cell line (Fig 11C). However, TEMS treatment did not have any effect on cholesterol in any
of these cell types. These data suggest that the changes in lipid droplets observed upon TEMS
treatment do not alter total cellular cholesterol levels.
Although LDs interact with mitochondria to promote energy production via the β-oxidation pathway
[244], the role of TEMS in regulating mitochondrial networks has not yet been investigated in
ccRCC. Thus, we analyzed whether mitochondrial networks are affected by 10 µM TEMS
following 72-hours treatment in renal cells. We detected mitochondrial alterations via
immunofluorescence staining of both TOM20 as well as TOM70 (outer mitochondrial membrane
proteins which facilitate the movement of pre-proteins through the TOM40 translocation pore)
[263]. As shown in Fig 3D, we observed that the fragmented mitochondrial appearance (in control
cells) changed to a fused tubular elongated structure following TEMS treatment. To assess
whether expression of these mitochondrial proteins was altered, we performed western blot
analyses of renal cells treated for 72 hours with 10 µM TEMS. As shown in Fig 11E, we identified
that TOM20, TOM40, and TOM70 proteins were decreased following TEMS treatment in the
malignant renal cancer cell lines (most notably in 786-O cells) in addition to HK-2 cells.
Interestingly, these changes coincided with decreased protein expression of perilipin, p62, and
the DRP1 (Dynamin-related protein1) mitochondrial fission protein. Further, marked alterations in
the lipidated form of LC3B was noted in the malignant renal cell lines and the total protein levels
of the DNA repair mediator PARP were reduced upon TEMS treatment suggesting that mTORC1
inhibition may deregulate autophagy as well as downregulate the DNA repair mechanism.
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Figure 10: TEMS alters activation status of AKT/mTOR, expression of autophagic
mediators and reduces cellular viability in normal and malignant renal cell lines
(*Continued on next page)
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Figure 10: TEMS alters activation status of AKT/mTOR, expression of autophagic
mediators, and reduces cellular viability in normal and malignant renal cell lines
(A) Western blot analyses of ccRCC cell lines and HK-2 cells treated with increasing doses of
TEMS (100 nM – 10 µM) with the indicated antibodies. Three independent experiments were
performed, and representative blots are displayed. (B) Assessment of cellular viability in ccRCC
cell lines and HK-2 cells at Day 1 – 3 in response to 10 µM TEMS. The composite of three
independent experiments is displayed.

Oleic acid alters LD abundance and cellular viability of normal immortalized HK-2 cells
Lipid metabolic pathways are commonly exploited by cancer cells, which contribute to increased
cellular proliferation and survival [264]. Since exogenous lipid supply (i.e., fatty acids) can
increase LDs [265] and we noted that TEMS increases LD abundance, we next assessed whether
oleic acid could modulate pathways similar to TEMS. Thus, we treated renal cells (three malignant
and a normal immortalized HK-2 cell line) with 0.25 mM oleic acid (selected after testing a range
of doses from 250 nM to 2.5 mM) [266-268].
First, we investigated whether exogenous presentation of oleic acid (for 24-hours) to these cell
lines could modulate lipid droplet formation. As shown in Fig 12A, oleic acid treatment increased
lipid droplet size in all four cell lines with statistically significant alterations in HK-2, 769-P, and A498 cells; in 769-P cells, the number of lipid droplets also significantly increased. However,
western blot analyses showed variable alterations in phospho-S6 levels and LC3B-II with no
change in p62, phospho-AKT, or TOM20 (Fig 12B) across the four cell types treated with oleic
acid for 72 hours. These results suggest that the mechanism of LD increase via oleic acid may
differ to that mediated by TEMS and across different cell types. Furthermore, we identified that
oleic acid could alter HK-2 cell viability (but not the malignant cancer cells) when treated up to
three days (Fig 12C).
These results suggest that excess fatty acids and possibly LD formation may have a
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negative effect on the viability of normal cells whereas the renal cancer cells may utilize this
monounsaturated fatty acid for essential cellular metabolic processes to support their current
proliferative and survival capacity.

Hydroxychloroquine (HCQ) alters LDs and synergizes with TEMS to reduce cellular
viability in renal cell lines
Since the PI3K/AKT/mTOR pathway negatively regulates autophagy, effective renal cancer cell
treatment with mTOR inhibitors (such as TEMS) may thus be antagonized by the resulting
increased cellular protective autophagy [245, 246]. Indeed, induction of autophagy with mTORC1
inhibition has previously been reported, and thus may provide a mechanism underlying low patient

Figure 11: TEMS alters LD abundance and mitochondrial networks in malignant renal cell
lines (*Continued on next page)
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Figure 11: TEMS alters LD abundance and mitochondrial networks in malignant renal cell
lines (*Continued on next page)
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Figure 11: TEMS alters LD abundance and mitochondrial networks in malignant renal cell
lines (*Continued on next page)
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Figure 11: TEMS alters LD abundance and mitochondrial networks in malignant renal cell
lines (*Continued on next page)
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Figure 11: TEMS alters LD abundance and mitochondrial networks in malignant renal cell
lines
(A) LD assessment of ccRCC cell lines and HK-2 cells in response to 24-hour treatment with 10
µM TEMS via immunofluorescence staining using LipidTOX. Three independent experiments
were performed, and representative images are displayed as well as quantification of Total Area
Covered/Cell and Total LDs/Cell (presented as normalized fold-change). (B) Real-time PCR
analyses of genes involved in LD biogenesis and regulation in ccRCC cell lines and HK-2 cells in
response to 24-hour treatment with 10 µM TEMS. Data shown is the composite of three
independent experiments. (C) Assessment of total cholesterol levels in ccRCC cell lines and HK2 cells in response to 72-hour treatment with 10 µM TEMS. The composite of three independent
experiments is displayed. (D) Mitochondrial network assessment of ccRCC cell lines and HK-2
cells in response to 24-hour treatment with 10 µM TEMS via immunofluorescence staining of
TOM20. Three independent experiments were performed, and representative images are
displayed. (E) Western blot analyses of ccRCC cell lines and HK-2 cells treated for 72-hours with
10 µM TEMS with the indicated antibodies. Three independent experiments were performed, and
representative blots are displayed.

response rates in clinical trials to mTOR inhibitors [94, 247]. In this regard, we assessed whether
the combinatorial treatment of hydroxychloroquine (HCQ) with TEMS alters LD abundance in the
normal and malignant renal cell lines. We first validated HCQ activity by treating cells (769-P,
786-O, A-498 and HK-2) with 25 µM HCQ alone or in combination with 10 µM TEMS and then
detecting lipidated LC3B levels via western blot analyses. As shown in Fig 13A, we observed that
LC3B-II and p62 protein levels were increased indicating that autophagic flux was effectively
inhibited. Further, we noted a significant reduction in cellular viability in response to the
combinatorial HCQ and TEMS treatment in the malignant cell lines but not in the normal HK-2
cells (Fig 13B). These findings suggest that the combinatorial treatment of autophagic and mTOR
inhibition is more effective than the individual treatment regimens.
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Interestingly, upon LipidTOX staining, we noted that the LDs appeared to be sequestered
within an autophagosomal compartment (Fig 13C); indeed, HCQ mediates inhibition of the
autophagosome-lysosome fusion event [246]. Altogether, these findings suggest that HCQ
dominates TEMS-induced alterations in LD abundance potentially leading to diminished LD
turnover.
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Figure 12: Oleic acid alters LD abundance and cellular viability of normal immortalized HK2 cells (*Continued on next page)
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Figure 12: Oleic acid alters LD abundance and cellular viability of normal immortalized HK2 cells (*Continued on next page)
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Figure 12: Oleic acid alters LD abundance and cellular viability of normal immortalized HK2 cells
(A) LD assessment of ccRCC cell lines and HK-2 cells in response to 24-hour treatment with 0.25
mM oleic acid via immunofluorescence staining using LipidTOX. Three independent experiments
were performed, and representative images are displayed as well as quantification of Total Area
Covered/Cell and Total LDs/Cell (presented as normalized Fold-Change). (B) Western blot
analyses of ccRCC cell lines and HK-2 cells treated for 72 hours with 0.25 mM oleic acid with the
indicated antibodies. Three independent experiments were performed, and representative blots
are displayed. (C) Assessment of cellular viability in ccRCC cell lines and HK-2 cells at Day 3 in
response to 0.25 mM oleic acid. The composite of three independent experiments is displayed.

LPA antagonizes TEMS-induced cellular alterations in a malignant renal cell line
LPA is a potent mitogenic lipid that mediates its extracellular effects via binding and activation of
G-protein coupled receptors [248, 249]. Although LPA is elevated (along with autotaxin (ATX)) in
kidney cancers [135, 250, 251] and can promote malignancy of patient-derived tumor cells [136],
the role of this mitogenic lipid in chemotherapeutic resistance with the mTOR inhibitor, TEMS,
has not yet been explored. First, we assessed whether ATX levels were altered by TEMS
treatment in the malignant and normal renal cell line via real-time PCR. As shown in Fig 14A (top
and bottom panels), we noted that ATX mRNA was significantly reduced following 24-hours of
TEMS treatment and unexpectedly, these levels were significantly lower in ccRCC cells in
comparison to HK-2 cells.
Since LPA mediates its effects via GPCRs to activate multiple intracellular signaling
pathways including AKT/mTOR [248, 249], we next assessed whether addition of LPA alters the
AKT/mTOR pathway in a malignant renal tumor cell line. The dose of LPA utilized (10 µM) was
based on reported pathophysiological concentrations identified within tumors and in serum [269].
Specifically, we selected A-498 cells to investigate whether LPA modulates TEMS

72

responsiveness since these cells displayed marked changes in LDs and mitochondrial networks
in addition to harboring the most genomic aberrations (out of the three malignant RCC lines
studied herein). We cultured A-498 cells in both serum free media (SFM) and complete media to
determine the effect of exogenously presented LPA in these cells. As shown in Fig 14B, we
observed that the reduction in protein expression in phospho-S6, TOM20, TOM70, LC3B-II, and
p62 under both culture conditions (consistently noted in SFM) were increased nearly to baseline
control levels in the presence of LPA with TEMS. We next assessed whether LPA could
antagonize TEMS-induced alterations in mitochondrial networks via immunofluorescence
analyses (staining for TOM20 and TOM70) in A-498 cells (Fig 14C and 14D).
Since the SFM culture conditions led to shrunken cells, which resulted in challenges in
assessing the mitochondrial networks, we focused this assessment using A-498 cells maintained
in complete media. In control cells, we observed mitochondrial networking (staining for TOM20
and TOM70 were similar) close to the nuclear compartment of which most had a fragmented
appearance (with a few extensions). LPA treatment alone did not modulate this mitochondrial
network and TEMS treatment, itself, caused the mitochondrial network to become more extended
(Fig 11D). Interestingly, the addition of LPA with TEMS cause a marked rearrangement of the
mitochondrial networks to a tubular shortened form, which we quantified (bottom panels, Fig 14C
and 14D). These findings suggest that LPA has the ability to partially antagonize the cellular
response to TEMS. Since the contribution of LPA in modulating LD biogenesis remains unknown
which may thus contribute to its pro-tumorigenic effect, we next investigated LD formation upon
cellular treatment with LPA in A-498 cells using CM (Fig 15A) culture conditions. In control cells,
we observed that 60-70% cells contained large LDs homogeneously dispersed in the cytoplasm
with the remaining 30-40% of the cell population containing finer LDs. In the presence of LPA,
nearly the entire cell population contained large LDs that were homogeneously dispersed in the
cytoplasm. In contrast to TEMS-treated cells which contained finer LDs in 80% of the cell
population, the combinatorial treatment of TEMS with LPA resulted in nearly the entire population
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Figure 13: Hydroxychloroquine alters LDs and synergizes with TEMS to reduce cellular
viability in renal cell lines (*Continued on next page)
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Figure 13: Hydroxychloroquine alters LDs and synergizes with TEMS to reduce cellular
viability in renal cell lines
(A) Western blot analyses of ccRCC cell lines and HK-2 cells treated for 72 hours with 25µM HCQ
and/or 10µM TEMS with the indicated antibodies. Three independent experiments were
performed, and representative blots are displayed. (B) Assessment of cellular viability in ccRCC
cell lines and HK-2 cells at Day 3 in response to 25 µM HCQ and/or 10 µM TEMS. The composite
of three independent experiments is displayed. (C) LD assessment of ccRCC cell lines and HK-2
cells in response to 24-hour treatment with 25 µM HCQ and/or 10 µM TEMS via
immunofluorescence staining using LipidTOX. Three independent experiments were performed,
and representative images are displayed.
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containing large LDs homogeneously distributed throughout the cell cytoplasm. These findings
suggest that LPA may antagonize the LD-induced changes mediated by TEMS.

LPA increases LDs in renal cell lines and alters cellular viability of the normal immortalized
HK-2 cells
The alterations in LDs mediated by LPA in A-498 cells were generalizable to other renal cell lines
including two other malignant cell lines (769-P and 786-O cells) as well as the normal immortalized
HK-2 cells (Fig 15B). Indeed, we uncovered that LPA caused the formation of larger LDs in all of
these renal cell lines. To assess the mechanism underlying alterations in LD formation upon LPA
treatment, we performed western blot analysis using lysates from HK-2 cells maintained in
complete media culture conditions treated with LPA across a time course (30 minutes up to 24
hours). As shown in Fig 15C, we observed MAPK and S6 activation in the absence of phosphoAKT or phospho-GSK3 alterations as early as 30 minutes following LPA addition. These levels

Figure 14: Lysophosphatidic acid antagonizes TEMS-induced mitochondrial alterations in
a malignant renal cell line (*Continued on next page)
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Figure 14: Lysophosphatidic acid antagonizes TEMS-induced mitochondrial alterations
in a malignant renal cell line (*Continued on next page)
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Figure 14: Lysophosphatidic acid antagonizes TEMS-induced mitochondrial alterations in
a malignant renal cell line
(A) Real-time PCR analyses of ATX in ccRCC cell lines and HK-2 cells in response to 24-hour
treatment with 10 µM TEMS. Data shown is the composite of three independent experiments. Left
panel, normalized to each cell line (untreated). Right panel, normalized to HK-2 cells (untreated).
(B) Western blot analyses of A-498 cells (grown in CM or SFM media conditions) treated with 10
µM TEMS in the absence or presence of 10 µM LPA with the indicated antibodies. Three
independent experiments were performed, and representative blots are displayed. (C)
Mitochondrial network assessment of A-498 cells in response to 24-hour treatment with 10 µM
TEMS with/without 10 µM LPA via immunofluorescence staining of TOM20. Three independent
experiments were performed, and representative images are displayed. (D) Mitochondrial
network assessment of A-498 cells in response to 24-hour treatment with 10 µM TEMS
with/without 10 µM LPA via immunofluorescence staining of TOM70. Three independent
experiments were performed, and representative images are displayed.
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appeared to be sustained up to 24 hours of LPA treatment. These changes were accompanied
by elevated mRNA levels of DGAT2 in HK-2 cells (Fig 15D) suggesting that the increased LDs
may be due to increased production and activity of enzymes in LD biogenesis.
As shown in Fig 15E, we observed a statistically significant increase in cell viability in HK2 cells following LPA treatment for 3 days. These findings suggest that LPA can enhance the
tumor-promoting effect of kidney cells in vitro. To determine whether LPA-induced activation of
the MAPK and/or S6 signaling cascade contributed to the LPA-induced LD formation in HK-2
cells, we inhibited MAPK using 10 µM of U0126 and inhibited S6 as well as p70S6K using siRNA.
We confirmed the effectiveness of these inhibitors via western blot analyses (Fig 16A at (30
minutes of LPA treatment) and Fig 16B).

Figure 15: Lysophosphatidic acid increases LDs in a malignant renal cell line (*Continued
on next page)
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Figure 15: Lysophosphatidic acid increases LDs in a malignant renal cell line (*Continued
on next page)
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Figure 15: Lysophosphatidic acid increases LDs in a malignant renal cell line (*Continued
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Figure 15: Lysophosphatidic acid increases LDs in a malignant renal cell line
(A) LD assessment of A-498 cells in response to 24-hour treatment with 10 µM LPA in the
absence/presence of 10 µM TEMS via immunofluorescence staining using LipidTOX. Three
independent experiments were performed, and representative images are displayed as well as
quantification of Total Area Covered/Cell and Total LDs/Cell (presented as normalized FoldChange). (B) LD assessment of ccRCC cell lines and HK-2 cells in response to 24-hour treatment
with 10 µM LPA in the absence/presence of 10 µM TEMS via immunofluorescence staining using
LipidTOX. Three independent experiments were performed, and representative images are
displayed as well as quantification of Total Area Covered/Cell and Total LDs/Cell (presented as
normalized Fold-Change). (C) Western blot analyses of HK-2 cells treated with 10 µM LPA across
a time course (30 minutes to 24 hours) with the indicated antibodies. Three independent
experiments were performed, and representative blots are displayed. (D) Real-time PCR analyses
of genes involved in LD biogenesis and regulation in HK-2 cells in response to 24 -hour treatment
with 10 µM LPA. Data shown is the composite of three independent experiments. (E) Cell viability
in HK-2 cells was assessed following LPA treatment for 3 days. Data shown is the composite of
three independent experiments.

We also analyzed LD abundance using LipidTOX (Fig 16C and 16D) and noted increased
numbers of finer LDs associated following MAPK inhibition; however, the larger LDs induced by
LPA alone were reduced following co-treatment with TEMS. Interestingly, we noticed that S6
protein reduction led to an increased number and size of LDs even in the absence of LPA, which
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was further enhanced with addition of LPA. These findings suggest that LPA mediates alterations
in LDs partially via MAPK activation and was independent of S6/p70S6K.

Discussion
Kidney tumors harbor a myriad of genetic alterations, including mutation or loss of the VHL gene,
a tumor suppressor which is a common occurrence in >90% of clear cell kidney cancer cases

Bi

Figure 16: Lysophosphatidic acid alters LD abundance via the MAPK pathway and cellular
viability in HK-2 cells (*Continued on next page)
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Figure 16: Lysophosphatidic acid alters LD abundance via the MAPK pathway and cellular
viability in HK-2 cells
(A) Western blot analyses of HK-2 cells treated with 10 µM LPA in the absence of presence of
U0126 for 30 minutes (left panels) or 24 hours (right panels) with the indicated antibodies. Three
independent experiments were performed, and representative blots are displayed. (B) Western
blot analyses of HK-2 cells treated with S6 or p70S6K siRNA with the indicated antibodies. Three
independent experiments were performed, and representative blots are displayed. (C) LD
assessment of HK-2 cells in response to 24-hour treatment with 10 µM LPA in the
absence/presence of U0126 via immunofluorescence staining using LipidTOX. Three
independent experiments were performed, and representative images are displayed as well as
quantification of Total Area Covered/Cell and Total LDs/Cell (presented as normalized FoldChange). (D) LD assessment of HK-2 cells in response to 24-hour treatment with 10 µM LPA in
the absence/presence of siRNA targeting S6 or p70S6K via immunofluorescence staining using
LipidTOX. Three independent experiments were performed, and representative images are
displayed as well as quantification of Total Area Covered/Cell and Total LDs/Cell (presented as
normalized Fold-Change).
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[240, 254]. The ccRCC cell lines used for this study (769-P, 786-O and A-498) are associated
with aberrations in VHL (TCGA data: Fig 9A). mTOR is a downstream effector of PI3K/AKT, a
pathway that is well-established to be hyperactivated in ccRCC. Furthermore, several agents
targeting mTOR have been developed including FDA-approved drugs such as everolimus and
temsirolimus (TEMS). However, resistance to these agents has been a major contributor to
suboptimal overall survival rates.
We now have identified that the mTOR inhibitor TEMS alters LD quality in both RCC and
normal immortalized HK-2 cells, possibly to enhance lipid mobilization, which antagonizes cellular
sensitivity to the treatment (Fig 10B and 11A). We also demonstrate that TEMS reduces
expression of autophagy markers, which is accompanied by a decrease in expression of
mitochondrial membrane proteins (TOM20, TOM40, and TOM70) and mitochondrial fused
networks (Fig 11D and 11E). These cellular alterations may serve to relieve cellular stress
induced by TEMS, thus promoting β-oxidation and fatty acid flux [244]. Since mitochondrial
networks are highly dynamic in cancer and contribute to cancer cell proliferation, migration and
altered cellular metabolism [270], it is notable that LDs have been found in close proximity to the
ER and mitochondrial compartments to facilitate lipid exchange across these organelles [271].
Thus, the mitochondrial remodeling noted following TEMS treatment in the malignant renal cancer
cell lines may thus promote increased energy usage to antagonize responsiveness to the mTOR
inhibitor. Remodeling of mitochondria is likely to occur via regulated fission and fusion dynamics
involving proteins present in the outer and inner mitochondrial membrane including MFN1/2,
Opa1, and DRP1 [270, 271]. Furthermore, there is another report that describes that inhibitor of
mTOR can lead to hyperfused and branched mitochondria, for which the underlying mechanism
is thought to involve reduced expression of the mitochondrial fission process 1 (MTFP1) and
DRP1 mitochondrial recruitment which may then regulate cellular survival [272].
With respect to increased LDs in response to exogenous supplementation with oleic acid,
this cellular response appears to be similar to that with fatty acid synthase (FAS) inhibitors along
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with mTOR inhibitors which results in synergistic toxicity in breast cancer cells. Moreover, the
mTOR inhibitor can modulate expression of FASN, which implicates the PI3K/AKT/mTOR
pathway in its regulation [273]. Thus, these pathways may be similarly involved with oleic acid
exogenous supplementation in our renal cell lines.
Suboptimal or ineffective cellular responses to mTOR inhibitors may be due to activation
of cytoprotective pathways including autophagic flux [94, 259, 260, 274]. We now demonstrate
that the autophagic flux inhibitor (HCQ) alters LD abundance in both malignant and normal renal
cell lines (Fig 13C). The accumulation of LDs with HCQ appeared to occur within
autophagosomes, implicating inhibition of the lipophagy pathway and hence promoting synergistic
cytotoxicity of HCQ and TEMS. Recently, combinatorial treatment of HCQ with the mTOR inhibitor
Everolimus was assessed in a phase 1 clinical trial, which showed promise as an effective
therapeutic regimen [259]. Additional pathways that may antagonize mTOR inhibitors include
feedback activation of the AKT signaling pathway [275, 276]. Indeed, targeting components in
these upstream PI3K-AKT cascade (as a multipronged approach) has been tested [275, 276].
Since ATX (which generates the potent LPA mitogen via its potent lyso-PLD activity) is
elevated in ccRCC [250, 269] and has been shown to mediate chemotherapeutic resistance to
sunitinib [135], this may be another mechanism underlying resistance to mTOR inhibitors. Indeed,
we noted that LPA could antagonize the cellular responsiveness of malignant renal cell lines to
TEMS, in terms of LDs and mitochondrial remodeling. LPA is linked to promotion of cell survival
and proliferation. For example, treatment of a rat myocardial infarction model with LPA promoted
cardiac hypertrophy which coincided with autophagic inhibition [277]; furthermore, this was noted
to occur via activation of the AKT/mTOR pathway [277]. Activation of this pathway following LPA
treatment is well established, as defined from other studies as well [278-280]. Therefore, in future
work, we will investigate the combinatorial treatment of LPA with TEMS compared to LPA alone
in RCC cell lines.
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Furthermore, since we demonstrated that LPA with TEMS treatment resulted in a
rearrangement of mitochondrial networks to a tubular shortened form, this could involve altered
LDs and autophagic response, leading to altered mitochondrial structures. Indeed, it is reported
that starvation can promote movement of autophagy-mediated LDs to mitochondria (needed for
fatty acid β-oxidation, where fatty acids are made available via the action of neutral lipases), thus
affecting fusion dynamics [244]. Such LDs are noted to be in close proximity to mitochondria to
allow the uptake of fatty acids. Based on this report, we propose that LPA-induced LD formation
and TEMS-induced autophagy may work coordinately to alter mitochondrial networks [244]. In
our results, we show that LPA and TEMS combinatorial treatment results in a tubular shortened
form of mitochondrial networking, suggesting that there may be resultant alterations in fatty acid
movement and hence, altered β-oxidative activity. Thus, altered mitochondrial networking may
result in restricted movement of fatty acids from lipid droplets to mitochondria (possibly, its
expulsion from the cells thus a reduction in fatty acid metabolism would ensue) and hence, lipid
accumulation in LDs.
Interestingly, we also noted that ATX mRNA levels were reduced with TEMS treatment
(Fig 14A). Although we did not measure LPA content in the culture media following TEMS
treatment, we propose that LPA may be elevated with mTOR inhibition and thus may
downregulate ATX expression in a feedback loop [281]. In future work, the contribution of LDs to
LPA-mediated drug resistance in renal cancers could be investigated. We propose that targeting
the LPA/ATX axis may be a strategy to improve the sensitivity of ccRCC tumors to
chemotherapeutic agents.
The molecular mechanisms involved in chemotherapeutic resistance in ccRCC are not
well established. Herein, we identify that LPA can antagonize the cellular response of renal cancer
cells to TEMS, specifically altering lipid droplets and mitochondrial networks. Moreover, in normal
immortalized renal cells, we discovered that LPA induced LD formation in a MAPK-dependent
manner, which was accompanied by changes in DGAT2 and cellular viability. Overall, this study
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implicates the LPA signaling pathway as an important target for combating the resistance
acquired by RCC cells towards molecular-based therapies.
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Chapter 4
Global miRNA/Proteomic Analyses Identify miRNAs at 14q32 and 3p21, Which Contribute
to Features of Chronic Iron-Exposed Fallopian Tube Epithelial Cells
Note to Reader
This chapter is a reorganized and reformatted version of the published article (Chhabra R,
Rockfield S, Guergues J, Nadeau OW, Hill R, Stevens SM Jr, Nanjundan M. Sci Rep. 2021 Mar
18;11(1):6270. doi: 10.1038/s41598-021-85342-y). This has been reproduced here with an open
access Creative Commons Attribution 4.0 international license from Springer nature (see
Appendix for copyright permissions).
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Introduction
Iron is essential for maintenance of cellular homeostasis and organismal survival [283]. Iron
participates in Fenton reactions, yielding reactive oxygen species (ROS) that are highly damaging
to macromolecules including proteins, lipids, and nucleic acids [284]. Increased intracellular iron
accumulation is a key feature of ferroptosis, a programmed cell death mechanism that is
characterized by increased lipid peroxidation [285, 286]. In contrast, deregulated expression of
mediators involved in iron metabolism (i.e., Transferrin Receptor) leads to increased intracellular
labile iron that promotes increased cellular proliferative capacity and cancer pathogenesis [171,
287]. In our prior report, in response to supraphysiological levels of NTBI (non-transferrin bound
iron, presented as ferric ammonium citrate (FAC)), we performed a proteomics screen utilizing
reverse phase protein array (RPPA) to identify global proteomic alterations, which confirmed
RAS- and MAPK-dependency in short-term iron-exposed ovarian cancer cell lines[239, 288].
High-grade serous ovarian cancer is the deadliest gynecological malignancy in women for
which the fallopian tube secretory epithelial cell (FTSEC) type is now considered an established
precursor cell [289]. Our recent findings have identified that chronic iron exposure contributes to
upregulated EVI1 (a transcriptional regulator, amplified at 3q26.2) and TERT expression,
accompanied by increased cell numbers and migration in FTSECs [19]. However, to our
knowledge, an assessment of global alterations induced by this mode of iron exposure in FTSECs
has yet to be performed and is thus necessary to identify comprehensive cellular changes for
which improved treatment regimens may be designed. Furthermore, since miRNAs elicit both
oncogenic and tumor suppressive functions by altering the expression of multiple protein targets,
a global miRNA screening approach in chronic iron exposed FTSECs is deemed to be an
additional highly valuable experimental approach.
Herein, we utilized a multiomics approach using the GeneChip miRNA 4.1 microarray and
mass spectrometry-based proteomics to identify deregulated miRNAs and protein targets,
respectively, in chronic iron exposed and transformed FTSECs. We applied stringent statistical
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approaches to identify the most significantly deregulated hits and integrated both of these
analyses using Ingenuity Pathway Analysis [282]. A majority of the identified downregulated
miRNAs are located at the 14q32 locus, a highly aberrant chromosomal region in multiple tumor
types [224, 290, 291]. Since 14q32 miRNAs can be regulated by differentially methylated
promoter regions (i.e., DLK1-DMR, IG-DMR and MEG3-DMR [292-295]), we investigated whether
FAC could epigenetically alter the methylation and acetylation status in genomic regions
potentially involved in miRNA regulation. Inhibition of methyltransferases and histone
deacetylases using 5-Azacytidine (AZA) and Suberoylanilide Hydroxamic Acid (SAHA),
respectively, resulted in rescuing the expression of miR-432-5p, miR-127-3p, with minimal effects
on miR-138-5p expression. IPA analyses identified notable proteomic targets of key miRNAs
including ALDH1A2 (for miR-138-5p target) and PAX8 (for miR-432-5p, miR-127-3p, and miR138-5p). Although these targets could not be validated experimentally, TERT RNA was identified
to be partially regulated by miR-138-5p. From a functional perspective, overexpression of these
miRNAs reversed cell survival induced by chronic iron exposure in FT194 cells.

Materials and methods
Experimental design and statistical rationale
Understanding the mechanism underlying transformation of FTSECs requires the use of an in
vitro model system, such as immortalized FT194 cells, generated via SV40 LTAg and hTERT
stable expression, characterized by p53 inactivation, as described previously [296]. We previously
reported the generation of oncogenically transformed FT194 cells; briefly, these were produced
by stable overexpression of c-MycT58A, H-RasV12A, and SV40 LTAg [19]. In addition, we described
the generation of a transformed-like FTSEC cell line following chronic iron overload (with 250 nM
Ferric Ammonium Citrate (FAC) for > 60 days in culture) which was characterized by alterations
in oncogene expression (based on a focused approach) and survivability[19]. Briefly, the FTSECs

91

were seeded at 500 cells/well in 6 well plates and subsequently treated with a range of FAC doses
(0, 25 nM, 250 nM, 2.5 µM, 25 µM, or 250 µM), as previously described[19]. Cell growth was
continually monitored, and cultures propagated in FAC-containing media (with media
replenishments every 4 days). Cells treated with 250 nM FAC elicited greater cell numbers
(compared with Untreated cells or other iron doses) and was therefore selected for expansion
and experimentation along with Untreated control cells which were maintained concurrently. Our
prior attempts with mM FAC doses similar to those previously reported [189, 297] was highly
toxic and therefore not further pursued.
To further characterize global changes in an unbiased manner, we prepared experimental
samples from Untreated [36], FAC-treated (FAC), control virus (CV), and oncogenic cocktail virus
(OCV) infected FT194 cells; these were utilized for both noncoding RNA microarray and
proteomic analyses. Specifically, the proteomic study utilized flash frozen cell pellets (UNT/FAC
or CV/OCV) of ~500,000 cells per replicate, based on the protein extraction yield obtained by the
S-trap sample processing approach previously reported by us [298, 299]. For LFQ-based
quantitation of protein expression, 5 replicates (from the same “batch” of UNT/FAC or CV/OCV
cells) per group were utilized based on the expected quantitation precision of our approach
obtained for cell lines [299]. For a statistical power of 90% with alpha=0.05 and n=5 replicates per
group, an effect size of 2.348 would be needed based on using a two-tailed, unpaired t-test. The
average coefficient of variation for each group was calculated for LFQ intensities obtained
experimentally and then used to determine the fold change to achieve this effect size, which was
then compared to the z-score cutoff used in this study (|z-score|>1).

A conventional FDR

correction approach (e.g., Benjamini-Hochberg) was not employed given the tendency for
decreased sensitivity; however, a combined filtering approach that considers variance and fold
change was used (Welch’s t-test p< 0.05 and |z-score|>1), which has been shown to adequately
control FDR while maintaining sensitivity [300].
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For the miRNA analyses, total RNA was isolated from 3 replicates (from the same “batch”
of UNT/FAC or CV/OCV cells), quantified by Nanodrop, and then analyzed using the GeneChip
4.1 Array (#902409, ThermoFisher Scientific, Waltham, MA, USA). The miRNA array contained
30,424 mature miRNAs, of which 2,578 were of human origin. To obtain a statistically relevant
dataset of differentially expressed miRNA targets, an approach was applied of a >2-fold change
cutoff along with an FDR-adjusted p-value <0.05 top miRNA targets were selected to generate
volcano plots and Venn diagrams.

Cell culture and treatments
Human immortalized FTSECs (FT194) were provided by Dr. Ronald Drapkin (Department of
Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA)[296]. These cells
were immortalized by SV40 LTAg and hTERT, and were maintained in DMEM:F12 (1:1, #15–
090-CV, Corning Incorporated, Corning, NY, USA) with phenol red, supplemented with 2%
Ultroser G Serum Substitute (#67042, Crescent Chemical Company, Islandia, NY, USA) and 1%
penicillin-streptomycin, as previously described [19]. Long-term FAC treated (annotated FAC or
F) and the corresponding Untreated FT194 (annotated UNT or U) cells were maintained in phenol
red-free DMEM:F12 (1:1, #21041-025, ThermoFisher, Waltham, MA, USA) with 8% charcoal
dextran-stripped FBS and 1% penicillin/streptomycin (denoted as -PR media), as previously
described[19]. Cells were incubated at 37°C in a 5% CO2 environment. Cell lines were tested for
mycoplasma and confirmed to be negative. Chronic iron-treated (250 nM for greater than 60 days)
immortalized FT194 cells were maintained in 250 nM ferric ammonium citrate (FAC) (day 111 to
170 and p=30-52) [19]. Oncogenic cocktail virus infected (OCV) and control virus infected FT194
cells (CV) cells generated by retroviral transduction of c-MycT58A, H-RasV12A, and SV40 LTAg
cDNAs were generated previously[19] and were used herein at passages of RV+11.
FAC (#I72-500, Fisher Scientific, Pittsburgh, PA, USA) stock was prepared in PBS and
used at a final concentration of 250 nM [19]. Stocks for the DNMT1 inhibitor, 5- Azacytidine (AZA,
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#S1782, Selleck Chemicals, Houston, TX) and the HDAC inhibitor, SAHA (#S1047, Selleck
Chemicals, Houston, TX) were prepared in dimethylsulfoxide (DMSO). Both drugs were utilized
at 0.5 µM, 1 µM, 5 µM, 10 µM, 25 µM and 50 µM final concentrations, which were based on a
literature review of the most appropriate doses[5, 301-303]. A dose range of 0.5 µM to 10 µM of
AZA and 0.5 µM to 50 µM of SAHA (as mentioned previously [5, 301-303]) were initially tested
individually for 24 hours in both Untreated and FAC-exposed FT194 cells (results not shown); the
optimal dose was then selected for further experiments. Following optimization studies, 1 µM AZA
and 50 µM SAHA doses were selected for use.

Mass spectrometry-based proteomic analyses
Suspension trap (S-trap) sample processing of each experimental group (U, F, CV, OCV) was
performed as previously described [299] using an approximate 500,000 cell count for each group
(n=5 per group). Tryptic peptide concentrations were normalized based on the original protein
concentration measurements determined by a Pierce 600 nm protein assay (Thermo Fisher
Scientific). LC-MS/MS analysis of the cell lysate digests was performed using a hybrid
quadrupole-Orbitrap instrument (Q Exactive Plus, Thermo Fisher Scientific) coupled to an
Ultimate 3000 UPLC system (Thermo Fisher Scientific). Digested samples were first concentrated
on a 2 cm x 75 µm ID PepMap C18 trap column (Thermo Fisher Scientific) followed by separation
on a 55°C-heated, 75 cm x 75 µm ID C18 PepMap column (Thermo Fisher Scientific). A 120 min
gradient from 2-28% B, where B was 0.1% formic acid in 80% acetonitrile:20% water was used
to separate peptides, as described in our prior publication[298]. An additional ramp to 40% B over
15 min followed by a wash at 95% B was implemented. For mass spectrometric analysis, datadependent acquisition [9] with a top-10 method was utilized. The full MS spectra were acquired
in the m/z range of 375-1200 at 70,000 resolutions followed by MS/MS scans at 17,500
resolutions. AGC target counts of 1E6 and 5E4 with maximum IT values of 20 and 50 ms for MS1
and MS2 were utilized, respectively. A normalized collision energy of 28 and isolation window of
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1.6 m/z was employed with charge state exclusion set for unassigned, 1, 6-8, and >8. Dynamic
exclusion was set for 20 sec with isotope exclusion enabled and the peptide match setting to
preferred. All details of the mass spectrometry data acquisition and LC parameters are embedded
in the raw data files, which have been deposited to the Proteome Xchange Consortium via the
PRIDE [304] partner repository with the dataset identifier PXD018416.
MaxQuant (version 1.6.6.0) was used to search raw files against the Uniprot protein
database for Homo sapiens (version UP000005640, 71607 entries). Search parameters included
the variable modifications of N-terminal protein acetylation and methionine oxidation as well as
the constant modification of cysteine by carbamidomethylation. An additional database of known
contaminants provided with MaxQuant was utilized where the first search tolerance was set to 20
ppm followed by a main search tolerance of 4.5 ppm, as described in our earlier work[298, 299].
Furthermore, a search strategy using reversed sequences in a decoy database was employed to
achieve protein and peptide FDR values of less than 1%[298, 299]. Label free quantification
(LFQ)-based quantitation was enabled, with a minimum ratio count of 1, and the “match-betweenruns” feature using default settings was employed to increase proteomic identification, as
described in our earlier work [298, 299].
The resulting Protein-Groups text file generated by MaxQuant was edited by removing the
reverse and contaminant sequences as well as proteins only identified by modification (similarly
described in our earlier work) [298]. The file was then uploaded into Perseus (version 1.6.1.1)
[298] twice for separate analysis of FAC-treated FT194 cells (F) relative to Untreated FT194 cells
(U), and oncogenic cocktail virus infected FT194 cells (OCV) relative to control virus infected cells
(CV). Each file was then analyzed whereby LFQ values were log2-transformed and proteins were
removed that had missing values in more than just 2 out of the 5 replicates, similarly described in
our earlier work[298]. The imputation function was utilized where missing values were replaced
using width parameters of 0.3 for both and downshift parameters set to 1.8 and 1.75 for F vs. U
and OCV vs. CV, respectively [298]. The average ratio of treatment over control was then
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calculated in Excel along with a Welch’s t-test (p-value < 0.05) and z-score (z-value > 1), similarly
described in our earlier work [298]. These filtered lists containing protein identification and
average ratio of each comparison were then uploaded to Ingenuity Pathway Analysis [282] in
order to determine upstream regulator overlap and activity, over-represented canonical pathways,
as well as other biological and disease functions (p < 0.05, Fisher’s exact test), similarly described
in our earlier work [298]. Additionally, differentially expressed miRNAs (described below) were
uploaded into IPA and paired against the proteins identified from proteomic analysis, which are
known (experimentally determined) or predicted (moderate or high confidence) downstream
targets of the miRNAs, through the miRNA Target Filter function. Paired miRNA-protein targets
were filtered to include those in which the observed miRNA up- or down-regulation resulted in
down- or up-regulation of the protein target, respectively. The corresponding network was
reconstructed in IPA to demonstrate the potential regulatory role of each selected miRNA on the
protein expression profile obtained.

MicroRNA microarray
Total RNA was isolated from FT194 cells maintained in 250 nM FAC for 104 days (p=31) along
with parental untreated FT194 cell line cultured simultaneously. In addition, total RNA was
isolated from CV and OCV-infected FT194 cell lines (p=RV+12). RNA isolation was performed
using the RNeasy Kit (#74106, QIAGEN, Valencia, CA, USA) according to manufacturer’s
instructions. Total RNA was quantified by Nanodrop and then analyzed using the GeneChip 4.1
Array (#902409, ThermoFisher Scientific, Waltham, MA, USA). The miRNA array contained
30,424 mature miRNAs, of which 2,578 were of human origin. To obtain a statistically relevant
dataset of differentially expressed miRNA targets, an approach was applied of a >2-fold change
cutoff along with a non-adjusted p-value <0.05 top miRNA targets were selected to generate
volcano plots and Venn diagrams. miRNA array and proteomics data were combined in Ingenuity
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Pathway Analysis [282] to associate miRNAs with top proteomic hits. Thirty-five miRNAs had 28
protein targets identified in the proteomic screen in FAC-treated (compared to Untreated) FT194
cell samples whereas 45 miRNAs had 74 protein targets identified in the proteomic screen in
transformed OCV (compared to control virus transfected), both with a cutoff of >4-fold change to
focus on the “top hits” of biological relevance. The experimental strategy is depicted in Fig. 1.

MicroRNA transfection
Untreated and FAC-treated FT194 cells were seeded at 250,000 cells (for protein isolation) in 6well plates and 500,000 cells (for miRNA isolation) in 60 mm dishes. After overnight cell
adherence, cells were transfected with 200 pmol control mimic (mirVana miRNA mimic Negative
control 1, #4464059, Life Technologies, Grand Island, NY) or hsa-miR-138-5p (mirVana miRNA
mimic, Assay ID# MC11727, Life Technologies, Grand Island, NY), hsa-miR-432-5p (mirVana
miRNA mimic, Assay ID# MC10941, Life Technologies, Grand Island, NY), or hsa-miR-127-3p
(mirVana miRNA mimic,Assay ID# MH10400, Life Technologies, Grand Island, NY) using Fugene
HD (Promega, Madison, MI). Twenty-four hours post-transfection, cells were recovered and at 48
hours post-transfection, protein lysates, total RNA, or miRNA were then collected.

MicroRNA isolation for real-time PCR
miRNA was isolated using the mirVana Isolation Kit (#AM1561, ThermoFisher Scientific,
Waltham, MA, USA) following the manufacturer’s protocol. miRNA was quantified by Nanodrop,
and real-time PCR was performed using the TaqMan RNA-to-CT 1-Step Kit (#4392938,
ThermoFisher Scientific, Waltham, MA, USA) with the following primer/probe sets: miR-432-5p
(assay ID #: 001026), miR-127-3p (assay ID #: 000452), and miR-138-5p (assay ID #: 002284).
The fold-change in miRNA expression was calculated using the 2-ΔΔCT correlative method, in which
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CT values were normalized to the RNU6B control (assay ID #: 001093, ThermoFisher Scientific,
Waltham, MA, USA).

Protein isolation, SDS-PAGE, and western blotting
Cell lysates were collected for separation on appropriate percentage SDS-PAGE gels and protein
expression analyzed via western blotting using previously published methods[234, 237]. Western
blotting was performed using the following Cell Signaling Technology (Danvers, MA, USA)
primary antibodies: DNMT1 rabbit monoclonal (1:1000, #5032), EVI1 rabbit monoclonal (1:500,
#2593), Pan-Actin rabbit polyclonal (1:1000, #4968), Acetyl Histone H3 (Lys9/Lys14) rabbit
polyclonal (1:1000, #9677), ALDH1A2 rabbit polyclonal (1:1000, #83805), and CRYAB rabbit
monoclonal (1:1000, #45844). ITGA2 rabbit monoclonal (1:1000, MA535243) was obtained from
ThermoFisher Scientific (Waltham, MA, USA). PAX8 rabbit polyclonal antibody (1:1000, #103361-AP) was obtained from Proteintech (Rosemont, IL, USA). The western blots were developed at
multiple exposures onto film, which were all scanned using a Flatbed Scanner (HP Scanjet 5590)
and inserted as images into powerpoint, without any manipulation (no contrast alterations) apart
from cropping to within 6 band widths above and below the band of interest. Each developed blot
(representing a specific antibody application) is presented in one powerpoint slide with space inbetween, delineating different antibody applications to the same blot. The EVI1 and Pan-Actin
antibodies were previously optimized in our laboratory [305]. The use of DNMT1[306], Acetyl
Histone H3[307], and PAX8[308] were utilized based on prior publications and ALDH1A2 was
utilized based on data available by Cell Signaling Technology.

EVI1 siRNA in FT194 cells
siRNA transfection in FT194 cells was performed as previously reported[19]. Briefly, cells were
seeded in six-well plates at a density of 500,000 cells/well or at 1,000,000 cells/dish in 60 mm
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dishes followed by overnight adherence. ON-Target Plus non-targeting control siRNA (#D001810-10-20, Dharmacon (Lafayette, CO, USA)) or EVI1-targeting siRNA (siB, custom designed
as described previously)[19, 305, 309] were transfected into cells using RNAiMax (#13778-075,
Invitrogen, Carlsbad, CA, USA). Cells were recovered 24 hours post transfection; cell lysates and
miRNAs were collected at 48 hours post-transfection for western blotting and real-time PCR,
respectively.

Bioinformatics of EVI1 binding site in miR-138-5p-1 promoter region
The UCSC Genome Browser (www.genome.ucsc.edu, Human Dec. 2013 (GRCh38/hg38
Assembly) was utilized to obtain the genomic sequence (5000bp upstream) of the promoter region
for miR-138-5p-1 (located at 3p21.32) and for miR-138-5p-2 (located at 16q13); miRBase was
utilized to obtain the pre-miRNA sequence for these miRNAs. Previous research identified the
DNA sequences that EVI1 binds to; EVI1 N-terminus binds to the sequence GACAAGATA[310,
311] while the C-terminus binds to the sequence GAAGATGAG[312, 313]. Overall, the

consensus EVI1 binding sequence is TGACAAGATAA [310, 313]. Thus, these reported EVI1
binding sequences were aligned with the promoter regions for both miR-138-5p-1 and miR-1385p-2 using the Genomatix software suite (version 3.11, http://www.genomatix.de/cgibin/dialign/dialign.pl).

Statistical analyses
Data from real-time PCR, densitometry, and cell counting studies were analyzed using the
Graphpad Prism software, version 6.04 (La Jolla, CA, USA). Error bars represent the mean  SD
and p-values were determined through the non-parametric Student’s t-test for which “ns”
represents non-significant values, * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤
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0.001, and **** indicates p ≤ 0.0001. Fold changes and percent reductions were calculated from
the average of at least three independent experiments.

Results
miRNA and proteomic profiling of chronic FAC-treated and oncogenically transformed
FTSECs
Elucidating molecular mechanisms involved in initiation and progression of ovarian cancer is
essential towards developing novel therapeutic strategies. We have previously identified a subset
of genes (including EVI1, located at 3q26.2 in HGSOC) that were altered following long-term iron
exposure in FTSECs [19]. However, to acquire a comprehensive understanding of the ironinduced alterations, a global mass spectrometry-based proteomics analysis was performed in
FAC-exposed and Untreated FT194 cells. We then compared the resultant proteomic alterations
to OCV- and CV-infected FT194 cells, as generated previously [19]. For FAC-exposed FT194
cells compared to Untreated cells, 4,402 total proteins were identified with 3,968 quantifiable
proteins after filtering. In OCV-infected compared to CV-infected FT194 cells, 4,691 total proteins
were identified with 4,148 quantifiable proteins after filtering. The average coefficient of variation
for the LFQ values of CV-infected, OCV-infected, FAC-treated, and Untreated FT194 cells was
25.4, 21.4, 21.9, and 19.6%, respectively. The median coefficient of variation for the LFQ values
of CV-infected, OCV-infected, FAC-treated, and Untreated FT194 cells was 16.8, 13.7, 15.0, and
11.7%, respectively. Statistically significant “top hits” were obtained using Welch’s t-test (p <0.05)
and z-score (z-score >1) which identified 700 protein targets in the OCV (relative to CV) cells and
459 protein targets in iron-exposed FTSECs (relative to untreated).
To achieve the effect size corresponding to a statistical power of 0.9 based on our
experimental conditions, a fold-change of ~1.7-1.8 would be needed (assuming the global
average of the coefficient of variation determined for each group), which is consistent with the
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implemented z-score cutoff. Additional restrictions were applied to this data set to identify the
protein targets that had LFQ intensity ratio of ≥ 2 or ≤ 0.5. Using this strategy, we thus identified
622 targets for OCV (relative to CV) and 243 targets for FAC-exposed FTSECs (relative to
Untreated) (Fig. 17). The list of total quantifiable as well as differentially expressed proteins are
provided as supplemental Tables 7 and 8.
Since alterations in miRNAs can contribute to cancer pathogenesis by targeting multiple
protein targets [282, 314], we performed microRNA array profiling using the GeneChip miRNA
4.1 Array. We compared chronic FAC-exposed FTSECs relative to Untreated cells as well as
OCV- relative to CV-infected FTSECs, which identified a total of 65 and 78 unique non-coding
RNAs, respectively, including mature miRNAs and snoRNAs (7 snoRNAs were repeated as
duplicates in the dataset resulting in a total of 71 and 79 ncRNAs identified in FAC/UNT and
OCV/CV analyses, respectively), with at least a 2-fold change (p-value >0.05, displayed as a heat
map, volcano plot, and Venn diagram (Fig. 18A – 18E).
There were 42 upregulated, 29 downregulated miRNAs in FAC-treated (relative to
Untreated) and 45 upregulated, 34 downregulated miRNAs in OCV (relative to CV). miRNAs
downregulated in FAC-treated (relative to Untreated) cells showed higher fold change (X-axis)
and statistical significance (p-value at Y-axis) compared to OCV cells (relative to CV) (Fig. 18C
and 18D). Since the quantity of changes are more numerous in the OCV versus CV FTSEC
comparison (relative to FAC versus Untreated FTSEC), this suggests that the combination of p53
inactivation, c-MycT58A expression, and H-RasV12A expression (within the OCV cocktail) may
mediate increased neoplastic cellular alterations.
Since alterations in protein expression can be regulated post-transcriptionally by miRNAs,
we integrated the top miRNA hits with the protein targets using IPA to identify associations
between the two analyses. Integrated proteomics and microarray analyses identified 35 miRNAs
in FAC-treated FT194 cells (relative to Untreated) and 45 miRNAs in OCV cells (relative to CV
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Figure 17: Schematic representation of the proteomics and microarray experimental
strategy and analyses in FTSECs
Global proteomics analyses via mass spectrometry and miRNA analysis via Gene Chip miRNA
4.1 array were performed using chronic iron treated FT194 cells (p=30 at day 104 of FAC
treatment) and transformed FT194 cells (p=RV+11) (with their corresponding control cells). This
was followed by implementation of IPA to identify “top hits” of altered miRNA associated with
protein changes.

cells) with the following characteristics: (1) >2-fold change and (2) with direct protein targets that
were altered with respect to miRNA levels (Fig. 19A and 19B).

Twenty of the 35 miRNAs (57.14%) altered in FAC-treated cells (relative to Untreated)
were located at chromosome 14q32 (Fig. 19A), while only 9 out of the 45 miRNAs (20%) altered
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in OCV cells (relative to CV) were located at this region (Fig. 19B). This region, amongst others,
also harbors common fragile sites (Table 7 and Table 8), possibly rendering the chromosomal
loci susceptible to replication stress, which is known to impact genomic stability in many cancers
[315]. Interestingly, the 14q32 locus contains a cluster of 54 miRNAs, one of the largest miRNA
clusters in the human genome[204]. Many of these miRNAs appear to be downregulated in
multiple cancer types associated with tumor suppressive properties [5, 215, 290, 316-319] and
oncogenic properties [320]. From the miRNA profiling, we identified that two miRNAs from this
cluster, miR-432-5p and miR-127-3p, were 97.9- and 111.7-fold downregulated, respectively, in
FAC-treated cells in contrast to only 11.7-fold downregulated in OCV cells. These results were
validated by real-time PCR in FAC-treated FT194 cells (Fig. 19C and 19D), which showed a
99.9% reduction for miR-432-5p and miR-127-3p (p-value < 0.0001) in FAC-treated relative to
Untreated FT194 cells.
Additionally, among other highly dysregulated miRNAs from other genomic regions such
as 3p21.31, we identified that miRNA-138-5p (located at 3p21) was 16.3-fold downregulated with
chronic FAC-exposure in FT194 cells (Fig. 19A) and validated via qPCR to be 90.1% reduced (pvalue < 0.0001, Fig. 19E). miR-138-5p also appears to be commonly downregulated in multiple
cancers [321-324]. We identified 28 protein targets in FAC-treated relative to Untreated cells and
74 protein targets in OCV relative to CV cells out of the total statistically significant “top hits” (p
<0.05 and z-value >1), which were associated with characteristics of gynecological cancers (Fig.
20A and 20B).
In Fig. 20C, we validated two of these “top hits”, namely CRYAB and ITGA2 via western blotting,
which have roles as molecular chaperones [325] and in adhesion to the extracellular matrix [326],
respectively. The number of identified proteins and miRNAs from the OCV FT194 cells (relative
to CV) were higher as compared to FAC-exposed cells (relative to Untreated), which suggests
that the extent of neoplastic alterations induced by the oncogenic cocktail (hTERT, LTAg, c-
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MycT58A, and H-RasV12A) is more extensive than that induced by iron exposure (see Experimental
Procedures).

Table 7: List of common fragile sites in FAC-exposed relative to Untreated FT194 cells
FAC vs. Untreated
miRNA ID
miR-34a-5p

Genomic Location
1p36.22

Fold Change
6.85

FDR p-value
0.02890000
*

miR-138-5p
hsa-miR-7110-5p
miR-145-5p
miR-146a-5p

3p21.31
3q21.1
5q32
5q33.3

-16.25
2.29
-2.38
10.26

0.00000189
0.49900000
0.45400000
0.31070000

****
NS
NS
NS

mir-182-5p
miR-31-5p
miR-1296-5p
miR-210-3p
miR-708-5p
miR-34c-3p
miR-125b-5p
miR-125b-1-3p
miR-615-3p
miR-17-3p
miR-127-3p
miR-432-5p
miR-433-3p
miR-493-3p
miR-431-5p
hsa-miR-770-5p
miR-342-5p
miR-409-3p
miR-382-5p
miR-379-5p
miR-487b-3p
miR-485-3p
hsa-miR-654-5p
hsa-miR-1185-1-3p
miR-485-5p
miR-323a-5p
miR-134-5p
miR-487a-5p
miR-409-5p
miR-329-3p

7q32.2
9p21.3
10q21.3
11p15.5
11q14.1
11q23.1
11q24.1
11q24.1
12q13.13
13q31.3
14q32.2
14q32.2
14q32.2
14q32.2
14q32.2
14q32.2
14q32.2
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31

-9.19
2.32
-5.42
-2.09
3.44
3.83
2.45
2.45
-15.09
2.24
-111.69
-97.87
-22.41
-11.59
-6.02
-2.45
-2.34
-49.16
-37.07
-23.84
-22.55
-18.02
-9.37
-8.64
-5.98
-5.85
-3.58
-3.04
-2.54
-2.52

0.03020000
0.06330000
0.08800000
0.01260000
0.00660000
0.19130000
0.48070000
0.48070000
0.00009200
0.16410000
0.00000003
0.00000009
0.00000703
0.00730000
0.06480000
0.25680000
0.41920000
0.00000034
0.00020000
0.00002020
0.00040000
0.00030000
0.00010000
0.00009730
0.00660000
0.00005460
0.24840000
0.41920000
0.61360000
0.25680000

*
NS
NS
*
**
NS
NS
NS
****
NS
****
****
****
**
NS
NS
NS
****
***
****
***
***
****
****
**
****
NS
NS
NS
NS

Nearest Common
Fragile Site
FRA1A (1p36)
FRA3A (3p24.2);
FRA3B (3p14.2)
FRA3D (3q25)
FRA5C (5q31.1)
FRA5C (5q31.1)
FRA7G (7q31.2);
FRA7H (7q32.3
N/A
FRA10D (10q22.1)
FRA11C (11p15.1)
FRA11F (11q14.2)
FRA11G (11q23.3)
FRA11G (11q23.3)
FRA11G (11q23.3)
N/A
FRA13D (13q32)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)

Note: >2-fold change cutoff along with an FDR-adjusted p-value <0.05 (**** p<0.0001; ***
p<0.001; ** p<0.01; * p<0.05; NS >0.05).
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Table 8: List of common fragile sites in OCV relative to CV FT194 cells
OCV vs. CV
miRNA ID
hsa-miR-4632-5p
miR-34a-5p
miR-128-3p
miR-378a-3p
miR-584-5p
miR-378a-5p
miR-146a-5p
miR-4640-5p
miR-589-3p

Genomic Location
1p36.22
1p36.22
2q21.3
5q32
5q32
5q32
5q33.3
6p21.33
7p22.1

Fold Change
2.6
2.08
-2.11
7.66
2.67
2.17
11.43
3.72
-2.2

miR-182-5p
miR-6850-5p
let7e-5p
miR-455-3p
miR-1343-5p
miR-210-3p
miR-139-5p
miR-125a-5p
miR-615-3p
miR-17-5p
miR-18a-5p
miR-18a-3p
miR-92a-3p
miR-127-3p
miR-432-5p
miR-433-3p
miR-134-5p
miR-409-3p
miR-382-5p
miR-370-3p
miR-485-3p
miR-487b-3p
miR-3180
miR-744-5p
miR-6776-5p
hsa-miR-6779-5p
miR-27b-3p
miR-23b-3p
miR-769-5p
hsa-miR-99b-5p
miR-125a-3p
miR-296-3p
miR-941
miR-99b-3p
miR-500a-5p
miR-424-3p

7q32.2
8q24.3
9q22.32
9q32
11p13
11p15.5
11q13.4
11q24.1
12q13.13
13q31.3
13q31.3
13q31.3
13q31.3
14q32.2
14q32.2
14q32.2
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
14q32.31
16p13.11
17p12
17p13.3
17q12
19p13.12
19p13.12
19q13.32
19q13.41
19q13.41
20q13.32
20q13.33
21q21.1
Xp11.23
Xq26.3

-3.58
2
-3.92
4.77
2.31
-2.19
8.53
-4.65
3.55
4.75
3.9
3.79
2.48
-11.76
-11.75
-2.62
-6.06
-6.04
-3.22
-3.13
-2.22
-2.04
2.82
-2.21
2.72
3.24
-2.31
-2.14
-2.62
-4.88
-3.51
3.11
2.87
-4.18
2.03
5.6

FDR p-value
0.61160000
0.64000000
0.43710000
0.00460000
0.73370000
0.49590000
0.08990000
0.49590000
0.88380000
0.49590000
0.87770000
0.00001450
0.00040000
0.61160000
0.10890000
0.00040000
0.00008670
0.02630000
0.33370000
0.25760000
0.12120000
0.00460000
0.00001450
0.00010000
0.53880000
0.61160000
0.00040000
0.18450000
0.17770000
0.58160000
0.87160000
0.87770000
0.03970000
0.87770000
0.04560000
0.65520000
0.24790000
0.61160000
0.00460000
0.24790000
0.00460000
0.87720000
0.00040000
0.84280000
0.13100000

NS
NS
NS
**
NS
NS
NS
NS
NS

NS
NS
****
***
NS
NS
***
****
*
NS
NS
NS
**
****
****
NS
NS
***
NS
NS
NS
NS
NS
*
NS
*
NS
NS
NS
**
NS
**
NS
***
NS
NS

Nearest Common
Fragile Site
FRA1A (1p36)
FRA1A (1p36)
FRA2F (2q21.3)
FRA5C (5q31.1)
FRA5C (5q31.1)
FRA5C (5q31.1)
FRA5C (5q31.1)
FRA6C (6p22.2)
FRA7B (7p22)
FRA7G (7q31.2);
FRA7H (7q32.3
FRA8D (8q24.3)
FRA9D (9q22.1)
FRA9E (9q32)
FRA11E (11p13)
FRA11C (11p15.1)
FRA11H (11q13)
FRA11G (11q23.3)
N/A
FRA13D (13q32)
FRA13D (13q32)
FRA13D (13q32)
FRA13D (13q32)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
FRA14C (14q24.1)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
FRAXD (Xq27.2)

Note: >2-fold change cutoff along with an FDR-adjusted p-value <0.05 (**** p<0.0001; ***
p<0.001; ** p<0.01; * p<0.05; NS >0.05)
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Figure 18: Altered miRNAs identified from microarray analysis in FTSECs (*Continued next
page)
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Figure 18: Altered miRNAs identified from microarray analysis in FTSECs (*Continued next
page)
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Figure 18: Altered miRNAs identified from microarray analysis in FTSECs (*Continued next
page)
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Figure 18: Altered miRNAs identified from microarray analysis in FTSECs (*Continued next
page)

109

Figure 18: Altered miRNAs identified from microarray analysis in FTSECs
Heat Map representing miRNAs derived from the microarray analysis showing a decrease [1] and
increase (Red) in miRNAs with (A) FAC treatment (FAC-1a, 1b, 1c) compared to Untreated and
(B) transformed OCV- relative to CV-infected FT194 cells. Dysregulated miRNAs are displayed
as Volcano Plots in (C) FAC-treated vs Untreated FT194 cells, (D) Transformed (OCV/CV) and
(E) dysregulated miRNAs are displayed in a Venn diagram showing 18 common (overlapping)
miRNAs between FAC-treated relative to Untreated as well as transformed OCV relative to CV
analyses.
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These ”hits” were not validated due to the expectation that oncogenic transformation of
FTSECs would lead to a comparatively larger array of alterations recapitulating more closely
tumorigenic profiles of ovarian tumors relative to chronic iron exposed FTSECs, which is the main
focus of this study. As the protein targets from the FAC versus Untreated analyses were found to
be involved in multiple signaling and molecular pathways (Fig. 20D and Table 9), we further
investigated the mechanism of FAC-induced dysregulation in FT194 cells, specifically focusing
on analyzing the mechanism by which FAC alters miR-138-5p, miR-432-5p and miR-127-3p
levels to potentially contribute towards increased tumorigenesis.

FAC-induced epigenetic regulation of PAX8
Integrated microarray and proteomics analyses were used to identify the most common protein
targets of miR-432-5p, miR-127-3p, and miR-138-5p in FAC-treated cells relative to Untreated
(Fig. 21A – 21C) as well as in OCV (relative to CV) FT194 cells (Fig. 22 – 24). Via IPA, the
analyses identified PAX8 (Paired Box 8) as a potential common target of miR-432-5p, miR-1273p, and miR-138-5p involved in ovarian cancer pathophysiology (Fig. 21D). Global proteomic
analyses demonstrated that PAX8 was increased 1.7-fold in FAC-exposed FT194 cells, which
was validated by western blotting and densitometric analyses (Fig. 25A, left and right panels).
Since iron-overload conditions are associated with epigenetic changes in various human
tissues [327, 328] and epigenetic modification of PAX8 is reported in ovarian cancer [329, 330],
we next investigated whether FAC-induced increase of PAX8 could be altered with AZA and/or
SAHA treatment. As shown in Fig. 25A, we observed a 95.6%-fold reduction in PAX8 protein
following combinatorial treatment of SAHA and AZA. These results suggest that the increased
PAX8 protein is epigenetically regulated as a result of chronic iron treatment in FT194 cells.
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Figure 19: Top miRNAs altered in FT194 cells, and their genomic locations (*Continued
next page)
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Figure 19: Top miRNAs altered in FT194 cells, and their genomic locations (*Continued
next page)

113

Figure 19: Top miRNAs altered in FT194 cells, and their genomic locations
These graphs show the miRNA targets (analyzed via microarray profiling) which correlate with
the protein changes (analyzed via mass spec proteomics analysis) as predicted by IPA. The
relative fold change of miRNAs is represented and organized according to their genomic locations
in (A) 250 nM FAC-treated FT194 cells compared to untreated, and (B) FT194 transformed cells
via Oncogenic cocktail virus (OCV), compared to control virus (CV) cells. Real-time PCR analysis
of (C) miR-432-5p, (D) miR-127-3p, and (E) miR-138-5p was performed after isolating total
miRNAs from 250 nM FAC-treated cells as compared to the untreated, at days 111 and 124 of
FAC treatment (p=33 and 37), to validate the downregulation of these miRNAs as predicted by
IPA analysis. RNU6B was used as a reference control and the data represents composite of three
independent experiments.

FAC-induced epigenetic regulation of miRNAs at 14q32 and 3p21
miRNAs are also regulated by epigenetic mechanisms [331-333] and miRNAs at chromosome
14q32 appear to be transcribed as a polycistronic miRNA cluster under control of epigenetic
mechanisms [334, 335]. In specific cancers, there is evidence to support hypermethylation at the
14q32 differentially methylated CpG regions (DMRs) which leads to cancer development [5, 223];
furthermore, promoter hypoacetylation, which can recruit HDACs through methyl CpG binding
proteins can also regulate gene expression at this locus [336].
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Figure 20: Protein targets and their genomic locations associated with top miRNAs altered
in FT194 cells (*Continued next page)
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Figure 20: Protein targets and their genomic locations associated with top miRNAs altered
in FT194 cells (*Continued next page)
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Figure 20: Protein targets and their genomic locations associated with top miRNAs altered
in FT194 cells (*Continued next page)
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E

Figure 20: Protein targets and their genomic locations associated with top miRNAs altered
in FT194 cells
These graphs show the protein targets associated with highly dysregulated miRNAs in FT194
cells, as determined by IPA analysis. Protein targets with >4-fold change, corresponding to the
miRNAs, were compiled, and organized by their genomic locations. Relative fold change of these
protein targets has been represented for (A) 250 nM FAC-treated FT194 cells compared to
untreated, and (B) transformed OCV cells compared to CV cells. (C) Western Blotting analysis of
250 nM FAC-exposed and Untreated FT194 cells, using cell lysates collected at day 170 of FAC
treatment (p=52). Three independent replicates were performed; representative cropped blots are
displayed. White space between cropped blots delineate different antibody applications to the
same blot. The full-length uncropped blots are displayed in the Supplementary Information File.
(D) Top 28 protein targets altered in gynecological cancers, with >4-fold change, identified for 250
nM FAC-treated FT194 cells compared to untreated. Upregulated proteins are shown in red and
downregulated proteins in green, ranging color intensity based on the fold change associated with
each. The detailed legend for all molecular processes in the protein network is included in tabular
form in (E).
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In view of these regulatory mechanisms and the identification of twenty 14q32 miRNAs
that were altered in FAC-exposed FT194 cells, we hypothesized that inhibition of DNA methylation
with AZA and/or inhibition of histone deacetylases with SAHA may alter the expression of miR432-5p and miR-127-3p (refer to Fig. 18 for “top hits” identified in the screening approach). Since
miR-138-5p is associated with epigenetic changes [337, 338], we therefore investigated whether
AZA and SAHA treatments could alter miR-138-5p levels. Inhibition of DNA methyltransferase
with AZA was validated by western blotting for DNMT1, which showed reduced protein levels (Fig.
6A).
In addition, HDAC inhibition was validated by demonstrating increased acetyl histone H3
levels via western blotting (Fig. 25A). Although SAHA treatment was more potent alone compared
to AZA alone, the combination of AZA with SAHA, resulted in a further fold-increase of 164.8,
48.8 and 2.3 in miR-432-5p, miR-138-5p, and miR-127-3p levels, respectively, as measurement
via real-time PCR (Fig. 25B – 25D). These results can be explained by the ability of the HDAC
inhibitor, SAHA, to inhibit not only HDAC but also DNMT1 protein expression via inhibition of
MAPK and thus the DNA methylation status [339]. HDAC inhibitors can also target DNMTs for
degradation via the ubiquitin-proteasome-pathway by an Hsp90 chaperone mediated mechanism
[340]. On the other hand, AZA specifically inhibits only DNMTs [341].

FAC-induced miR-138-5p downregulation is mediated independently of EVI1
We have previously reported that telomerase reverse transcriptase (TERT) can be
transcriptionally regulated by EVI1 (genomically amplified at chromosome 3q26) in FAC exposed
FT194 cells [19]. Prior work has shown that miR-138 levels are inversely correlated with TERT
as a result of direct binding of miR-138 to the 3’-UTR of TERT [342-344]. Therefore, we
hypothesized that the EVI1 may upregulate TERT transcripts in a miR-138-dependent manner.
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Mature miR- 138 originates from two primary transcripts: pri-miR-138-1 (encoded on chromosome
3p21, Genecard) and pri-miR-138-2 (encoded on chromosome 16q13, Genecard).
Indeed, we identified predicted EVI1 binding sites ~2500 bp upstream of miR-138-5p-1
(Fig. 26A and Fig. 27); specifically, the C-terminal binding site, GAAGATGAG, was 100% aligned
in this region, while the N-terminal and consensus sequences were imperfectly aligned (5 out of
9 nucleotides and 5 out of 11 nucleotides, respectively). To determine whether EVI1 is potentially
involved in the direct regulation of miR-138-5p-1 expression in chronic iron-exposed FT194 cells,
we reduced EVI1 levels using an siRNA transfection (siB) approach and validated the efficiency
of knockdown via western blotting (Fig. 26B). We then determined the levels of miR-138-5p via
real-time PCR analysis.
Although we confirmed that the levels of miR-138-5p were reduced following chronic FAC
exposure (p <0.0001), as noted previously (see Fig. 26D), its levels were not significantly altered
upon siB (EVI1 knockdown) treatment in FAC-exposed FT194 cells relative to FAC-exposed
parental cells (p= 0.8509) (Fig. 26C). These results indicate that miR-138-5p expression is
regulated in an EVI1-independent manner and that other factors likely contribute to the
downregulation of miR-138-5p under these conditions.

miR-138-5p partially regulates transcript expression of the stem cell marker TERT but not
ALDH1A2 protein
Cancer stem cells (CSCs or tumor initiating cells) represent a subpopulation of cells that are
responsible for tumor initiation and progression [345, 346]. Dysregulated iron homeostasis in
CSCs may also aggravate cancer phenotypes [174, 347]. CSCs are notably characterized by the
expression of stem cell markers including elevated activity by aldehyde dehydrogenase (ALDH,
represented by multiple isoforms) [348], a superfamily of metabolic markers which serves as a
potential poor prognostic factor of cancer [349]. One family member, ALDH1A2, is aberrantly
expressed in acute lymphoblastic leukemia cells [350] and ovarian cancer [351, 352].
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Interestingly, the proteomics analyses identified a 3.2-fold increase in ALDH1A2 levels upon FAC
exposure in FTSEC cells and IPA analyses suggests that ALDH1A2 is a potential direct target of
miR-138-5p (Fig 28C). Indeed, prior published work supports miR-138-5p involvement in
ALDH1A2 regulation [353, 354]. To investigate whether ALDH1A2 is a target of miR-138-5p in
human FTSECs, we transfected FAC-exposed FT194 cells with miR-138-5p mimic. Although
overexpression of miR-138-5p was confirmed by real-time PCR (Fig. 28A) and western blotting
demonstrated that ALDH1A2 protein was increased in iron-exposed FTSECs, its levels were not
altered by miR-138-5p overexpression (Fig. 28B). These results suggest that miR-138-5p is not
a regulator of ALDH1A2 expression in FTSECs. Another stem cell marker TERT [355, 356] has
also been reported to be directly regulated by miR-138-5p [344, 357].
Since chronic iron exposure can induce TERT mRNA levels [19] and TERT sequence
alignment with miR-138-5p mature sequence has shown direct binding (Fig. 28D) [342], we
analyzed whether TERT increase is mediated via miR-138-5p. Indeed, we observed that miR138-5p mimic transfection partially rescued the TERT mRNA levels by 25% (Fig. 28E), suggesting
that FAC-induced increase in TERT transcript levels could be partially regulated via miR-138-5p.
IPA analysis identified 10 upregulated proteins predicted to be downstream of either miR-432-5p
(5 proteins) or miR-127-3p (5 proteins) in FT194-OCV cells relative to FT194-CV and associated
with malignant solid tumors.

miR-432-5p, miR-127-3p, and miR-138-5p overexpression does not alter PAX8 protein but
reduces cell numbers in FAC-treated FT194 cells
PAX8 (a member of paired box PAX gene family) is a positive marker of FTSECs [168] and is
elevated in a variety of tumors [358-363]. Our prior findings demonstrated that PAX8 was
upregulated following chronic iron exposure[19]; we now validate this observation and further
show that it is epigenetically regulated, also supported by prior literature [330].
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Furthermore, PAX8 appears to be a common target of miR-432-5p, miR-127-3p, and miR-138-5p
via the IPA analyses; target analyses using bioinformatic programs (Targetscan, miRDB,
miRNA.org, miRpath v.3 and miRmap) identified PAX8 to be a target of the aforementioned
miRNAs in a subset of these databases (data not shown). However, western blot analyses did
not identify any marked changes in PAX8 protein expression in FTSECs upon overexpression of
these miRNAs (Fig. 28B and 28C).
Thus, it remains to be experimentally determined whether these miRNAs interact directly
with PAX8 to regulate its expression. Since miR-432-5p, miR-127-3p, and miR-138-5p levels were
reduced in chronic FAC-exposed FT194 cells (Fig. 23C - 23E) and evidence supports their tumorsuppressive role [364-366], we proposed that rescuing their expression in the chronic iron-

Figure 21: Protein targets of miR-138-5p, miR-432-5p, and miR-127-3p associated with
gynecological cancers, predicted via IPA analysis (*Continued next page)
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Figure 21: Protein targets of miR-138-5p, miR-432-5p, and miR-127-3p associated with
gynecological cancers, predicted via IPA analysis (*Continued next page)
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Figure 21: Protein targets of miR-138-5p, miR-432-5p, and miR-127-3p associated with
gynecological cancers, predicted via IPA analysis
Protein targets of miR-138-5p, miR-432-5p, and miR-127-3p associated with gynecological
cancers, predicted via IPA analysis. In co-relation with ovarian serous tumors, (a) 7 targets
identified for miR-432 analysis and in correlation with gynecological malignancies, (b) 3 targets
identified for miR-127-3p and (c) 7 targets for miR-138-5p analysis. (d) Combined target network
analysis of miR-432, miR-127-3p and miR-138-5p in relation to their association with ovarian
carcinoma revealed PAX8 as a common target of all three miRNAs

exposed FT194 cells could antagonize the FAC-induced increase in cell numbers, as previously
reported [19]. Validation of miRNA overexpression for miR-432-5p, miR-127-3p, and miR-138-5p
was performed by real-time PCR (Fig. 28A and 29A). Cell counting identified reduced numbers
of cells in the chronic iron-exposed FT194 cells, with statistical significance following miR-432-5p
expression (p ≤ 0.05), relative to the parental FAC-exposed FT194 cell line (Fig. 29B).
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Figure 22: Protein targets of miR-127-3p and miR-432-5p, associated with malignant solid
tumors, predicted via IPA analysis
IPA analysis identified 10 upregulated proteins predicted to be downstream of either miR-432-5p
(5 proteins) or miR-127-3p (5 proteins) in FT194-OCV cells relative to FT194-CV and associated
with malignant solid tumors.

Discussion
Iron is an important dietary component that is critical in maintenance of various cellular functions;
however, it elicits activity as a mutagenic factor through its participation in Fenton reactions
whereby it is involved in generating ROS that may promote DNA damage such as oxidation of
DNA bases [172]. In this manner, iron may contribute to the pathophysiology of cancer.
Deregulated iron levels and expression of key mediators of iron metabolism are established
features of multiple tumors[178] including an established tumor “addiction” to iron [175],. Indeed,
multiple studies have linked the exposure to supraphysiological levels of iron with an increased
incidence of cancer including renal tumor formation in a rat model exposed to ferric nitrilotriacetate
[367], iron overload patients (e.g., hemochromatosis) with an increased risk of developing liver
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tumors [367, 368]. On the other hand, dietary iron (in excess) can enhance tumor formation in
mice harboring abnormalities in Adenomatous polyposis coli (APC) whereas iron chelation could
hinder tumor development [369]. Collectively, these reports implicate the potential tumor
promoting activities of iron in various experimental systems.
Although a recent report identified that chronic iron exposure in human pancreatic ductal
epithelial cell line supported epithelial-mesenchymal transition (EMT) and tumorigenesis through
a p53-dependent mechanism [370], the role of chronic iron overload in ovarian cancer initiation
by mediating transformation of fallopian tube secretory epithelial precursor cells (FTSECs)
remains unclear [371]. Iron sources in the pelvic cavity has been suggested to originate from
ovulation, retrograde menstrual reflux, and the rupture of follicles [372-374]; furthermore, a link
between hemochromatosis and ovarian cancer has been reported [176]. However, there is
currently limiting data regarding the contribution of iron to high grade serous ovarian tumor
initiation. Recently, we reported that long-term FAC exposure (at 250 nM) to FTSECs leads to
cellular changes that are reminiscent of those identified in HGSOC including alterations in EVI1,

Figure 23: Protein targets of miR-432-5p, associated with binding of DNA, predicted via
IPA analysis (*Continued on next page)
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Figure 23: Protein targets of miR-432-5p, associated with binding of DNA, predicted via
IPA analysis
IPA analysis identified 5 upregulated proteins predicted to be downstream of miR-432-5p in
FT194-OCV cells relative to FT194-CV. Of these, three were associated with binding of DNA.
FTSECs. iron-exposed and transformed FTSECs.

Figure 24: Protein targets of miR-127-3p, associated with binding of DNA, predicted via
IPA analysis
IPA analysis identified 5 upregulated proteins predicted to be downstream of miR-127-3p in
FT194-OCV cells relative to FT194-CV. Of these, three were associated with binding of DNA.

Figure 25: miR-432-5p, miR-127-3p, and miR-138-5p are epigenetically regulated by FAC
(*Continued on next page)
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Figure 25: miR-432-5p, miR-127-3p, and miR-138-5p are epigenetically regulated by FAC
(A) Western Blotting analysis of 250 nM FAC-exposed FT194 cells treated with 1 µM AZA and/or
10 µM SAHA for 24 hours, using cell lysates collected at days 129, 134 and 137 of FAC treatment
(p=38 and 39). Three independent replicates were performed; representative cropped blots and
the densitometric analysis for PAX8 are displayed. Real-time PCR analyses of (B) miR-432-5p,
(C) miR-127-3p, and (D) miR-138-5p in 250nM FAC-exposed FT194 cells treated with 1 µM AZA
and/or 10 µM SAHA for 24 hours. The data shown represents the composite of three independent
experiments. RNU6B was used as a reference control.

Figure 26: EVI1 knockdown does not alter miR-138-5p expression level (*Continued on next
page)
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Figure 26: EVI1 knockdown does not alter miR-138-5p expression level
(A) Schematic representing the predicted EVI1 binding site upstream from miR-138-5p. EVI1
splice variants were reduced in FAC-treated FT194 cells using siRNA (siB) in FAC-treated cells.
Cell lysates and miRNAs were collected at days 125 and 128 of FAC treatment (p=37 and 38).
(B) Western blotting was performed to validate the knockdown. Three independent experiments
were completed, and a representative blot is shown. (C) Real-time PCR of miR-138-5p was
performed using RNU6B as a reference control. The data represents the composite of three
independent experiments.

Figure 27: Prediction of EVI1 binding with miR-138-5p, using Dialign Genomatrix 49
software
The genomic sequence (5000bp upstream) of the promoter region of miR-138-50 5p-1 (located
at 3p21.32) was obtained from the UCSC Genome Browser (www.genome.ucsc.edu, Human
Dec. 2013 (GRCh38/hg38 Assembly). The EVI1 N-terminal Zinc-finger binding, C-terminal Zinc129

finger binding and consensus sequences were previously published. Prediction of EVI1 binding
with miR-138-5p-1 promoter region was completed by aligning the sequences using Genomatix
software suite (version 3.11, http://www.genomatix.de/cgi-bin/dialign/dialign.pl), and the aligned
region is presented.

β-catenin, and c-Myc protein expression, together with functional changes including increased
cell numbers and migratory potential [19]. The work reported herein extends these findings to
uncover miRNA and protein level changes under these chronic iron exposure conditions in
Further, it is well recognized that aberrant expression of miRNAs is a characteristic of ovarian
tumors with potential to serve as biomarkers and/or aid as potential diagnostic tools[282, 375,
376]; however, the contribution of iron in altering their expression has not yet been reported in
precursors to ovarian tumors.
Thus, to comprehensively assess the iron-induced molecular changes in FTSECs, we
performed an integrated miRNA and protein analysis approach in chronic iron-exposed and
transformed FTSECs. To our knowledge, this is the first study to utilize a multi-omics approach to
assess miRNA and protein level changes in FAC-exposed and transformed FTSECs. Herein, we
have identified a subset of dysregulated miRNAs along with their corresponding protein targets
via our integrated experimental approach following chronic iron exposure in FTSECs.
Furthermore, we identified that several miRNAs were epigenetically dysregulated which may
therefore be potentially associated with the transformative-like alterations observed in FTSECs
[19]. Fig. 30 displays a proposed model of the findings presented herein.
Analyses of oncogenetically transformed FTSECs (which harbors p53 inactivation, cMycT58A mutant, and H-RasV12A mutant) revealed a higher number of altered miRNAs and protein
targets relative to long-term iron exposed cells (see Fig. 18C and 18D). This suggests that these
OCV cells are likely to be more extensively transformed than FAC-treated cells. This is not
surprising since iron may only be one of many contributing factors mediating tumorigenesis.
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Figure 28: miR-138-5p overexpression partially regulates stem cell marker hTERT
transcript levels but does not alter another stem cell marker ALDH1A2 (*Continued next
page)
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Figure 28: miR-138-5p overexpression partially regulates stem cell marker hTERT
transcript levels but does not alter another stem cell marker ALDH1A2
(A) Real-time PCR analysis of miR-138-5p after isolating total miRNAs from miR-138-5p
transfected 250 nM FAC-treated cells relative to control transfected FAC-treated and Untreated
FT194 cells, at days 122, 125 and 129 of FAC treatment (p=35, 36, and 37) to validate the
overexpression. (B) Western blotting was performed for cell lysates collected from miR-138-5p
transfected and control transfected Untreated and FAC-treated FT194 cells to analyze ALDH1A2
levels at days 119, 122, and 126 of FAC treatment (p= 35 - 37) (C) Western blotting was
performed using cell lysates collected from control or miR-432-5p or miR-127-3p, transfected
Untreated and FAC-treated FT194 cells with the indicated antibodies at days 123, 131, and 137
of FAC treatment (p=35, 37, and 38). (D) The predicted miR-138-5p binding site in the TERT
sequence is shown. (E) Real-time PCR analysis of TERT in miR-138-5p transfected FAC-treated
FT194 cells, relative to control transfected Untreated and FAC-treated FT194 cells after isolating
miRNAs at days 119, 122, and 126 of FAC treatment (p=35 - 37). The data is the composite of
three independent experiments.

Indeed, profound alterations of the cellular regulatory networks may indicate the concept of
“multiple events” needed to promote propagation of the tumor [377]. Our work presented herein
encourages future investigations, including 3-D organoid culture and in vivo mouse xenografts to
further explore the contribution of iron dysregulation to tumor initiation and/or the metastatic
process. Two-dimensional in vitro culture models lack the complexity of the tumor
microenvironment and thus limit physiological relevance [378]. Although murine models have
been developed to investigate HGSOC pathophysiology [379, 380], these in vivo model systems
pose challenges in terms of studying iron derived from the reproductive organs due to a lack of
menstruation in mice. Therefore, alternative strategies such as intra-bursal or intraperitoneal
delivery using iron dextran may be needed. Three-dimensional organoid cultures may also
provide an alternative approach to investigate the response of FTSECs to exogenous iron [381].
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Figure 29. Overexpression of miR-432-5p, miR-127-3p and miR-138-5p in FAC-treated
FT194 cells alter the cell counts and Pax8 expression level
(A) Real-time PCR of miR-432-5p and miR-127-3p was performed after isolating total miRNAs
from the respective mimic-transfected 250 nM FAC-treated cells relative to the Untreated cells at
days 123, 131, and 137 with FAC (p=35, 37, and 38). RNU6B was used as a reference control
and the data represents a composite of three independent experiments. (B) Representation of
cell counts obtained from overexpression of miR-432-5p, miR-127-3p, and miR-138-5p compared
to control miRNA transfected Untreated and 250 nM FAC-treated FT194 cells. The data presented
is the composite of five independent experiments.
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Figure 30: Proposed model for 14q32 miRNA regulation with combination of DNMT
inhibition and HDAC inhibition
We previously reported that chronic iron overload contributes towards oncogenic transformative
events, which potentially recapitulate early events in HGSOC transformation. Microarray analyses
identified markedly reduced levels of miR-432 and miR-127 (located at 14q32) in FAC-treated
FT194 cells. We propose that the FAC-induced reduction in the miRNA levels was a result of
epigenetic alterations, specifically in their methylation and acetylation status. Inhibition of DNA
methyltransferases (using AZA) and HDACs (using SAHA) led to a reversal of the levels of these
specific miRNAs in these chronic iron exposed FTSECs. We previously reported that chronic FAC
treatment of FT194 cells notably increased TERT mRNA levels[19] as well as ALDH1A2 protein
(from our proteomic analyses, validated via western analysis). We now identified that
overexpression of miR-138-5p (located at 3p21) could antagonize the FAC-induced TERT
transcript levels; however, miR-138-5p expression did not modulate ALDH1A2 protein. The above
described three miRNAs also commonly alter Pax8 protein expression, which may contribute to
FAC-induced changes in FT194 cells. Green arrows denote partial regulation.

However, our initial attempts to maintain our oncogenically transformed and chronic iron
exposed FTSECs in spheroid culture failed to produce spheroids (data not shown). Thus,
implementation of alternative 3-D methods including hanging drop method in future studies could
be implemented [382]. Interestingly, there exists literature supporting the association between
iron and miRNAs. In one aspect, miRNAs can behave as iron sensors to suppress expression of
proteins associated with iron regulation [228]. On the other hand, the role of iron in deregulating
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miRNAs is comparatively understudied. Although cytosolic iron can regulate miRNA biogenesis
by altering miRNA precursor processing [233], the role of iron-induced miRNA regulation in cancer
requires further investigation. Herein, we have identified global dysregulation of miRNAs following
chronic iron exposure. There is evidence implicating iron in the regulation of epigenetic control.
Specifically, iron deprivation alters DNA methylation and histone deacetylation in preadipocytes
[383] whereas brain iron overload reduces DNA methylation [328]. However, the specific
underlying mechanism through which iron modulates these events remains to be explored. The
microarray analysis presented herein, we identified 20 out of 35 miRNAs (including miR-432-5p
and miR-127-3p) that were down-regulated in FAC-treated FT194 cells and also part of a large,
imprinted miRNA cluster at 14q32 locus. Interestingly, there is evidence implicating epigenetic
modification in the regulation of the miRNAs located within this cluster [334, 335]. miR-138-5p,
although located at a different chromosomal region at chromosome 3p21, was also identified to
be markedly down-regulated following iron exposure.
Current evidence supports miR-138-5p as a tumor suppressor in various cancer types
[357, 384-386]. This locus harbors a tumor suppressor gene cluster comprised of 8 genes within
a ~120Kb spanning region [387] whose expression can be regulated epigenetically [388]. Besides
miR-138-5p, 4 miRNAs (miR-135a-1, miR-let-7g, miR-1226, miR-564) out of total 16 miRNAs at
this locus have been reported to perform tumor suppressive functions in various cancers [389393]. Furthermore, upregulation of six miRNAs has been identified in different cancer types,
including miR-4271 [394], miR-191 [395-397], miR-425 [330, 398, 399], miR-4793 [71], miR-2115
[400], and miR-4443 [401], suggesting potential oncogenic functions in these cancers.
The miR-138-5p down-regulation was partially reversed via inhibition of methylation and
histone deacetylases, suggesting that iron can regulate miRNA expression by mediating
epigenetic changes in FTSECs. Out of the 15 miRNAs (from a total of 35 miRNAs) identified from
the integrated microarray analysis (see Table 1) that are not located at 14q32, 9 are reported to
be epigenetically regulated (miR-34a [302, 402], miR-145 [403], miR-182 [404], miR-31 [405],
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miR-708 [406], miR-34c [407], miR-125b [408], miR-615 [409], and miR-17 [410]). Similarly, miR17, which is a part of the 17-92 miRNA cluster located at chromosome 13q31, can also be
regulated by epigenetic mechanisms [410]. We also identified 5 miRNAs at chromosome 19q13
to be altered in OCV transformed FT194 cells (relative to CV) via proteomics analysis. Notably,
chromosome 19 contains a large imprinted miRNA cluster comprising 46 miRNAs, which can also
be regulated via epigenetic mechanisms [411, 412]. Collectively, our miRNA analyses have
verified epigenetic regulation as a common mechanism underlying miRNA expression, which is
also supported by literature for miRNA cluster regulation at different loci in the human genome.
As shown in Fig. 25B, inhibition of methylation and histone deacetylation rescued the
levels of miR-432-5p and miR-127-3p in chronic iron exposed FTSECs. This suggests that iron
may regulate the activities of epigenetic regulators. There is also evidence that differential miRNA
regulation may occur within this locus as independent miRNA regulation of 14q32 at unique
miRNA promoters by nuclear receptors may be responsible [226], although there is also evidence
supporting transcription of this miRNA cluster as a polycistronic transcript [204]. Since we
observed differential expression of 14q32 miRNAs via our microarray analysis, this may implicate
independent regulatory mechanisms for multiple miRNAs within this region.
PAX8 (a member of paired box PAX gene family) is a positive marker of FTSECs[168]
and is elevated in a variety of tumors [358-363]. Our prior findings demonstrated that PAX8 was
upregulated following chronic iron exposure [19]; we now validate this observation and further
show that it is epigenetically regulated, also supported by prior literature[330]. Furthermore, PAX8
appears to be a common target of miR-432-5p, miR-127-3p, and miR-138-5p via the IPA
analyses; target analyses using bioinformatic programs (Targetscan, miRDB, miRNA.org,
miRpath v.3 and miRmap) identified PAX8 to be a target of the aforementioned miRNAs in a
subset of these databases (data not shown). However, western blot analyses did not identify any
marked changes in PAX8 protein expression in FTSECs upon overexpression of these miRNAs.
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Table 9: Top protein targets in FAC-exposed relative to Untreated FT194 cells

Protein
Target

Alias

Rho GTPase
Activating Protein
ARHGAP12
Rho12
GDP
Dissociation
ARHGDIB

ARRB1
BST1
CELF2
COL5A1
CRABP2
CRYAB

Arrestin
Beta 1
Bone Marrow
Stromal Cell
Antigen 1
CUGBP Elav-like
Family Member 2
Collagen Type V
Alpha 1Retinoic
Chain
Cellular
Acid Binding
Crystallin Alpha B

2,4-Dienoyl-CoA
Reductase
Family With2
Sequence
Similarity 171
FAM171A1
Ferredoxin
Reductase
FDXR
IsopentenylDiphosphate Delta
Isomerase
IDI1
Internexin1
Neuronal
Intermediate
INA
Integrin Subunit
Alpha
ITGA2
Kin17
DNA2 and
RNA
Binding
KIN
Microtubule
Associated
Serine/Threonine
MASTL
Nmyristoyltransferas
e2
NMT2
Neurotrimin
NTM
Proteasomal
ATPase
Associated
Factor
PAAF1
PAT1 Homolog
1,
Processing Body
mRNA Binding
Decay
PATL1
Retinol
1
RBP1
RhoProtein
Associated
Coiled-Coil
ROCK1 Containing Protein
SEC14 Like Lipid
Binding
2
SEC14L2
Solute
Carrier
SLC1A4 Family 1 Member 4
DECR2

TGFBI

Transforming
Growth Factor
Beta 1

Transmembrane
Protein
123
TMEM123
Thiamin
Pyrophosphokinas
TPK1
Tubulin Beta 4A
Class Iva
TUBB4A

Fold-Change
(Welch's TChromosomal
test LFQ
Location
intensity F v
U)
10p11.22
12p12.3

11.77340121
0.086813615

11q13.4

5.124634149

4p15.32

6.122146871

10p14

13.84767274

9q34.3
1q23.1
11q23.1

0.112864701
0.09458846
17.53439428

16p13.3

9.463406179

10p13

6.197873721

17q25.1

4.595277

10p15.3

0.156436427

10q24.33

7.346539312

5q11.2
10p14

16.44875121
11.27786487

10p12.1

6.20270082

10p13
11q25

4.073197008
7.970555423

11q13.4

4.390010657

11q12.1
3q23

5.037787567
0.072160245

18q11.1

7.346539312

22q12.2
2p14

0.10067807
0.235645725

19q13.2

0.113836913

11q22.2
7q35
19p13.3

6.71872719
4.34870065
4.021247785

Note: p <0.05 and z-value >1.
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UniProtKB/Swiss-Prot Summary

a member of a large family of proteins that
activate Rho-type
GTP metabolizing
enzymes
regulates
the GDP/GTP
exchange reaction
of
the Rho proteins
functions in regulating
agonist-mediated Gprotein coupled receptor signaling by mediating
both receptor desensitization and resensitization
processes
synthesizes the second
messengers cyclic ADPribose and nicotinate-adenine dinucleotide
phosphoate
RNA-binding protein implicated in the regulation
of several post-transcriptional events
Type V collagen is a member of group I collagen
(fibrillar forming collagen)
Transports
retinoic
to the nucleus
May
contribute
to theacid
transparency
and
refractive
index of theof
lens
Participates
in the degradation
unsaturated
fatty enoyl-CoA esters having double bonds in
both even- and odd-numbers positions in
peroxisome
Involved in the regulation
of the cytoskeletal
dynamics/plays a role in actin stress fiber
formation
Serves as the first electron transfer protein in all
the the
mitochondrial
P450 systems of the
Catalyzes
1,3-allylic rearrangement
homoallylic substrate isopentenyl to its highly
eletrophilic allylic isomer, dimethylallyl
diphosphate
Class-IV neuronal
filament that is able to selfassemble and is involved in the morphogenesis
of neurons.
Integrin alpha-2/beta-1
is a receptor for laminin,
collagen, collagen C-propeptides, fibronectin,
andreplication
E-cadherin
Involved in DNA
and the cellular
response
to DNA
Serine/threonine
kinase
that damage
plays a key role in
M phase by acting as a regulator of mitosis
entry and maintenance'\
Adds a myristoyl group to the N-terkinal glycine
residue of certain cellular and viral proteins
Neural
cell adhesion
molecule and
Inhibits
proteasome
26S assembly
proteolytic activity by impairing the association
of the 19S regulatiry
the 20S core
RNA-binding
protein complex
involved with
in deadenylationdependent decapping of mRNAs, leading to the
degradation of mRNAs.
Cytoplasmic retinol-binding protein
Rho-kinases are serine/threonine kinases
by RhoA
GTPases
Carrier activated
protein. Binds
to some
hydrophobic
molecular and promotes their transfer between
thefor
different
Transporter
alanine,cellular
serine,sites
cysteine, and
threonine
Multifunctional protein
that regulates growth and
differentation of various cell types and is
invovled in various processes such as normal
development, immune function, microglia
function, and responses to neurodegeneration
Implicated in oncotic cell death, characterized by
cell swelling, organelle swelling, vacuolization,
and increased
membrane permeability
Catalyzes
the phosphorylation
of thiamine to
thiamine pyrophosphate
Tubulin is the major constituent of microtubules.

Future studies are needed to experimentally validate whether PAX8 is a target of these miRNAs.
Our earlier findings demonstrated that long-term iron exposure in FTSECs leads to altered
expression of EVI1 variants [19]. Although we identified an EVI1 binding site within the promoter
region of miR-138-5p through our bioinformatics analysis (see Fig. 27), EVI1 knockdown did not
alter miR-138-5p levels implicating the involvement of other regulatory mechanisms.
The stem cell marker, ALDH1A2 [349, 413, 414] is reported to be a direct target of miR138-5p, as identified via a proteomics screen in zebrafish embryos [353] but as of yet has not
been confirmed in humans. As shown in Fig. 28B, overexpression of miR-138-5p in iron exposed
FTSECs did not result in an alteration in ALDH1A2 expression; thus, this suggests that ALDH1A2
is not regulated by miR-138-5p in FTSECs. However, another stem cell marker TERT [355, 356],
which has already been demonstrated to directly regulate miR-138-5p [344, 357], appears to be
at least partially regulated by miR-138-5p (see Fig. 28D).
Although the quantitation accuracy of both the miRNA transcriptomic and proteomic
datasets was validated through orthogonal methods such as qPCR and western blot analysis of
selected targets, the miRNA target filtering through IPA is based on previously experimentally
determined interactions or computational prediction (e.g., TargetScan). Potential regulatory
miRNAs will need to be validated in future studies based on the expression pairing of miRNAs
and proteins relevant to specific cancer-related pathways identified in our high-confidence
transcriptomic and proteomic datasets. Further improvement can also be made in the proteomicsbased methodology, which includes fractionation of the proteome and application of DIA
approaches to enhance proteome coverage. In addition to deeper proteome coverage to reveal
further differentially expressed proteins, global-scale phosphoproteomic analysis can be
employed to identify altered signaling pathways, collectively providing detailed global-scale
insight into changes of the molecular landscape associated with iron exposure and oncogenenic
mechanisms in FTSECs.
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Conclusion
Overall, the methodological approach utilized herein served to identify miRNAs and protein
targets associated with long-term FAC treatment in FT194 cells. To our knowledge, this is the first
study elucidating a comprehensive set of alterations at the miRNA and protein levels in chronic
iron exposed FTSECs, which may identify pathways that may contribute to increased tumorigenic
potential. In future studies, epigenetic mapping of chronic iron-exposed cells could be performed
to further our understanding of the changes induced by long term iron treatment in fallopian tube
precursors.
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Chapter 5
Future Perspectives and Significance of the Study
Overview of the Major Conclusions
Tumor microenvironment is characterized by vast molecular and genomic alterations [415]. Due
to the limited understanding and sub-optimal treatment regimens of different cancer types, it is
imperative to identify the contributing factors. The work presented in this dissertation focuses on
analyzing the changes occurring at cellular and molecular levels to study the pathophysiology of
renal cancer chemoresistance towards Temsirolimus (TEMS) mediated by Lysophosphatidic acid
(LPA), and miRNA alterations involved in iron-induced transformative events in the fallopian tube
secretory epithelial cells.
In Chapter 3, we analyzed the effect of LPA in reversing the chemoresistance of ccRCC
towards the mTOR inhibitor TEMS, which is an FDA approved drug. The role of LPA in promoting
invasion and metastasis via Arf6 based mesenchymal pathway activation [136] and by inducing
resistance towards the tyrosine kinase inhibitor, Sunitinib [135] had been previously described.
However, the novel mechanistic aspect of LPA-induced lipid droplets and mitochondrial
alterations possibly leading to sub-optimal efficacy of TEMS in ccRCC is described in this thesis.
We compared the molecular alterations in four renal cell lines, including immortalized human
kidney cell line (HK-2) and three ccRCC cell lines (769-P, 786-O, and A-498 associated with VHL
mutations and varying genomic aberrations). We determined the variability in baseline and postTEMS treatment levels in AKT/mTOR pathway markers, as hyperactivation of this pathway is one
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of the common aberrations found in ccRCC patients [416]. Since ccRCC is a metabolic disease
associated with accumulation of lipid droplets [114], which interact with mitochondria for
production of energy [3], we also analyzed the levels of LDs, markers involved in LD biogenesis
and mitochondrial network alterations in all four renal cell lines. We noticed that cells also reduced
the size of LDs, increased LD abundance and hyperfuse mitochondrial networks to increase the
usage and conservation of energy, conferring resistance against TEMS treatment [417]. TEMS
also reduced the cellular viability in ccRCC cells, as expected [417]. When TEMS was used in
combination with Hydroxychloroquine (HCQ), the autophagic flux inhibitor, LDs were found to be
sequestered in autophagosomal compartments and ccRCC cellular viability was further reduced
[417]. This confirmed the increased efficacy of TEMS in combination with HCQ, which has also
been reported previously in a phase I clinical trial [94]. Additionally, this suggested that HCQ can
dominate over the effect of TEMS-induced LD alterations.
Further, when cells were treated with a combination of TEMS and LPA, TEMS-induced
molecular alterations were found to be reversed by the LPA treatment in vitro [417]. LPA treatment
increased cellular viability in a MAPK-dependent manner in HK-2 cells and post-combinatorial
treatment of TEMS and LPA, there were larger, more abundant LDs and mitochondrial networks
which were found to be more fragmented in all ccRCC cells. This suggested the role of LPA in
antagonizing cellular response to TEMS in renal cancer, potentially contributing to the
chemoresistance [417].
Additionally, genetic aberrations also play a major role in cancer development and
aggressiveness in ccRCC patients. More commonly, chromosomal arm-level aberrations have
been reported [37, 418], such as loss of 3p associated with VHL inactivation (which is an obligate
event in ccRCC), gain of 5q [54], and loss of 14q [37]. Interestingly, the miRNA cluster located at
chromosome 14q32 is reported to be epigenetically regulated in mice (corresponds to
chromosome 12F1 in mice) [204, 292] and is dysregulated in a variety of tumor types [72, 206,
215, 223, 224, 237, 290, 291, 320, 419]. Loss of heterozygosity at chromosome 14q was reported
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to be associated with 49% of the 67 ovarian cancer tumors studied representing different stages,
grades and sub-types [316] and eight miRNAs located at 14q32 miRNA cluster were identified to
possess potential tumor suppressive functions in epithelial ovarian cancer [420], suggesting
substantial contribution of this region in OVCA pathophysiology. We focused on analyzing the
specific 14q32 miRNAs and their role in ovarian cancer initiation in chronic iron exposed fallopian
tube secretory epithelial cells (FTSECs) in Chapter 4. In this chapter, we applied a multi-omics
approach to examine the global protein-level alterations via Mass-spectrometry based proteomics
and miRNA alterations via microarray analysis in FT194-FTSECs which were treated with 250nM
ferric ammonium citrate (FAC), a non-transferrin bound iron form, for a period of >60 days. To
analyze the association between these analyses, we integrated them to derive a list of miRNAs
with more than two-fold change as well as direct protein targets corresponding with the miRNA
alterations in FAC-FTSECs compared to Untreated [421]. Twenty out of thirty-five miRNAs were
located at 14q32 locus, including the miRNAs with highest fold reduction, i.e., miR-127-3p and
miR-432-5p. Additionally, another miRNA, i.e., miR-138-5p located at chromosome 3p21, was
analyzed because of the potential EVI1 binding site in the promoter region of this miRNA [421].
Since EVI1 is altered in FAC-FT194 cells [19], we hypothesized that this FAC-induced alteration
is miR-138 dependent. However, when EVI1 was knocked down, there was no change in miR138 levels indicating existence of an alternate mechanism. Since 14q32 miRNA locus is
epigenetically regulated [72, 223, 292, 419], we analyzed the effect of DNA methyltransferase
inhibitor (AZA) and Histone deacetylase inhibitor (SAHA) on FAC-FTSECs and observed that
FAC-induced reduction in miRNAs (miR-127, miR-432 and miR-138) was partially reversed with
the combinatorial treatment of AZA and SAHA, suggesting that FAC possibly downregulates
14q32 miRNAs via epigenetic alterations[421]. Additionally, FAC-induced increase in hTERT
mRNA levels were found to be partially reversed with miR-138 mimic transfection. FAC-induced
increase in cell survival in FT194 cells was also partially reversed when miRNA mimics were
overexpressed, specifically the effect was statistically significant with miR-432 overexpression
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[421]. Overall, we found that 14q32 miRNAs may have a potential tumor suppressive role in vitro
in FTSECs and these miRNAs can be epigenetically downregulated by chronic iron treatment.
This can potentially contribute to the transformative features in FTSECs, ultimately leading to
development of HGSOC characteristics [421].

Chapter 3 and 4: Limitations of the Studies
In Chapter 3, our data supported the role of LPA in mediating chemoresistance towards TEMS
[417], however, we acknowledge that being an in vitro analysis, the findings must be carefully
interpreted, and further investigation would be required via organoid cell culture in 3D [9, 422] or
through in vivo studies, recapitulating the tumor microenvironment. Although we used 3 different
ccRCC cell lines, the data cannot be generalized to all ccRCC cells and comparison with a primary
renal proximal tubule cell line instead of immortalized cells (such as HK-2) could be considered.
Within individual cell-based assays, the number of markers analyzed were limited, and further
investigation would be required for large scale characterization of lipid and mitochondrial
alterations.
In Chapter 4, although we identified Pax8 to be a common protein target of miR-432, miR127 and miR-138 via proteomics and bioinformatics analyses, the protein expression of Pax8 was
not changed as identified via western analysis [421]; further experimentation would be required
to determine whether these miRNAs interact directly with PAX8 to regulate its expression.
Additionally, ALDH1A2 was identified as a target of miR-138 via proteomics, but this data could
not be validated experimentally. Potential reason for this discrepancy could be due to variability
in protein expression across different study models as reported in literature, such as ALDH1A2
was identified as a direct target of miR-138 in zebrafish embryos [353], but was not identified in
our study in human FTSECs [421]. We also acknowledge that the large-scale score filtering
criteria of Mass-spectrometry based proteomics and Gene Chip microarray can also lead to
potential false positives [423, 424]. Although these quantitative methods are sensitive and allows
144

large number of parallel analyses, we must consider that matching and scoring of large data sets
can be specific to certain search engines/platforms optimized to particular instruments, which may
differ from other algorithms and scoring systems [425]. We also focused on only 3 miRNAs for
investigation, as mentioned above. miR-432 and miR-127 were the two most downregulated out
of total 20 identified 14q32 miRNAs altered with chronic iron treatment in FTSECs [421]. Since
miRNAs are present in the form of sub-clusters at this locus (as shown in figure 31), it is possible
that many of these miRNAs work synchronously to mediate the iron-induced alterations, which
requires further investigation.

14q32 miRNAs in cancer
Existing evidence and Implications
Genomically imprinted region on chromosome 14 is ~1 Mb in size and contains paternally
expressed genes, such as DLK1, RTL1 and DIO3 as well as maternally expressed genes, such
as MEG3, MEG8 and DIO3 [294, 426]. These imprinted genes have been reported to play
significant role in various cellular pathways and diseases, including cancer [427-430].
Interestingly, this locus also contains 54 miRNAs [295] within ~300 kb region, present in form of
2 sub-clusters (as shown in Figure 31). These miRNAs have been identified to be downregulated
in glioblastoma multiforme, ovarian cancers, osteosarcoma, invasive breast cancer, renal clear
cell carcinoma [431, 432]. There have been reports suggesting the role of the 14q32 miRNA
cluster in driving lung adenocarcinoma [206] and are differentially expressed, acting as potential
biomarkers in non-alcoholic fatty acid liver disease [209]. In ovarian cancer, existing evidence
suggests that eight miRNAs from this cluster can act as tumor suppressors [420] as well as allelic
loss of potential tumor suppressor genes at locus 14q32 is associated with substantial increase
ovarian cancer cases [316]. As summarized in Table 10, this cluster targets various
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tissues/diseases in humans and their functions are co-related with upregulation or downregulation
of miRNAs in cell-type specific manner.

14q32 miRNA cluster in Renal cell carcinoma
Loss of chromosome 14q32 in ccRCC is reported to be associated with increase in disease
aggressiveness [433], but the role and mechanism of these miRNA aberrations in renal cancer is
not well studied. We hypothesize that 14q32 miRNAs possess tumor suppressive properties in
ccRCC. We performed a preliminary analysis of basal expression of eight 14q32 miRNAs
(selected based on their approximate equidistant location on chromosome 14q) via RT-PCR in
renal cells. The results showed highest expression in primary renal proximal tubule epithelial cells
(RPTEC) and low/no expression in immortalized cell lines HEK293T and HK-2, suggesting that
perhaps immortalization process can lead to 14q32 miRNA reduction (data not shown).
Furthermore, we compared the 14q32 miRNA expression pattern in three ccRCC cell lines: 769P, 786-O and A-498. Interestingly, the expression level of sub-cluster A miRNAs (miR-493, miR431, miR-432) were low/not detectable in all three cells lines, while analysis of sub-cluster B
miRNAs (miR-411, miR-495, miR-539 and miR-323b) showed miRNA expression to be highest
in 769-P, followed by 786-O and A-498 (miRNA expression: 769-P>786-O>A-498) (data not
shown). These expression levels were inversely related with the level of genomic aberrations in
these cell lines (769-P<786-O<A-498) as expected, supporting that increased aggressiveness
can lead to reduction of these miRNAs. As the expression pattern was different among sub-cluster
A and B miRNAs, this also provides an indication of difference in regulation of these sub-clusters
(data not shown).
To decipher the role and regulation of 14q32 miRNAs in ccRCC, we attempted to
overexpress these miRNAs in vivo using 786-O cells. We established a renal tumor xenograft
model by injecting these cells subcutaneously, followed by intratumoral administration of control
adeno-associated virus or those expressing the miRNA cluster at 14q32.
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Table 10: 14q32 miRNA alterations and their corresponding functions in different
diseases/target tissues.
14q32 miRNA cluster
14q LOH

Disease/Target
PMID
Function
Renal cell
carcinoma
15202004 High grade malignancy and poor survival
Transformation of low grade into high
Clear cell RCC 17922474
grade ccRCC

Loss of 14q32
Downregulation of 14q32
miRNAs (focusing on miR- Papillary thyroid
654-3p)
cancer
28030816
Overexpression of 14q32
miRNAs (focusing on miR323b-3p, miR-487a-3p, and
Lung
miR-539-5p)
adenocarcinoma 29330288

14q32 miRNA expression
Downregulation of 14q32
miRNAs (focusing on miR323-3p)

14q32 hypermethylation
miR-379/miR-410 cluster
ablation

14q32 miRNAs (focus on
mir-376a and mir-376c)

28506242

Tumor cell migratory and invasive
properties
Suppress metastatic colonization in
preclinical models of lung and liver
metastasis and correlates with improved
clinical outcomes in patients with
metastatic cancer
IPA analysis revealed various potential
functions, including cell proliferation, cell
cycle progression and migration
Associated with pathogenesis of AML
(hypermethylation observed in leukemic
cells compared to control)
Neonatal metabolic adaptation (inefficient
mobilization of hepatic glycogen stores,
hypoglycemia, defective gluconeogenesis)
Enhances anxiety-related behavior
(influences behavior and energy
homeostasis)
Associated with high aggressiveness in
osteosarcoma cell lines

29129685

Drivers of pluripotency

29330288

Metastasis and poor prognosis

31919282

Promote gluconeogenesis
14q32 miR cluster downregulated in
melanoma and downregulation of miR376a and miR-376c increases insulin
growth factor 1 receptor

Lung and liver
cancer
30538122
Primary human
desmoplastic
medulloblastoma 24093088
Acute
promyelocytic
leukemia
24493669
Mouse neonatesdevelopment and
metabolic pathway 25124681

Deletion of the miRNeonatal mice
379/miR-410 cluster
brain
Expression of several 14q32
miRNAs
Osteosarcoma
Dlk1-Dio3 Locus-Embedded Embryonic Stem
MicroRNAs
cells
14q32 miRNA Cluster (focus
on miR-323b-3p, miR-487aLung
3p, and miR-539-5p)
adenocarcinoma
Upregulation of Dlk1-Dio3
locus miRNAs
Mouse liver

Melanoma

Progression of cancer: cell proliferation,
adhesion, migration, and angiogenesis

26744330

22747855
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We were able to establish the tumor models but injecting the AAV-associated miRNAs did
not alter the tumor size or volume (data not shown). Further we also isolated the tumors and
analyzed miRNA expression levels of miR-410, miR-432 and miR-494 via qPCR, which were not
found to be expressed (data not shown). A scientific conclusion could not be made due to
technical issues with the experiment. Additionally, since multiple genomic aberrations are
associated with tumor development, the subcutaneous injections of ccRCC cells may not
recapitulate ccRCC microenvironment. Since AAVs were injected intratumorally, it was not
feasible to estimate the efficiency of AAV-miRNA uptake by all tumor cells, which could have been
different throughout the tumor. Simultaneously, in vitro culture of 786-O cells with AAV-associated
miRNA transfection was also attempted, but miRNAs were not successfully expressed (data not
shown).
To resolve these issues, we attempted to overexpress selected miRNAs from this cluster
individually via miRNA mimic transfection in 786-O cells. These miRNAs were selected based on
extensive literature review of the roles of all 54 miRNAs in cancer and other molecular pathways,
such as lipid metabolic pathway, as ccRCC has been described as a metabolic disease
characterized by dysregulated lipid metabolism and increased intracellular lipid content [99]. Top
5 miRNAs from this list and their reported roles are mentioned below in table 11, which were used
for miRNA mimic transfections. We did not observe any changes in cell viability via crystal violet
assay and no changes in EMT markers via western blotting (data not shown). This could possibly
be due to potential technical issues with experiments; therefore, no definitive conclusions were
drawn. Additionally, as miRNAs exist in the form of sub-clusters on this locus (figure 31), it is
possible that these miRNAs work synergistically to exert their tumor suppressive functions.
Therefore, a next possible step is overexpression of miRNA mimics together to analyze changes
in cell morphology, viability, growth related functions such as cell migration and expression of
EMT markers. Based on the results, lipid metabolic alterations can be examined, such as
cholesterol levels and lipid droplet analysis.
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An alternative approach is CRISPR-Cas9 mediated re-activation of 14q32 miRNA cluster
in ccRCC cells. This approach was adapted from a lung adenocarcinoma study, which analyzed
the effect of miRNA cluster hyperactivation on migration and patient prognosis in lung
adenocarcinoma patients [223]. A 2-fold approach can be used to reactivate 14q32 miRNA
cluster, using lentiviral infection and stable transfection of Cas9-expressing plasmid (Lenti-EFS-

Table 11: 14q32 miRNAs selected based on extensive literature review of the roles of these
miRNAs in cancer and lipid metabolic pathways
miRNAs
miR431-5p

Cancer-related studies
Hepatocellular carcinoma,
pancreatic cancer, breast
cancer, medulloblastoma,
Glioblastoma, colorectal
cancer [434-439]

miR411-5p

Bladder cancer, Renal cell
cancer, Breast cancer, head
and neck squamous
carcinoma, Lung
adenocarcinoma [447-451]

Lipid-related studies
IFN-beta (involved in lipid metabolic
regulation in diseases such as multiple
sclerosis and hepatitis C) [440]
Grave's disease (related with altered serum
cholesterol) [441]
Platelet function (Platelets related to lipid
rafts for membrane domains) [442]
Alzheimer's disease (AD is related to
increased LDs) [443]
Differentiation and regeneration of old
skeletal muscle by targeting SMAD4 (TGF
beta related to abnormal lipid metabolism)
[444]
Spinal muscular atrophy (related to
abnormal fatty acid metabolism) [445]
Myostatin regulates miR-431 expression via
the Ras-MEK-ERK signaling pathway
(Myostatin involved in adipogenic
differentiation) [446]
Caloric Restriction-Mediated Induction of
Lipid Metabolism Gene Expression in Liver
is Enhanced by Keap1-Knockdown [452]
Genome-wide identification of microRNA
expression quantitative trait loci [453]
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Table 11 (Continued)
miR433-3p

Esophageal, cervical,
pancreatic, breast, gastric and
liver cancer [454, 455]

miR433-5p

Human glioma, Osteosarcoma,
Cervical cancer, Human gastric
carcinoma, Hepatocellular
carcinoma, Gastric cancer,
Breast cancer, Bladder cancer,
nasopharyngeal carcinoma
[454, 455, 459-464]
Breast, ovarian, gastric,
glioma, osteosarcoma,
pancreatic cancer, Human
esophageal squamous cell
carcinoma [364, 461, 467-471]

miR127-3p

miR432-5p

Prostate cancer,
Hepatocellular carcinoma,
cervical cancer, lung
adenocarcinoma, colorectal
cancer, breast cancer [474479]

MicroRNA-433-3p promotes osteoblast
differentiation through targeting DKK1
expression [456]
miR-433-3p is one of the miRNAs regulated
by rHDL [457]
Potential therapeutic target in renal fibrosis
[458]
Targets HIF1a [465]
miR-433 expression is altered in the
adipose tissue of patients with nonalcoholic fatty liver disease [466]

miR-127-3p is one of the 4 differentially
expressed miRNAs between exosomes and
their original cell samples in ovarian cancer
cell lines [472]
The miR-127 gene overlaps with the miR433 gene in a compact genomic space.
CREB, which controls hepatic lipid
metabolism by repression of PPARγ and
induction of PGC-1 (Peroxisome
proliferator-activated receptor-gamma
coactivator-1), is one of the targets of miR433 [473]
Expressed in bovine backfat [480]
Inhibits myogenesis through
PI3K/AKT/mTOR signaling pathway [481]

dCas9-VPR-PGK-Puro), followed by double stable cell line generation using sgRNA-expressing
plasmid (pLKO-U6sgRNA_improved-EF1s-GFP-P2A-Blasticidin) (See Appendix for technical and
methodological details), followed by selection with both blasticidin and puromycin for double
stable cell line generation. As shown in table 6, we determined the appropriate doses of blasticidin
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and puromycin for this purpose in different cell lines (dose response data not shown), which can
be used in preliminary studies.
Once the double stable cell lines are generated, these will be used to assess functional
properties of the miRNA cluster in relation to cell viability, migration capacity and lipid metabolic
alterations. Furthermore, we can also perform metabolomics analysis in 14q32 activated renal
cancer cells to analyze global metabolic pathway alterations. These cells can also be used to
generate a murine orthotropic RENCA model [482] to study the effects of 14q32 miRNAs in vivo.

14q32 miRNA Alterations: Epigenetic Factors and Potential role of Iron
Imprinted chromosome 14q32 region is regulated by differentially methylated regions (DMRs)
located upstream of miRNAs at this locus. Intergenic DMR (IG-DMR) is located between DLK1
and MEG3 genes, MEG3-DMR is located in the promoter region of MEG3 [292] and MEG8-DMR
is located within intron 2 of MEG8 gene [483]. IG-DMR and MEG3-DMR are methylated on the
paternal and unmethylated on the maternal allele, however, MEG8-DMR is methylated on the
maternal allele [222]. Literature supports the presence of DLK1-DMR, IG-DMR and MEG3-DMR
at chromosome 12p of mice [484], which correspond to the 14q32 locus in humans. DLK1-DMR
has paternal allele-specific methylation during embryogenesis and the methylation pattern
remains dynamic with further growth [484]. The IG-DMR is the germline primary DMR [485].
Evidence suggests that IG-DMR acts as upstream regulator of MEG3-DMR methylation pattern
[294, 486] and DNA-methylation pattern of IG-DMR functionally influences MEG3- and MEG8DMR DNA-methylation [487].
In addition to methylation, this region is also regulated by promoter acetylation, recruiting
HDACs through CpG binding proteins [336]. Role of epigenetic alterations, leading to silencing of
this miRNA cluster has been reported in some cancer cases [5, 223, 224, 488]. However, the role
and regulation of 14q32 epigenetic alteration in renal cancer and ovarian cancer development is
understudied. We showed that chronic iron exposure can alter these epigenetic changes leading
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to 14q32 miRNA downregulation (as mentioned above) in FTSECs [421]. Interestingly, Iron is
known to cause epigenetic alterations [225, 328] and iron accumulation in cancer cells is well
known to promote tumorigenesis in different cancer types [178]. Studies suggest that iron in the
form of nitrilotriacetic acid (Fe-NTA) can contribute to RCC development [489, 490] and can lead
to genomic aberrations by inducing Fenton reaction in renal proximal tubules of rodents; these
chromosomal aberrations were similar to human copy number alterations associated with RCC
[367]. Therefore, we hypothesize that iron can also lead to silencing of 14q32 miRNAs in renal
cancer by altering promoter methylation and acetylation patterns.
Additionally, since VHL mutation exists in 90% of ccRCC patients, VHL-HIFα axis is
dysregulated in these tumors, leading to iron accumulation as one of the downstream effects due
to increase in Transferrin Receptor 1 (TfR1) [181] and inhibition of ferritin expression at mRNA
and protein level [491]. VHL-loss also leads to increased iron susceptibility in ccRCC cells [492].
This evidence supports the role of iron in ccRCC pathophysiology. As a preliminary analysis, we
used a non-physiological means of altering iron levels by treating HK-2 cells with FAC (NTBI) for
a period of ~3 months and we were expecting an increase in cell viability, but we did not notice
any change in cellular growth or morphology (data not shown).
It is possible that either NTBI alone is not sufficient to induce any obvious cellular changes
or HK-2 cells, being immortalized with EBV leading to genomic alterations [252], do not
appropriately represent the renal proximal tubule cell environment and may not be susceptible to
iron-induced changes. Since it has been reported that human proximal tubular epithelial cells can
uptake iron in form of both transferrin bound (TBI) as well as non-transferrin bound (NTBI) forms
[21], we can treat the primary renal cells (immortalized via another mechanism such as hTERT/cMyc/LTAg/Ras overexpression) using a combination of both iron forms for long time duration then
analyze if there is a direct effect on expression level of 14q32 miRNAs.
Iron can also cause epigenomic alterations via iron-dependent enzymes such as Teneleven translocation (TET) enzymes and Jumonji C (JmjC) domain containing demethylases [493]
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and catalyze oxidative demethylation of transcription factors [494]. H2O2- induced oxidative stress
has also been shown to induce epigenetic alterations associated with malignant transformation in
human kidney epithelial cells [495]. Additionally, iron chelation by DFO can modulate histone
methylation in colorectal cells [496] and enhances chemoresistance in breast cancer cells by
causing promoter histone methylation in gene-specific manner [225]. Deferiprone (DFP)mediated iron chelation can alter histone modification profile to promote anti-tumor properties in
breast cancer xenograft mouse model [497]. Therefore, we can compare the ccRCC patient tumor
samples and with corresponding normal kidney samples to analyze the TET and JmjC enzymatic
activities as well as overall accumulated iron content before and after iron chelation. We can
further examine the epigenetic modifications caused by iron on 14q32 miRNA promoter region by
performing anti-histone specific Chromatin Immunoprecipitation (ChIP) and bisulphite sequencing
analysis using iron-treated primary immortalized renal cells.

Figure 31: Schematic representation of the miRNA-clusters at 14q32 chromosomal region
54 miRNAs present in the form of 2 sub-clusters, regulated by differentially methylated regions
IG-DMR, MEG3-DMR and MEG8-DMR. The distance between miRNAs as calculated through
UCSC genome browser data is also included within ~300 kb region.
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Figure 32: Overall Model of Proposed Hypothesis for Role and Regulation of 14q32
miRNAs in Epithelial Ovarian Cancer initiation clear cell Renal cancer pathophysiology
The model presented herein summarizes the potential crosstalk between increased iron content,
leading to 14q32 miRNA downregulation via epigenetic silencing. This may lead to potential
transformative cellular alterations leading to OVCA initiation. Additionally, 14q32 miRNA
dysregulation may also be associated with increase in chemoresistance towards mTOR inhibitor
drug Temsirolimus, increased RCC aggressiveness, and lipid dysregulation.

Concluding Remarks and Overall Clinical Significance
Aberrations at 14q32 region brings attention to the possible prognostic value of the miRNA cluster
at this locus which may not only act as a biomarker for examining patient vulnerability towards
certain diseases but can also serve as potential therapeutic target for gene-based therapies. With
examination of iron-induced 14q32 miRNA downregulation, potentially caused by epigenetic
alterations, leading to transformative changes in FTSECs, this data moves us one step ahead in
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understanding of HGSOC initiation which has remained an open-ended question for years. It is
also possible that altered iron metabolism mediates drug resistance to TEMS and the related
signaling pathway markers as downstream targets of 14q32 miRNA dysregulation. Since lipid
reprogramming is one of the hallmarks of ccRCC [497], assessment of the role of 14q32 miRNAs
on lipid metabolism can provide direction to further understanding of altered cellular energetics in
this disease. With subsequent analyses, these altered metabolic pathways can also possibly
serve as diagnostic biomarkers at different stages of ccRCC [498], and a potential means of
therapeutic intervention via miRNA-based gene therapy [499] to restore the tumor suppressive
miRNAs and inhibit the translation of metabolic enzymes and other target proteins, hyperactivated
in ccRCC patients. Additional studies would be required to establish the role of these miRNAs in
cancer pathogenesis and drug resistance at both cellular and clinical level.
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Appendix B:
Additional Methods and Protocols used for current and future projects
RPTEC cell Immortalization
The primary renal proximal tubule cells were immortalized using different plasmids simultaneously
to determine which (if any) methods can lead to reduction in 14q32 miRNA levels. For RPTEC
immortalization, the retroviral plasmids (pBabe-puro, pVSVG, pCGP, hTERT, LTAg, c-Myc and
H-Ras) were transfected in various permutations into HEK293T cells. First, HEK293T cells were
seeded in 6-well plates at 1,500,000 cells/well. Post-cell adherence, the complete media was
exchanged to pre-warmed serum free media. Transfection reactions were next prepared in
cryovials by adding 100 µl serum free media, 1 µg plasmid DNA and 3 µl Fugene HD. After 6
hours of transfection, cells were overlaid with 2 ml of pre-warmed complete media. The
concentrations for all plasmids used are mentioned in the table below:
Table A1: Details of the plasmids used for RPTEC Immortalization.
Plasmid

Catalog Number
(Addgene)

Concentration

pBabe-puro

#1764

2282.03 ng/ µl

hTERT-HA

#1772

2761.44 ng/ µl

SV40 LTAg

#14088

1670.14 ng/ µl

H-Ras V12A

#9051

1082.86 ng/ µl

psPAX2

#12260

2038.3 ng/ µl

pVSVG

#12259

2805.8 ng/ µl

c-Myc T58A

#20076

2170.51 ng/ µl
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Twenty-four hours post-transfection, the cells were recovered by replacing the media in
6-well plates with 2 ml of pre-warmed complete media. Forty-eight hours post-transfection, the
retrovirus (1X RV) was collected from the supernatant media of the HEK293T cells and filter
sterilized using a 0.45-micron filter. The cells were then replenished with fresh complete media in
the 6-well plates and allowed to incubate for a further 24-hour period to collect the 2X RV
retrovirus supernatant media. The retrovirus solutions were stored at -80°C freezer until ready to
use.
Simultaneously, RPTEC cells were seeded into T25 flasks for retroviral infection to initiate
the immortalization process. These cells were seeded at 125,000 cells per T25 flask to generate
the following cultures in 7 independent flasks:
hTERT only
LTAg only
hTERT+LTAg
LTAg+hTERT+c-Myc+H-Ras
hTERT+Control shRNA
hTERT+ VHL shRNA.
Once ready, these cells were infected with appropriate retrovirus which was thawed at
37C. The infection media was prepared by adding 2ml of 1X retrovirus to 2ml complete media
with 8 µg/ml polybrene. The cultures were placed into the BSL-II incubator and monitored daily
for viral toxicity. The following day, the media was exchanged in all flasks with fresh appropriate
basal media and the media replenished once a week for maintenance and expansion of the
cultures.
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CRISPR-Cas9 mediated 14q32 miRNA cluster activation
HEK293T and FAC-FTSEC cells (in progress): The 54 miRNAs present at 14q32 locus are subdivided into two sub-clusters, as represented in the figure below. For explanation purpose, I will
refer to the first sub-cluster as miRNA sub-cluster A and second one as miRNA sub-cluster B (as
shown in figure 31).

sgRNA Design
The first step to CRISPR-Cas9 mediated activation was obtaining appropriate sgRNAs for specific
14q32 miRNA loci. The oligonucleotide sequences for sgRNAs targeting miR-381 loci in subcluster B were derived from a prior published study [223], which have been called as sgRNAs A
and B in our studies, the sequences of which are included below:
sgRNA A: CGCACCAGGTGCGTGCATG
sgRNA B: CAGTCGGGGTGTAAAAAGC
For sub-cluster A, miR-493 locus was targeted and sgRNAs were designed using different
CRSIPR activation tools, as follows:
1. CRISPR-ERA (http://crispr-era.stanford.edu/finish.jsp#s3) was used first to select gene
activation and added the gene MIR493 (first gene to be targeted for activation). Then,
selected U6 promoter (based on the vector pLKO-U6sgRNA_improved-EF1s-GFP-P2ABlasticidin). The table derived for sgRNAs list was downloaded (obtained in form of .txt
file) and copied this into excel file. Now, to narrow down the sgRNA sequences, deleted
sgRNAs with transcription start site (TSS) distance of more than 200 bp; selected the ones
targeting negative strand and Efficacy+Specificity score of less than 10. Further, narrowed
down the sgRNAs by selecting the ones with less than 100 bp TSS distance, considering
the promoter region will be present upstream of the target miRNA.
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2. Another tool used for sgRNA design was from Broad institute specific for “CRISPRa”:
Added the NCBI gene ID for MIR493 (i.e. 574450), and searched for sgRNAs. The results
obtained were downloaded as .txt file and saved as excel file.

Once both lists were generated, I compared the gRNAs from the two websites and selected
the two common sgRNAs obtained from both the tools. To double check these sgRNAs, I used
CAS OFFINDER (http://www.rgenome.net/cas-offinder/), which showed the same specific target
positions on chr14 as desired, and 0 mismatches.

The two sgRNAs (C and D) designed targeting site upstream of miR-493 were:
sgRNA C: AGCCGTGATGATGGAGTCCA
sgRNA D: AGAGATGAGATGCTGTGCCC
The locus of each miRNA is included in the table below:

Table A2: MicroRNA loci at chromosome 14q32 derived from UCSC genome browser.
miRNA Position
2392 chr14:100,814,491-100,814,574
770 chr14:100,852,390-100,852,487
493 chr14:100,869,060-100,869,148
337 chr14:100,874,493-100,874,585
665 chr14:100,875,033-100,875,104
431 chr14:100,881,007-100,881,120
433 chr14:100,881,886-100,881,978
127 chr14:100,882,979-100,883,075
432 chr14:100,884,483-100,884,576
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Table A2 (Continued)
136 chr14:100,884,702-100,884,783
370 chr14:100,911,139-100,911,213
379 chr14:101,022,066-101,022,132
411 chr14:101,023,325-101,023,420
299 chr14:101,023,325-101,023,420
380 chr14:101,025,017-101,025,077
1197 chr14:101,025,564-101,025,651
323a

chr14:101,025,732-101,025,817

758 chr14:101,026,020-101,026,107
329-1 chr14:101,026,785-101,026,864
329-2 chr14:101,027,100-101,027,183
494 chr14:101,029,634-101,029,714
1193 chr14:101,030,052-101,030,129
543 chr14:101,031,987-101,032,064
495 chr14:101,033,755-101,033,836
376c chr14:101,039,690-101,039,755
376a2 chr14:101,040,069-101,040,148
654 chr14:101,040,219-101,040,299
376b chr14:101,040,436-101,040,535
376a1 chr14:101,040,782-101,040,849
300 chr14:101,041,363-101,041,445
1185-1 chr14:101,042,977-101,043,062
1185-2 chr14:101,044,198-101,044,283
381 chr14:101,045,920-101,045,994
487b chr14:101,046,455-101,046,538
539 chr14:101,047,321-101,047,398
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Table A2 (Continued)
889 chr14:101,047,901-101,047,979
544a chr14:101,048,658-101,048,748
655 chr14:101,049,550-101,049,646
487a chr14:101,052,446-101,052,525
382 chr14:101,054,306-101,054,381
134 chr14:101,054,687-101,054,759
668 chr14:101,055,258-101,055,323
485 chr14:101,055,419-101,055,491
323b chr14:101,056,219-101,056,300
154 chr14:101,059,755-101,059,838
496 chr14:101,060,573-101,060,674
377 chr14:101,062,050-101,062,118
541 chr14:101,064,495-101,064,578
409 chr14:101,065,300-101,065,378
412

chr14:101,065,447-101,065,537

369 chr14:101,065,598-101,065,667
410 chr14:101,065,912-101,065,991
656 chr14:101,066,724-101,066,801
1247 chr14:101,560,287-101,560,422

Cloning and sequencing:
The plasmids used for this experiment were “Lenti-EFS-dCas9-VPR-PGK-Puro” and “pLKOU6sgRNA_improved-EF1s-GFP-P2A-Blasticidin”, the maps of which are included below:
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Figure A1: Plasmid Map for Lenti-EFS-dCas9-VPR-PGK-Puro used for Cas9 expressing cell
line generation
The figure above shows the plasmid map of Lenti-EFS-dCas9-VPR-PGK-Puro plasmid which was
used for stable cell line generation.

The sgRNAs were derived as Top and bottom sequence oligos. Prepared 100uM oligos
in molecular grade water by pulse spinning the oligo tubes at 1000 rpm for 10 seconds and adding
water directly to the tube (putting the tubes upright in ice bucket).
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Figure A2: Plasmid Map for pLKO-U6sgRNA_improved-EF1s-GFP-P2A-Blasticidin used for
double stable cell line generation for CRISPR activation
The figure above shows the plasmid map of pLKO-U6sgRNA_improved-EF1s-GFP-P2ABlasticidin which was used for stable cell line generation.
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For example: Oligo C [29]: 26.4 nmoles. Added 264 µl water to the tube directly at the bottom.
Oligo C (Bottom): 23.5 nmoles. Added 235ul water to the tube directly at the bottom.
Once added, these tubes were allowed to sit on ice for 10 minutes and vortexed briefly to mix
thoroughly. Rolled the tubes on side as well properly making sure that it is mixed well.
Next step was phosphorylation and annealing each pair of oligos: prepared the reactions in PCR
tubes. Added the following reagents directly to the bottom of the tubes and pulse spin if required:
Oligo (Top) 100uM -

1ul

Oligo (bottom) 100uM -

1ul

10X T4 ligation buffer -

1ul

dd H2O -

6.5ul

T4 PNK (NEB M0201S) -

0.5ul

Total -

10ul

Run these reactions in the thermocycler with the set CRISPR-1 program at 37°C for 30
minutes: 95°C for 5minutes; 25°C at 5°C/1 min and 4°C forever.
Next, diluted the annealed oligos from this step at a 1:200 dilution in molecular grade water
(1ul in 199 µl water) in eppendorf tubes. Now the ligation reaction was set up in eppendorf tubes
for control and individual oligos at room temperature as follows:

Control:
Digested pLKO -50ng -

0.6ul

Molecular grade water -

4.4ul

2X Quik ligase buffer -

5ul

DNA Quick ligase -

1ul

Total -

11ul
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Oligo sample:
Digested pLKO- 50ng -

0.6ul

Oligo annealed -

1ul

2X Quik ligase buffer -

5ul

DNA Quick ligase -

1ul

Molecular grade water -

3.4ul

Total -

11ul

Incubated this reaction at room temperature for 10 minutes.
Once ligation was completed, 4 µl of ligation reaction was added into Top10 F’ E. coli
competent cell tubes (already thawed on ice) and incubated for 30 minutes on ice. Then, this was
heat shocked for 30 seconds at 42°C in thermomixer. After Placing on ice immediately for 2
minutes, 250µl of SOC media was added (already at room temperature) directly in the tubes. This
was Incubated for 1 hour at 37°C in the thermomixer with shaking on. bacteria were spun at
14,000rpm for 3 minutes to pellet the bacteria. supernatant was discarded and pellet was
resuspended into 20µl of SOC media. This mixture was then plated onto the appropriate three
pre-prepared pre-warmed LB-AMP plates. Incubated overnight at 37°C in incubator.
Next day, post observation, 5 colonies were selected for each sgRNA. Colonies were
picked with a pipette tip, one for each, and were added in 2ml LB media/2µl Amp in the white
capped tubes. These tubes were placed on the shaker overnight at 37°C.
Next day, 16-18 hours post inoculation, mini plasmid prep procedure was performed as
follows:1ml of bacterial suspension was transferred into an Eppendorf tube and centrifuged for 2
minutes at 15,000 rpm. The supernatant was discarded in a 50ml tube containing bleach, retaining
pellet, which was resuspended in 250μl of Buffer P1 (stored in fridge). 250μl of Buffer P2 was
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added and the tubes were inverted 5 times. These were incubated for 5 minutes and 350μl of
Buffer N3 was added. all the tubes were inverted 5 times and centrifuged at 13,000 rpm for 10
minutes. supernatant was added to QIAprep spin column and pellet was discarded. Thus, was
centrifuged for 1 minute at 13,000 rpm and flow-through was discarded. Buffer PB (500μl) was
added to spin column. This was centrifuged for 1 minute at 13,000 rpm and discarded flowthrough. Buffer PE (700μl) was added, and this was centrifuged for 1 minute at 13,000 rpm and
flow-through was discarded. This was centrifuged for an additional 1 minute at 13,000 rpm. Spin
column was placed into a clean, labeled eppendorf. Collecting tube was discarded. Then, 50μl of
Buffer EB to was added to the This was added directly to the center of the filter at the bottom of
the column. This was allowed to stand for 1 minute and then centrifuged for 1 minute at 13,000
rpm. Removed and discarded column. The plasmids were quantified using nanodrop.
Next step was to set up double digest to check the presence of insert, using Cut Smart buffer:
*BamHI- HF (2529 bp) and Esp31/BsmBI (1962 bp)
Restriction digest was set up as follows:
Miniprep DNA: 8ul
10X Cutsmart buffer: 1ul
BamHI-HF: 1ul
Total Volume- 10ul
Pulse spun and kept this at 37°C overnight.
Next day, digested the BamHI-digested product with BsmBI as follows:
BamHI-digested product: 10 µl
10X fast digest buffer: 5 µl
Fast digest BsmBI/Esp3I: 1 µl
Water: 34 µl
Total- 50 µl
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Kept at 37°C for 30 minutes on thermomixer.
Agarose gel was run and one specific band of 7000bp was observed suggesting the
presence of insert (Include agarose gel results below). These samples were then sent for
sequencing analysis to further validate the presence of sgRNAs within the plasmid. Sequencing
results showed all clones to be positive, meaning that all sgRNAs were successfully cloned within
the “pLKO-U6sgRNA_improved-EF1s-GFP-P2A-Blasticidin” plasmid. Based on the results, the
specific clones selected for double stable cell line generation were sgRNAs A5, B2, C2 and D1.
Large plasmid prep procedure was completed for these sgRNAs to extract the plasmid DNA at
higher concentration in larger volume. The volume of tissue culture grade water used for resuspension of large plasmid prep pellets were 50 µl for sgRNAs A5 and B2, 150 µl for sgRNA C2
and 30 µl for sgRNA D1.

Cell culture details for double stable cell line generation
HEK293T and FAC-FT194 cells were first transfected with “Lenti-EFS-dCas9-VPR-PGK-Puro”
plasmid and selected with an appropriate dose of puromycin (see Table 12) to generate Cas9expressing stable cell lines. The transfection was set up using 100 µl serum free media, 1 µg
plasmid DNA and 3 µl Fugene HD for each sample. Cells were overlaid with complete media 6
hours post-transfection. Twenty-four hours post-transfection, cells were replenished with prewarmed complete media and 48 hours post-transfection media was replaced to add cell-specific
appropriate dose of puromycin. These cells were maintained for long-term with replenishment of
media every few days with puromycin containing media. Once ready, cells were seeded for
western blotting analysis using Cas9 antibody and frozen at different passages with continued
selection with puromycin for multiple passages.
After generation of Cas9 expressing stable cell lines, sgRNAs A5, B2, C2, D1 and control (empty
pLKO plasmid) were transfected in these cells using 100µl serum free media, 1 µg plasmid DNA
and 3 µl Fugene HD for each sample. Cells were then overlaid with complete media after 6 hours.
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Twenty-four hours post-transfection, cells were replenished with pre-warmed complete media and
48 hours post-transfection media was replaced to add cell-specific appropriate dose of puromycin
and blasticidin. The media was replenished every few days for double stable cell line generation.
To validate the expression of pLKO plasmid in these cells, GFP expression was analyzed via
western blotting analysis from the total cell lysates. The detailed steps for double stable cell line
generation are summarized in the excel file saved on the USF Cloud storage Box drive in
Ravneet’s Experimental Planning folder: “HEK293T-Cas9_sgRNA steps” and “FT194-Cas9sgRNA cell line generation”.
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